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Peritoneal carcinomatosis is a condition characterised by the development of solid tumor 
deposits on the peritoneal surface following detachment of tumour cells from the primary 
tumour1. Shedding of tumour cells may occur spontaneously or as a result of spill during 
surgical procedures. The process of attachment of tumour cells to the mesothelial cells 
of the peritoneum involves neoangiogenesis and is mediated by several growth factors. 
Tumour implantation and growth may lead to invasion of any organ or structure that is 
covered by the peritoneum. Besides the presence of solid tumours, occlusion of lymphatic 
drainage and excessive fluid production caused by increased capillary permeability lead to 
intraperitoneal fluid accumulation and eventually result in ascites2;3. 
In patients with colorectal cancer, spread of tumour cells to the peritoneal cavity and the 
subsequent development of peritoneal carcinomatosis is usually regarded as metastatic 
disease (stage IV). Because this condition has always been considered to be an end stage of 
disease, treatment was offered with palliative intent only, consisting mostly of supportive 
care and occasionally systemic chemotherapy. The role of surgery used to be restricted to 
minimally invasive interventions aiming for symptom relief. Results of palliative treatment 
in this group of patients are infamous for a poor prognosis with invariably fatal outcome4-7. 
Therefore, peritoneal carcinomatosis of colorectal origin has received little interest from 
oncologic research perspectives. This has resulted in a lack of data regarding incidence, 
clinical course of disease and accurate treatment evaluation.
In the 1980’s, peritoneal carcinomatosis gained more interest, triggered by the observation 
that a subgroup of patients presented solely with peritoneal tumour implants in the absence 
of systemic metastases8;9. This initiated the development of aggressive surgical treatment 
modalities combining radical cytoreductive surgery with intraperitoneal application of 
chemotherapy10-14. With this approach, prolonged overall survival and even cure of disease 
has been reported15-22. 
Until now, only one completed phase III randomised trial investigating the outcome of surgical 
intraperitoneal treatment has been published. Verwaal et al. reported a significant increase 
in median overall survival in patients treated with cytoreductive surgery and Hyperthermic 
Intraperitoneal Chemotherapy (HIPEC) as compared to patients receiving standard palliative 
care consisting of systemic 5-fluorouracil and leucovorin21-23. The promising outcomes of 
this study have convinced many surgeons to accept this technique as standard of care for 
selected patients with peritoneal carcinomatosis, and HIPEC treatment is nowadays offered 
in specialised centres all over the world. However, this study was heavily criticised for 
not including a control group receiving cytoreductive surgery only. Therefore it remained 
unclear whether both cytoreductive surgery and HIPEC are indeed required for the reported 
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improvement in survival, or if the observed benefit may have been the result of one of both 
components only24. Interestingly, until recently no experimental data at all were available 
that investigated the efficacy of this treatment. 
Meanwhile, the availability and use of palliative systemic treatment for patients with 
metastasised colorectal cancer has markedly increased. The development of new 
combinations of chemotherapy regimens and additional new agents has resulted in a 
significant increase in survival in patients with metastasised colorectal cancer25-27. 
With both new surgical and medical treatment strategies available, the choice of care for 
the patient presenting with peritoneal carcinomatosis requires an individual approach, 
exploration of all options of cure and care and detailed counseling. The present colorectal 
cancer treatment guidelines that are used for treatment of patients with peritoneal 
carcinomatosis are based on results among patients with metastatic colorectal cancer in 
general. More evidence regarding the baseline characteristics of the group of patients with 
peritoneal carcinomatosis and the natural course of this disease is required, in order to 
facilitate interpretation of outcomes of new treatment strategies. Furthermore, a better 
understanding of treatment mechanisms and effectiveness of different components of 
treatment is essential for an optimal patient selection and prevention of unnecessary 
morbidity and mortality. 
Incidence & prognosis
Very little has been documented on incidence, natural course and prognosis of peritoneal 
carcinomatosis in patients with colorectal cancer. This can be explained by a lack of sensitive 
imaging tools for accurate diagnosis, and the traditional view of this condition as an end-
stage of disease. In a single hospital-based study including 2756 patients with colorectal 
cancer, 214 (8%) patients were diagnosed with synchronous peritoneal carcinomatosis and 
135 (5%) with metachronous disease6. Two older studies, also single-hospital based, reported 
10% to 15% of patients with colon cancer to present with peritoneal carcinomatosis5;28.  
Peritoneal carcinomatosis developing metachronously is reported in 4-12% of patients after 
curative resection for colon cancer and in 2-19% of patients after curative resection for 
rectal cancer29. In patients undergoing repeat procedures for colorectal cancer after primary 
curative resection, 21%-44% of patients is diagnosed with peritoneal tumour deposits30;31. In 
autopsy studies, peritoneal carcinomatosis is found in up to 40% of patients who succumb 
to colorectal carcinoma32;33. 
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The prognosis of patients with peritoneal carcinomatosis is poor, even with systemic 
treatment. In a French prospective multicenter study including 118 patients with peritoneal 
carcinomatosis of colorectal origin a median survival was reported of only 5.2 months7. 
In a large series of colorectal cancer patients presented by Jayne et al., including 392 
patients with peritoneal involvement, a median survival of 7 months was reached6. Chu 
et al. reported a median survival of 6 months in a series of 45 patients, mainly treated 
with 5-fluorouracil and leucovorin5. An analysis performed by Kohne et al. on 3825 patients 
with metastatic colorectal cancer treated with 5-fluorouracil (5-FU)-based therapy showed 
a median survival of 7.7 months in patients with peritoneal carcinomatosis34. In a phase III 
randomised controlled trial (RCT) conducted by Verwaal et al., a group of 50 patients with 
peritoneal carcinomatosis but without haematogenous metastases who were fit for surgery 
were treated with systemic chemotherapy and palliative surgery. Overall median survival 
was 12.6 months, with a 2-year survival rate of approximately 18%4;21. 
Surprisingly few studies have been published on the epidemiological and clinical features 
of this disease, and no population-based data are currently available. Yet population-based 
data are essential for the evaluation of the impact of treatment developments on survival 
outcomes of the general population. Furthermore, these data can be used to assess risk 
factor profiles and address complex questions regarding determinants of outcomes of 
disease.  
Clinical features
Deposition and growth of tumour cells on the peritoneal surface may lead to bulky 
tumours which can involve any organ in the abdomen. Preference sites for peritoneal 
implants are the omentum, mesentery, bowel surface, pouch of Douglas, right paracolic 
gutter, and diaphragm35;36. Patients initially present with aspecific symptoms like abdominal 
discomfort, nausea, weight loss, cachexia, and fatigue, which are often indistinguishable 
from more general features of malignant disease. The tumour growth on intestinal surfaces 
and associated fluid accumulation eventually result in signs of bowel obstruction37 and 
invalidating amounts of ascites. However, a considerable number of patients does not report 
any symptoms at the moment of diagnosis, especially when only small nonobstructing 
tumour implants are present without ascites. 
Diagnosis
The assessment of peritoneal tumour spread is important for the initial diagnosis and staging 
of disease as well as for the evaluation of treatment response. Quantification of tumour 
volume and registration of tumour distribution is essential for selecting those patients who 
may benefit from an aggressive surgical approach. Unfortunately, despite technological 
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developments, the accuracy of the currently available imaging techniques is far from optimal 
and radiological findings often do not correlate with surgical observations38;39. 
The sensitivity and specificity of imaging techniques like abdominopelvic ultrasound and 
computed tomography (CT) are limited for peritoneal carcinomatosis. The sensitivity is 
negatively influenced by the small size of the tumour deposits, typically well below 1 cm38;40;41, 
and the characteristic appearance of peritoneal spread that follows the outline of normal 
structures in the abdomen. Consequently, the extent of peritoneal disease is frequently 
underestimated by imaging modalities39, and the presence of peritoneal involvement often 
remains unknown until laparotomy is performed.
Laparoscopy remains the most reliable tool for the diagnosis of peritoneal carcinomatosis. 
Yet, this invasive procedure necessitates anaesthesia and is associated with a risk for 
complications. Furthermore, adhesions from prior surgery may preclude adequate 
examination and complete inspection of the abdomen42.
Thus, currently the role of diagnostic imaging in the diagnosis and evaluation of peritoneal 
tumour deposits is limited and inaccurate. However, radiologists should be aware of the 
importance of adequate preoperative assessment of peritoneal involvement and should 
be triggered to detect and describe the often subtle signs of peritoneal carcinomatosis. 
Furthermore, preoperative imaging remains essential in the evaluation of the presence of 
extraperitoneal disease and may assist surgeons in the design of cytoreductive procedures 
by revealing encasement of organs in the peritoneal tumour mass.
Treatment
Systemic treatment
Only few data have been published describing the effectiveness of systemic chemotherapy 
in this specific group of patients. Due to the lack of possibilities for accurate measurement 
and treatment response evaluation, peritoneal tumours usually do not meet the 
inclusion criteria for randomised trials. The scarce studies describing the results of 
chemotherapeutic treatment mainly review treatment with systemic 5-fluorouracil and 
leucovorin in retrospective analyses. The results of these studies invariably show a poor 
prognosis of patients with peritoneal carcinomatosis as compared to other metastatic sites, 
with disappointing results of systemic treatment. Median survival is typically around six 
months6;7;34;43;44. A few studies have aimed to describe the influence of newer combinations 
of chemotherapeutic agents, including oxaliplatin and irinotecan15;43;44. Reported results 
with these therapies are contradictive and require a careful interpretation. Many of these 
studies are carried out to compare systemic treatment with surgical treatment, which 
introduces a selection bias, only including patients in a good condition with limited extent of 
disease and without systemic metastases. The introduction of targeted therapies including 
monoclonal antibodies specifically targeted at growth factors like Epidermal Growth Factor 
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Receptor (EGFR) and Vascular Endothelial Growth Factor (VEGF) has resulted in a significant 
prolongation of overall survival in patients with metastasised colorectal cancer25;26. Although 
these agents are now routinely included in the treatment of patients with stage IV disease, 
there are no studies available at all that have evaluated the effect of these targeted therapies 
in patients with peritoneal carcinomatosis. 
Cytoreductive surgery and intraperitoneal chemotherapy
Nowadays, the surgical treatment of solitary hepatic and pulmonary metastases from 
colorectal cancer is well accepted. The observation that a subgroup of patients presents with 
peritoneal carcinomatosis in the absence of systemic metastases has led to the hypothesis 
that peritoneal carcinomatosis should be regarded as locoregional spread of disease rather 
than as systemic metastasis. This approach has encouraged surgical oncologists to explore 
possibilities for locoregional therapies. In the last two decades of the last century, new 
treatment strategies have been developed consisting of aggressive cytoreductive surgery 
and the intraperitoneal application of chemotherapy, often combined with hyperthermia.
Surgical procedures invariably start with a careful and systematic exploration of the abdomen 
and registration of the extent of peritoneal disease. The abdomen is divided in 13 regions, 
and for each region the number and size of tumour deposits is assessed and recorded. The 
sum of these scores represents the Peritoneal Cancer Index (PCI), ranging from 0-39. For 
peritoneal carcinomatosis from colorectal cancer, a PCI score of 15 or more is a generally 
accepted exclusion criterion. In the Netherlands a simplification of this score is commonly 
used (simplified PCI, sPCI) describing the involvement of 9 regions of the abdomen21. 
The PCI or sPCI is a well-known predictive factor for the outcome of patients undergoing 
cytoreductive surgery and perioperative chemotherapy45. 
During cytoreductive surgery, an attempt is made to remove all visible tumour deposits from 
the peritoneal surface. In order to achieve a radical resection, resection of grossly involved 
organs may be required. In addition, peritonectomy procedures can be performed12. The 
completeness of resection is recorded using the Completeness of Cytoreduction Score 
(CCR). A CCR-0 score indicates that no macroscopic peritoneal tumour deposits remain after 
cytoreduction. A CCR-1 score is reported in case tumour nodules less than 2.5 mm persist 
after cytoreduction. Residual disease between 2.5 mm and 2.5 cm is scored as CCR-2. A CCR-3 
score represents tumour nodules greater than 2.5 cm or a confluence of unresected tumour 
nodules at any site within the abdomen or pelvis46. An alternative scoring system is the R1-
R2a-R2b classification, in which R1 resection represents no macroscopic residual tumour, 
R2a macroscopic residual disease less than 2.5 mm, and R2b represents the situation when 
tumour deposits of more than 2.5mm are left behind21. Treatment outcome is negatively 
influenced by the presence of residual tumour after optimal cytoreduction, especially when 
the diameter of the remaining tumour mass is greater than 2.5 mm. This is thought to be the 
maximum penetration depth of chemotherapeutic agents45. 
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After macroscopically complete cytoreduction, intraperitoneal chemotherapy is given 
to eradicate microscopic disease. This chemotherapy can be administrated immediately 
following the surgical procedure in the operating room, usually combined with hyperthermia 
(hyperthermic intraperitoneal chemotherapy, HIPEC) or started from the first postoperative 
day on and be continued for 5 days (early postoperative intraperitoneal chemotherapy, EPIC). 
HIPEC perfusion may be performed with a closed abdomen, or with an open technique (also 
known as ‘coliseum technique’). Chemotherapeutic agents and doses vary widely between 
centres worldwide. In the Netherlands, HIPEC perfusion during 90 minutes is routinely 
performed with mitomycin C in a dose of 35 mg/m2 body surface (maximum dose 70 mg) at 
a temperature of 41-42°C. 
Experimental studies
Several questions remain to be answered after the completion of a randomised trial 
performed to evaluate the effect of cytoreduction and intraperitoneal chemotherapy as 
compared to systemic palliative chemotherapy using 5-fluorouracil and leucovorin21;24. 
For example, the contribution of each of the components (cytoreductive surgery and 
HIPEC) remains unknown and also the individual effects of hyperthermia and presence of 
chemotherapy. Nevertheless, the combination treatment is currently widely accepted as 
standard of care. Ideally, these questions should be addressed in future randomised trials 
but this appears to be difficult if not impossible as was demonstrated by a phase III trial in 
France which failed to reach the required number of patients due to patient dissatisfaction 
with randomisation47. Best available clinical evidence now comes from multi-institutional 
registries but this requires careful interpretation as experience of the surgeons, techniques 
and perioperative care differ between institutions. 
Animal models simulating peritoneal carcinomatosis provide an interesting alternative for 
studying separate components of treatment techniques under standardised conditions, 
allowing randomisation of treatment between homogenous groups. Surprisingly few 
experimental studies have been performed. 
Rats are the most frequently used animals in experimental studies for peritoneal 
carcinomatosis of colorectal origin. Administration of 1,2-dimethylhydrazine in syngeneic 
WAG/Rij rats results in growth of moderately differentiated colon carcinoma, known as 
CC53148;49. One week after percutaneous intraperitoneal injection of these isolated tumour 
cells in healthy rats, macroscopic tumour deposits have developed providing a validated 
and reproducible model of peritoneal carcinomatosis of colorectal origin that resembles 
the clinical situation in humans48;50. The CC531 cell line has been shown to be sensitive to 
mitomycin, making this experimental model an attractive option to study the effect of HIPEC 
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with this particular anticancer drug51. The feasibility of performing cytoreductive surgery 
has been demonstrated in this model52 and the model has been proven to be suitable for 
performance of HIPEC after cytoreductive surgery53;54.  
 
Outline of the thesis
The content of this thesis is divided into three parts. The first part aims to clarify the incidence 
and prognosis of patients with peritoneal carcinomatosis receiving palliative treatment for 
metastasised colorectal cancer. In the second part, the efficacy of cytoreductive surgery 
and HIPEC as well as the individual contribution and necessity of the separate components 
are evaluated in experimental studies, using an established animal model for peritoneal 
carcinomatosis which is suitable for the assessment of survival outcomes. The third part 
of the thesis questions some of the clinical selection criteria for cytoreductive surgery and 
perioperative intraperitoneal chemotherapy. Outcomes of different groups of patients 
undergoing cytoreductive surgery and intraperitoneal chemotherapy were evaluated by 
means of retrospective analysis of data from tertiary referral centres in the Netherlands and 
Australia. 
Part I Palliative treatment
In chapter 1, a study is presented aiming to identify predictive factors for the synchronous 
presentation with peritoneal carcinomatosis at diagnosis of primary colorectal cancer, and 
to provide incidence and survival data. For this purpose the population-based registry of the 
Eindhoven Cancer Registry was used, which covers a population of 2.4 million inhabitants in 
the South of the Netherlands, and is representative for the general Dutch population. 
By use of the same database, trends in chemotherapeutic treatment in patients with 
peritoneal carcinomatosis and the effect of treatment on population-based survival 
are evaluated and reported in chapter 2. Factors influencing the likeliness of receiving 
chemotherapy are analysed and the effectiveness of chemotherapy regimens is assessed in 
different time periods between 1995 and 2008 in the South of the Netherlands. 
Chapter 3 reports the results of a subanalysis of the CAIRO and CAIRO2 randomised control-
led trials. In these analyses the effectiveness of modern systemic combination chemotherapy 
including irinotecan, oxaliplatin and targeted agents (bevacizumab and cetuximab) were 
separately evaluated in patients with signs of peritoneal carcinomatosis and compared with 
the outcomes among patients with metastases on other locations. 
The results of palliative surgery and outcomes in terms of survival, morbidity and mortality 
are investigated in chapter 4. Different surgical approaches are compared and factors 
predicting survival are identified.
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Part II Surgical combination therapies with curative intent in experimental studies 
The second part of the thesis consists of preclinical studies investigating the necessity of 
various components of the combined surgical treatment strategies. 
The additional benefit of HIPEC after cytoreductive surgery on survival was investigated in 
an animal model for peritoneal carcinomatosis by means of a randomised controlled study. 
Results are described in chapter 5. In this experiment, animals were randomised between 
treatment with cytoreductive surgery only or cytoreductive surgery followed by HIPEC using 
two different concentrations of mitomycin. 
In chapter 6, an experimental study designed to evaluate the necessity of the separate 
elements hyperthermia and chemotherapy for the effectiveness of the HIPEC therapy as 
a whole on survival is reported. In this study, cytoreductive surgery only was compared to 
hyperthermic perfusion with chemotherapy, normothermic perfusion with chemotherapy 
and hyperthermic perfusion without chemotherapy. 
The impact on survival of the two most widely used treatment regimens for application of 
intraperitoneal chemotherapy, HIPEC and EPIC, was compared to that of treatment with 
cytoreductive surgery only in rats. The results of this experimental study are described 
in chapter 7. In addition, the effect of a combination of both therapies on survival was 
investigated. 
Part III Clinical aspects of surgical combination therapies with curative intent
The selection of patients for cytoreductive surgery and perioperative intraperitoneal 
chemotherapy remains essential for successful treatment. In chapter 8 it is investigated 
whether patients who developed intraperitoneal recurrent disease during or shortly after 
the use of adjuvant systemic chemotherapy, and thus show a relative resistance against 
systemic chemotherapy, should be eligible for local treatment with cytoreductive surgery 
and HIPEC. 
Another group of patients in which the performance of aggressive surgery is debatable is 
the group of elderly patients. The ageing population and the associated increased cancer 
incidence lead to an increased demand for oncological surgery. Outcomes of elderly patients 
(aged 70 years or older) undergoing cytoreductive surgery and perioperative intraperitoneal 
chemotherapy are described in chapter 9. 
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Despite aggressive treatment with cytoreductive surgery and intraperitoneal chemotherapy, 
a significant proportion of patients develops a peritoneal recurrence. This raises the question 
whether a second procedure consisting of cytoreductive surgery and intraperitoneal 
chemotherapy should be offered. In chapter 10, a study is described evaluating the oncologic 
efficacy and feasibility of repeat cytoreductive surgery and intraperitoneal chemotherapy 
for recurrent disease. 
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Abstract
 
Background
The aim of this study was to provide population-based data on incidence and prognosis of 
synchronous peritoneal carcinomatosis, and to evaluate predictors for its development. 
Methods
Diagnosed in 1995-2008, 18 738 cases of primary colorectal cancer were included. Predictors 
of peritoneal carcinomatosis were analyzed by multivariable logistic regression analysis. 
Median survival in months was calculated by site of metastasis. 
Results
In the study period, 904 patients were diagnosed with synchronous peritoneal carcinomatosis 
(4.8% of total, constituting 24% of patients presenting with M1 disease). The risk of 
peritoneal carcinomatosis was increased in case of advanced T-stage (T4 vs. T1,2: odds ratio 
(OR) 4.7, confidence interval 4.0-5.6), advanced N-stage (N0 vs. N1,2: OR 0.2 (0.1-0.2)), poor 
differentiation grade (OR 2.1 (1.8-2.5)), younger age (< 60 years vs. 70-79 years: OR 1.4 (1.1-
1.7)), mucinous adenocarcinoma (OR 2.0 (1.6-2.4)), and right-sided localisation of primary 
tumour (left vs. right: OR 0.6 (0.5-0.7). Median survival of patients with peritoneum as 
single site of metastasis remained dismal (1995-2001: 7 (6-9) months; 2002-2008: 8 (6-11) 
months), contrasting the improvement among patients with liver metastases (1995-2001: 8 
(7-9) months; 2002-2008: 12 (11-14) months. 
Conclusion
To conclude, synchronous peritoneal metastases from colorectal cancer are more 
frequent among younger patients, and among patients with advanced T-stage, mucinous 
adenocarcinoma, right-sided tumours, and tumours which are poorly differentiated. The 
prognosis of synchronous peritoneal carcinomatosis remains poor with a median survival of 
8 months, and even worse if concomitant metastases in other organs are present. 
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Introduction
Approximately one fourth of newly diagnosed colorectal cancer patients presents with 
disseminated disease, the liver being the most commonly affected. The recognition that 
early treatment of liver metastases may lead to a favourable outcome has resulted in 
high levels of radiological screening for synchronous liver metastases1. Consequently, the 
incidence and prognosis of patients with liver metastasis is currently well documented. 
Besides the liver, a common site of synchronous metastases is the peritoneum. Until recently, 
medical oncologists and gastrointestinal surgeons considered peritoneal carcinomatosis (the 
implantation of tumour cells throughout the peritoneal cavity2) to be a virtually untreatable 
condition, suitable for palliative measures at most. Since several years, peritoneal 
carcinomatosis regained interest because of the introduction of locoregional therapies. 
Several centres worldwide have published their experiences offering cytoreductive surgery 
combined with intra-operative intra-peritoneal chemotherapy to selected patients with 
peritoneal carcinomatosis from colorectal cancer, with promising results3-8. 
However, surprisingly few studies have been published on the epidemiological and clinical 
features of this disease; none of them on a population-based level. The best available 
data are currently derived from single or multicenter studies of at most 214 patients with 
synchronous peritoneal carcinomatosis of colorectal origin9;10. 
Therefore, the primary aim of this study including all patients diagnosed with synchronous 
peritoneal carcinomatosis of colorectal origin between 1995 and 2008 in the south of the 
Netherlands was to provide reliable population-based data on the incidence of synchronous 
peritoneal carcinomatosis related to relevant patient and tumour characteristics, and 
to identify predictors for the development of synchronous peritoneal carcinomatosis. 
Furthermore, data were provided on the prognosis of these patients, representing an era of 
evolving treatment. 
Methods
The Eindhoven Cancer Registry collects data on all patients with newly diagnosed cancer in a 
large part of the southern Netherlands, which comprises about 2.4 million inhabitants. This 
population-based registry is notified by 6 pathology departments, 10 community hospitals 
at 17 locations, and 2 radiotherapy institutions. 
Between 1995 and 2008, 18 738 cases of primary colorectal cancer (C18.0-C20.9) were 
diagnosed in the Eindhoven Cancer Registry area. Information on patient and tumour 
characteristics is routinely extracted from the medical records by specially trained 
administrators of the cancer registry. Anatomical sites of distant metastasis at time 
of diagnosis are registered according to ICD-O (International Classification of Disease 
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– Oncology). Registration takes place 6 to 12 months after diagnosis. By means of an 
independent case ascertainment method, the completeness of the registration is estimated 
to exceed 95%11. TNM-stage in this study was based upon the TNM Classification of Malignant 
tumours by the International Union Against Cancer (UICC), 6th edition12. Vital status of all 
patients diagnosed until 31st of December 2008 was assessed on 1st of January 2009 through 
merging with the Municipal Administrative Databases, where all deceased and emigrated 
persons in the Netherlands are registered. 
Statistical analyses
Incidence rates are shown as the 5-year moving average of the number of new patients 
per 100 000 inhabitants per year. The rates are age-standardised, using the European 
Standardised Rate (ESR)13. Patient and tumour characteristics of patients with different sites 
of metastases were compared and analysed using a two-sided Chi2 test. In case of unknown 
postoperative T or N stage, clinical T or N stage was used. The proportion of patients 
undergoing resection of the primary tumour, and/or cytoreductive surgery with or without 
intra-operative hyperthermic intra-peritoneal chemotherapy (HIPEC) was calculated by 
period of diagnosis (1995-2001, 2002-2005, and 2006-2008). The independent influence 
of relevant patient and tumour characteristics on the risk of presenting with peritoneal 
carcinomatosis was analysed by means of a multivariable logistic regression analysis. Crude 
survival proportions were presented up to 200 weeks (46 months) after diagnosis, for 
patients diagnosed between 1995 and 2008. Survival time was defined as the time from 
diagnosis to death; patients still alive at January 1st 2009 were censored. A log rank test was 
used to compare survival proportions between patients with different sites of metastases. 
The independent influence of relevant patient and tumour characteristics on the risk of 
death (hazard ratio) was analysed by means of a multivariable proportional hazards 
regression analyses. Median survival in months and corresponding 95% confidence interval 
were calculated by site of metastasis. All tests of statistical significance were two-sided. SAS/
STAT® statistical software (SAS system 9.1, SAS Institute, Cary, NC) was used for all analyses. 
Results
Of the 18 738 patients who were diagnosed with colorectal cancer between 1995 and 2008, 
3 817 patients (20%) were diagnosed with synchronous M1 disease (stage IV) (figure 1). 2 086 
patients had metastases confined to the liver (M1liver), 102 had synchronous lung metastases 
only, and 160 patients presented with metastases limited to one other location. The patients 
with stage IV disease included 904 patients (24%) with peritoneal carcinomatosis. Of the 
904 patients with peritoneal carcinomatosis, 395 patients (44%) had the peritoneum as the 
only site of disseminated disease (M1
PC
), while 509 patients (56%) had metastases next to 
the peritoneal carcinomatosis (M1pc+).
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3 817 patients with
synchronous
distant metastases
(stage IV)
904	patients	with
synchronous
peritoneal
carcinomatosis
395	patients	with
synchronous
peritoneal
carcinomatosis
only
509	patients	with
synchronous
peritoneal
carcinomatosis and
at least 1 metastasis 
elsewhere
2086 patients with
synchronous liver
metastasis only
102 patients with
synchronous lung
metastasis only
160 patients with a
synchronous
metastasis at a
single location
elsewhere
565 patients with
multiple sites
affected excluding
peritoneum
14 921 patients
without clinical or
pathological
evidence of
synchronous distant 
metastases
18	738	patients
diagnosed	with
colorectal cancer
1995-2008
Figure 1. Numbers of patients with colorectal cancer and synchronous metastases in the south of the 
Netherlands diagnosed between 1995 and 2008. 
The incidence of patients with newly diagnosed colorectal cancer and concurrent peritoneal 
carcinomatosis remained stable, being somewhat higher among men than among females 
(2-3 per 100 000 individuals per year, standardised for age) (figure 2). However, since 2001 
an increase among females could be noted, the incidence catching up with males in the 
most recent years.
M1
PC
 patients appeared to be somewhat older than M1pc+ patients (table 1). Forty-five 
percent of M1
PC
 patients were younger than 70 years, compared to 58% of M1pc+ patients. 
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Table 1. General characteristics of patients diagnosed with colorectal cancer between 1995 and 2008 
in the south of the Netherlands: patients with synchronous peritoneal carcinomatosis compared to 
patients with liver metastases, and no synchronous metastases.a
Synchronous 
peritoneal 
carcinomatosis 
only
Synchronous 
peritoneal 
carcinomatosis 
and 1 or more 
metastases 
elsewhere
Synchronous 
liver 
metastases 
only
No 
synchronous 
metastases
P-valueb
n (%) n (%) n (%) n (%)
Age 
  < 60 89 (23) 136 (27) 494 (24) 3125 (21)
  60-69 89 (22) 160 (31) 645 (31) 4209 (28)
  70-79 133 (34) 158 (31) 667 (32) 5057 (34)
  80+ 84 (21) 55 (11) 280 (13) 2530 (17) <0.0001
Gender
  Male 194 (49) 249 (49) 1233 (59) 7940 (53)
  Female 201 (51) 260 (51) 853 (41) 6981 (47) <0.0001
Number	of	comorbid	conditions
  0 117 (30) 191 (38) 742 (35) 4863 (35)
  1 114 (29) 140 (28) 581 (28) 4131 (28)
  2+ 101 (26) 108 (21) 550 (26) 4262 (29)
  Unknown 63 (16) 70 (14) 219 (10) 1673 (11) <0.0001
Period of diagnosis
  1995-2001 180 (46) 203 (40) 882 (42) 6459 (43)
  2002-2008 215 (54) 306 (60) 1210 (58) 8470 (57) <0.0001
Localisation	of	primary	tumour
  Colon, caecum 86 (22) 102 (20) 261 (13) 1748 (12)
  Colon, appendix 2 (0.5) 13 (3) 7 (0.3) 85 (0.6)
  Colon, ascending 60 (15) 62 (12) 184 (9) 1472 (10)
  Colon, hepatic flexure 24 (6) 29 (6) 98 (5) 564 (4)
  Colon, transverse 33 (8) 27 (5) 90 (4) 771 (5)
  Colon, splenic flexure 21 (5) 21 (4) 55 (3) 415 (3)
  Colon, descending 13 (3) 21 (4) 60 (3) 406 (3)
  Colon, sigmoid 78 (20) 122 (24) 545 (26) 3769 (25)
  Colon, overlapping, not otherwise specified 13 (3) 16 (3) 49 (2) 170 (1)
  Rectosigmoid 25 (6) 34 (7) 164 (8) 1083 (7)
  Rectum 40 (10) 62 (12) 573 (27) 4438 (30) <0.0001
T stage of primary tumour (cT in case of 
unknown	pT)
  T1 2 (0.5) 0 (0) 17 (0.8) 1304 (9)
  T2 7 (2) 2 (0.4) 74 (4) 2790 (19)
  T3 136 (34) 163 (32) 1057 (51) 8435 (57)
  T4 139 (35) 185 (36) 306 (15) 1356 (9)
  Tx 111 (28) 159 (31) 635 (30) 1033 (7) <0.0001
N stage of primary tumour (cN in case of 
unknown	pN)
  N0 70 (18) 51 (10) 414 (20) 6564 (44)
  N1 106 (27) 152 (30) 674 (32) 3321 (22)
  N2+ 71 (18) 105 (21) 369 (18) 1182 (8)
  Nx 148 (37) 201 (39) 629 (30) 3854 (26) <0.0001
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Synchronous 
peritoneal 
carcinomatosis 
only
Synchronous 
peritoneal 
carcinomatosis 
and 1 or more 
metastases 
elsewhere
Synchronous 
liver 
metastases 
only
No 
synchronous 
metastases
P-valueb
n (%) n (%) n (%) n (%)
Number of examined lymph nodes c,d
  0-6 64 (41) 81 (40) 340 (36) 4768 (44)
  7-11 24 (15) 39 (19) 256 (27) 2749 (26)
  12+ 32 (20) 35 (17) 193 (20) 2092 (19)
  Unknown 38 (24) 50 (24) 162 (17) 1167 (11) <0.0001
Number	of	positive	lymph	nodes c,d
  0 33 (21) 26 (13) 205 (22) 6222 (58)
  1-3 39 (25) 59 (29) 352 (37) 2354 (22)
  4+ 50 (32) 73 (36) 277 (29) 958 (9)
  Exact number unknown e 36 (23) 47 (23) 117 (12) 1242 (12) <0.0001
Lymph	node	ratio c,d
  0 26 (16) 21 (10) 169 (18) 5596 (52)
  0.01-0.24 12 (8) 17 (8) 146 (15) 1195 (11)
  0.25-0.49 26 (16) 20 (10) 151 (16) 827 (8)
  0.5-1 42 (27) 76 (37) 271 (29) 1001 (9)
  Unknown 52 (33) 71 (35) 214 (23) 2157 (20) <0.0001
Differentiation	grade	of	primary	tumour
  Well/moderately 151 (38) 186 (37) 1098 (53) 10118 (68)
  Poorly/undifferentiated 127 (32) 159 (31) 412 (20) 2369 (16)
  Unknown 117 (30) 164 (32) 576 (28) 2434 (16) <0.0001
Histology of primary tumour
  Adenocarcinoma, non- 
  mucinous
266 (67) 375 (74)
1787 (85) 12859 (86)
  Adenocarcinoma, 
  mucinous
105 (27) 106 (21)
155 (7) 1776 (12)
  Other/not specified 24 (6) 28 (6) 150 (7) 294 (2) <0.0001
a The ‘other’ group, consisting of patients with simultaneous liver metastases and metastases in other 
organs, and patients with metastases in other organs than those described above (N=827), is not depicted 
here for reasons of clarity.
b Chi2 test for equal proportions, the null hypothesis specifies equal proportions of the sample size for each 
class
c Excluding patients diagnosed between 1995 and 1998 since this item was not registered in that period
d Excluding patients who did not undergo resection of the primary tumour 
e Often stated in the medical file as: ‘several’ or ‘a number of’
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M1liver patients had a clear divergent gender distribution, with 59% males compared to 53% 
males among M0 patients, and 49% among M1pc+ patients. M1PC and M1pc+ patients more 
often had a right-sided primary tumour location. A T4 tumour was much more frequently 
present among M1
PC
 patients (35%) and M1pc+ patients (36%) than among M1liver patients 
(15%) or M0 patients (9%). N stage did not differ among M1 patients, but was more often 
unknown among M1
PC
 and M1pc+ patients. The number of lymph nodes examined seemed 
not be lower among M1
PC
 and M1pc+ patients who underwent resection than among M0 
patients. However, the number of positive nodes was much higher among M1
PC
 and M1pc+ 
patients, going together with a higher lymph node ratio. Differentiation grade was more 
unfavourable among M1
PC
 and M1pc+ patients. Mucinous adenocarcinoma was much more 
frequent among M1
PC
 (27%) and M1pc+ (21%) patients compared to M1liver (7%) and M0 (12%) 
patients. Only for a subset of patients, information was available on microsatellite instability 
(MSI) status (18% instable), and on the proportion of patients presenting with perforation 
(2%) and obstruction (8%) (data not shown).
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Figure 2. Trends in incidence of patients with newly diagnosed colorectal cancer and synchronous 
peritoneal carcinomatosis (n=904) between 1995 and 2008 in the south of the Netherlands (European 
Standardised Rate, 5-year moving averages).
In a multivariable logistic regression analysis, the risk of synchronous peritoneal 
carcinomatosis (including M1
PC
 and M1pc+) among patients with colorectal cancer clearly 
decreased by age (table 2). Females tended to have a higher risk, while patients with left-
sided tumours had an apparent lower risk of developing peritoneal carcinomatosis. With 
increasing T and N stage, the risk of peritoneal carcinomatosis expanded. Poor/moderately 
differentiated tumours and mucinous adenocarcinoma showed a higher risk of peritoneal 
carcinomatosis. Sensitivity analyses repeating the multivariable logistic regression analysis 
calculating the risk of peritoneal carcinomatosis only (M1
PC
) showed similar results, only 
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here there was a smaller age effect and no influence of gender (results not shown).
The proportion of patients who did not undergo resection of the primary tumour or 
cytoreduction of peritoneal metastases remained high (46% in 2006-2008); in the most 
recent period HIPEC was introduced: 11% of M1
PC
 patients underwent this procedure in 
2006-2008 (supplemental data).
Table 2. Multivariable logistic regression modelling the risk of peritoneal carcinomatosis among 
patients with colorectal cancer diagnosed between 1995 and 2008 in the south of the Netherlands.
ORb 95% CIc
Age 
  < 60 1.36 1.11-1.66
  60-69 1.14 0.94-1.37
  70-79 a 1.00
  80+ 0.65 0.52-0.81
Gender
  Male a 1.00
  Female 1.07 0.92-1.24
Period of diagnosis
  1995-2001 a 1.00
  2002-2008 1.26 1.08-1.47
Localisation	of	primary	tumour
  Right-sided tumour a 1.00
  Left-sided tumour 0.57 0.48-0.66
T	stage	of	primary	tumour	(cT	in	case	of	unknown	pT)
  T1,2 0.09 0.05-0.17
  T3 a 1.00
  T4 4.72 3.95-5.64
N stage of primary tumour (cN	in	case	of	unknown	pN)
  N0 0.17 0.13-0.23
  N1,2 a 1.00
Differentiation	grade	of	primary	tumour
  Well/ Moderately a 1.00
  Poorly/undifferentiated 2.10 1.76-2.51
Histology of primary tumour
  Adenocarcinoma, non-mucinous a 1.00
  Adenocarcinoma, mucinous 1.97 1.64-2.38
  Other/not specified 0.58 0.39-0.79
a Reference group
b Odds ratio, adjusted for all variables listed in the table
c 95% Confidence Interval
There were evident differences in survival between patients with different metastatic 
location patterns (figure 3 and table 3). Patients with liver metastases exhibited an improved 
survival in time (median survival 8 months in 1995-2001 vs. 12 months in 2002-2008). 
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Patients with peritoneal carcinomatosis (M1
PC
) had a median survival of 8 months in the 
most recent period. M1pc+ patients had a dismal prognosis of only 5 months. There was no 
improvement in time during the study period. 
The dismal prognosis of M1pc+ patients compared to M1PC patients was confirmed by 
multivariable survival (proportional hazards regression) analyses (hazard ratio 1.16, 95% 
confidence interval 1.07-1.25) (supplemental data). Furthermore, age, T stage, N stage, 
differentiation grade and histology of the primary tumour had a prognostic impact among 
patients with peritoneal carcinomatosis. 
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Figure 3. Crude survival of patients with synchronous metastatic colorectal cancer diagnosed between 
1995 and 2008 in the south of the Netherlands, by site of metastasis. 
Table 3. Median survival of patients with synchronous metastatic colorectal cancer diagnosed between 
1995 and 2008 in the south of the Netherlands, by site of metastasis and period of diagnosis.
Median survival in months (95% CI)
1995-2001 2002-2008
Peritoneal carcinomatosis only 7 (6-9) 8 (6-11)
Liver metastases only 8 (7-9) 12 (11-14)
Lung metastases only 22 (17-29) 20 (11-29)
Other distant metastases at a single location 8 (6-12) 12 (10-20)
Peritoneal carcinomatosis and ≥ 1 metastasis at other location 5 (5-8) 5 (4-7)
Other distant metastases at multiple locations 7 (6-8) 8 (7-10)
CI=Confidence Interval
Predictors and survival of synchronous peritoneal carcinomatosis
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Discussion
Despite the significant burden of peritoneal carcinomatosis in terms of incidence 
and especially mortality, very little has been documented on its clinical features and 
natural course. The present study including 904 patients with synchronous peritoneal 
carcinomatosis of colorectal origin is the largest series published to date, and unique in its 
population-based nature, representing 2.4 million inhabitants over a 14-year-period. These 
904 patients constituted nearly a quarter of all patients diagnosed with M1 disease in the 
south of the Netherlands between 1995 and 2008. They represented almost 5% of patients 
of all patients with colorectal cancer. This proportion is slightly lower than the 7% stated in 
another relatively large cohort of patients with synchronous peritoneal carcinomatosis of 
colorectal origin described in literature, a single hospital-based study which included 214 
patients9. Two older studies excluding rectal cancer reported 10% to 15% of patients with 
colon cancer to present with peritoneal carcinomatosis, which is higher than the well-over 
6% of patients with colon cancer and peritoneal carcinomatosis at initial diagnosis in our 
study, but those studies were single-hospital based series comprising selected patients14;15. 
Since peritoneal carcinomatosis is best diagnosed during an operative procedure, one might 
speculate that our population-based study may have underestimated the true incidence of 
peritoneal carcinomatosis in the population. However, in over 93% of the patients eventually 
diagnosed with non-metastasised colorectal cancer (being 97% under the age of 80) the 
peritoneal surface was explored during a surgical procedure and therefore the chance that 
patients with peritoneal carcinomatosis were missed was likely to be very small. The only 
category for which this may be partly true is the group of patients aged 80 years or older. In 
this category 86% of the patients underwent a surgical exploration as part of the treatment. 
In the remaining patients, the abdominal cavity was usually screened for peritoneal 
carcinomatosis by various imaging modalities such as CT-scanning but these studies are all 
known for their moderate 60%-79% sensitivity in diagnosing peritoneal carcinomatosis16-19. 
Indeed, patients older than 80 years exhibited a smaller risk of presenting with peritoneal 
carcinomatosis. However, this does not explain the significant higher risk of presenting with 
peritoneal carcinomatosis at a younger age, especially younger than 60 years, for which 
we do not have a straightforward explanation. Besides a correlation with younger age, 
the present study also showed a positive relation between a more advanced T-stage and 
the risk of presenting with peritoneal carcinomatosis. The highest incidence of peritoneal 
carcinomatosis is found in patients with T4 tumours, while lower T-stages contribute less 
to the incidence of peritoneal carcinomatosis. This phenomenon has been documented 
before and lends support to the hypothesis that peritoneal carcinomatosis is caused by 
serosal infiltration of the primary tumour and subsequent shedding of malignant cells into 
the peritoneal cavity2;20-23. In contrast, the risk of patients with T3 tumours compared to T4 
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tumours to present with liver metastases is more or less similar, which suggests a different 
pathophysiological mechanism. The risk to present with peritoneal carcinomatosis was also 
associated with the location of the primary tumour in the colorectal tract, with a clearly 
higher risk for right-sided tumours. This relation has not been quantified previously in peer-
reviewed literature. A possible explanation for this phenomenon may be the observation 
that, due to a longer asymptomatic period, right-sided T4 tumours are usually larger in 
diameter at the time of diagnosis than left-sided T4 tumours. Larger tumours infiltrate the 
serosal surface over a larger area which consequently may result in increased shedding 
of tumour cells into the peritoneal cavity, again confirming the previously mentioned 
pathophysiological mechanism of peritoneal carcinomatosis. Another explanation may be 
the hypothesised inherent difference in right-sided and left-sided colonic tumours caused by 
their distinct embryological origin and exposure to luminal agents, also resulting in survival 
differences24. Indeed, typical genetic differences have been found when comparing right- 
and left-sided tumours and these genotypes might result in a phenotype with a different 
likelihood to be associated with peritoneal carcinomatosis25. The higher risk of right-sided 
tumours to present with peritoneal carcinomatosis is also reflected in the age-adjusted 
incidence by sex, which showed an initially lower but more increasing incidence of peritoneal 
carcinomatosis among females over time. This can be explained by a sharply increased 
incidence of right-sided colon tumours among females in the south of the Netherlands 
within the study period26. Last but not least, mucinous adenocarcinoma was associated with 
the risk of peritoneal carcinomatosis. A negative prognostic impact of mucinous histologic 
cell type, including a lower effectiveness of oxaliplatin- and irinotecan based chemotherapy 
and a higher tendency to metastasise towards the peritoneal surface, has been described 
earlier27-29. However, once the disease has spread to the peritoneal surface, mucinous 
tumours interestingly appeared to be associated with a lower risk of death in our study.
The median survival of patients with peritoneal carcinomatosis as the only site of 
disseminated disease did not improve during the study period. The survival of 7-8 months is 
somewhat longer the median survival of 5-6 months previously reported by the two other 
studies which reported on the natural course of the disease14;21. While survival of patients 
with metastases confined to the liver was equal to that of peritoneal carcinomatosis in 1995-
2001, population-based survival of these patients rose considerably from 8 to 12 months in 
the most recent period thanks to the introduction of more efficient chemotherapeutics30. 
Patients with peritoneal carcinomatosis do not seem to benefit at population level from the 
availability of the new treatment arsenal. 
Efforts have been made to develop locoregional treatment strategies for patients with 
potentially resectable peritoneal metastases. A recent systematic review concluded that the 
current evidence suggests that radical cytoreductive surgery combined with perioperative 
intraperitoneal chemotherapy is associated with improved survival compared to systemic 
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chemotherapy alone5;31. In a consensus statement following the Society of Surgical 
Oncology Annual meeting in 2006 it was advised that all patients suffering from peritoneal 
carcinomatosis should be eligible for such treatment in whom a complete cytoreduction can 
be achieved in the absence of systemic metastases32. In our study, from 2006 onwards indeed 
a growing proportion of patients has been treated by cytoreductive surgery combined with 
perioperative intraperitoneal chemotherapy (11%). Future studies will have to monitor the 
effect of a growing proportion of patients undergoing this procedure on population-based 
survival of patients with peritoneal carcinomatosis.
The results of the present study may help to understand the natural history of the disease, 
and contribute to identifying subgroups of patients at risk of peritoneal carcinomatosis. The 
prognosis of patients suffering from peritoneal carcinomatosis remains dismal, especially 
compared to the improvements that have been reported for patients with liver metastases 
from colorectal origin. This underlines the importance of initiating studies on new treatment 
strategies for this population32-35.
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Abstract
Background
Palliative chemotherapy improves survival in patients with metastasised colorectal cancer. 
However, there is a lack of data regarding effectiveness of modern chemotherapy in patients 
with isolated peritoneal carcinomatosis (PC). 
Patients	and	methods
All patients with synchronous PC of colorectal origin diagnosed in the Eindhoven Cancer 
Registry registration area between 1995 and 2008 were included (n = 904). We assessed use 
of chemotherapy and overall survival in three time periods related to availability of different 
chemotherapy regimens. 
Results
Chemotherapy use gradually increased over time. Median survival (MS) for patients with 
PC without other metastases diagnosed in 1995–2000 was 35 weeks (95% confidence 
interval (CI) 24-43) and 34 weeks (25-54) in 2005-2008. MS in patients diagnosed with PC 
plus other metastases was 21 weeks (15-27) in 1995–2000 and 26 weeks (18-33) in 2005-
2008. In multivariable regression analysis, use of chemotherapy had a beneficial influence 
on survival only in 2005-2008. In the first two periods, chemotherapy treatment did not 
decrease the risk of death.
Conclusion
Despite increasing usage of palliative chemotherapy and availability of new agents 
population-based survival of patients with PC did not improve until very recently. Response 
to palliative chemotherapy in PC should be evaluated separately from haematogenous 
metastases.
Survival of patients with peritoneal carcinomatosis in the era of palliative chemotherapy
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Introduction
In the past two decades, chemotherapeutic treatment of patients with metastatic colorectal 
cancer has rapidly evolved. Subsequent randomised trials have defined the standard 
combination chemotherapy containing 5-fluorouracil (5-FU) derivatives together with 
oxaliplatin or irinotecan and a monoclonal antibody such as bevacizumab or cetuximab1-5. 
Several studies have reported a median survival of >20 months with these regimens, which 
implies a dramatic improvement as compared with historical series usually reporting a 
median survival of less than 6 months in untreated patients6. Therefore, palliative systemic 
chemotherapy is considered standard of care for most patients with metastatic colorectal 
cancer. 
However, in a subset of patients the beneficial effect of systemic chemotherapy remains 
questionable, the patients being diagnosed with peritoneal carcinomatosis (PC). Peritoneal 
metastases are difficult to detect by imaging techniques, and often classified as ‘non-
measurable disease’ and considered ineligible for response evaluation. As a result, these 
patients are not included in randomised studies. The sparse knowledge concerning patients 
with PC that is currently available is derived from a few non-randomised studies revealing 
that survival in the presence of PC is poor with reported median survival typically around 6 
months3;7-9. 
In spite of this lack of evidence it is entirely conceivable that in daily clinical practice patients 
suffering from PC are considered as ‘regular’ metastasised colorectal cancer patients to 
whom palliative chemotherapy should be offered. The aim of this retrospective study was to 
investigate over time in a large unselected population the usage and the effect of palliative 
chemotherapy on survival in patients with PC. 
Patients	and	Methods	
The Eindhoven Cancer Registry (ECR) maintains a population-based cancer registry in a large 
part of the south-eastern Netherlands, collecting data on all patients with newly diagnosed 
cancer in an area with approximately 2.3 million inhabitants. The ECR is notified by 6 
pathology departments, 10 community hospitals at 17 locations, and two large radiotherapy 
institutions. 
Analyses for this study were based on data of all patients diagnosed with primary colorectal 
cancer (C18.0-C20.9) in the registration area of ECR between 1995 and 2008. Specially 
trained administrators of the cancer registry routinely extract data on patient and tumour 
characteristics on the basis of information in medical files, 6 to 18 months after diagnosis. 
By means of an independent case ascertainment method, the Dutch cancer registries attain 
an estimated completeness of >95%10.
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Subsites of systemic metastasis at time of diagnosis are registered according to the 
International Classification of Diseases for Oncology. Stage of the primary tumour is 
established according to the TNM (tumour- node-metastasis) classification. In patients 
who were treated surgically, the pathological TNM system was used for stage classification. 
Otherwise, the clinical stage was used. Chemotherapy (yes versus no) was defined as 
prescription of cytostatic drugs of any kind at initial diagnosis. Three periods were separately 
analysed according to the availability of chemotherapy regimens for metastasised colorectal 
cancer. 
All colorectal cancer cases in this area have been documented in the ECR11;12. All patients 
diagnosed with primary colorectal cancer (C18.0– C18.9) between 1995 and 2008, who 
presented with synchronous peritoneal were selected from the database (n = 904). In all 
patients, follow-up of vital status was complete until January 2009. This information was 
obtained from the municipal administrative databases, in which data on all deceased and 
emigrated persons in the Netherlands are collected. 
Analyses
Trends in treatment across the three periods (1995–1999, 2000–2004, and 2005-2008) 
were analysed by means of a Cochran-Armitage trend test. Crude survival proportions were 
presented up to 60 months after diagnosis. Survival time was defined as the time from 
diagnosis to death or last follow-up date (January 2009) for patients who were still alive. 
Factors influencing the probability of receiving chemotherapy treatment were evaluated by 
multivariable logistic regression analysis. Differences between hospitals were included and 
corrected for in the analysis but are not shown in the results. 
Changes in the percentages of patients treated with chemotherapy in the hospitals were 
evaluated over time. Survival proportions of patients diagnosed with PC in different periods 
and treated with chemotherapy were compared by means of the log-rank test. Multivariable 
survival analyses, using Cox proportional hazards regression modeling, were performed to 
estimate hazard ratios (HRs) for the various patient and tumour characteristics, including 
year of diagnosis. The model was first built without treatment variable (chemotherapy yes 
versus no); this was added separately to the model to investigate the effect of therapy on 
the HR of dying according to period of diagnosis. If adjustment for chemotherapy attenuated 
this association, this would suggest that increasing chemotherapy administration had 
contributed to the reduced mortality over time. Conversely, if adjustment did not attenuate 
this association, other reasons were more likely to be responsible for reduced mortality 
over time. Median survival in weeks and corresponding 95% confidence intervals (CIs) were 
calculated. 
SAS/STAT® statistical software (SAS system 9.1, SAS Institute, Cary, NC) was used for all 
analyses. 
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Table 1. General characteristics of patients with peritoneal carcinomatosis, diagnosed between 1995 
and 2008 in the South of the Netherlands (n=904), by extent of metastatic disease.
Synchronous peritoneal 
carcinomatosis	with	or	
without	other	metastases
n (%)
Age 
  < 70 years 474 (52)
  70+ years 430 (48)
Gender
  Male 443 (49)
  Female 461 (51)
Period of diagnosis
  1995-1999 272 (30)
  2000-2004 316 (35)
  2005-2008 316 (35)
Comorbidity
  Yes 308 (34)
  No 463 (51)
  Unknown 133 (15)
Localisation	of	primary	tumour
  Caecum 188 (21)
  Appendix 15 (2)
  Colon 511 (58)
  Rectosigmoid 59 (7)
  Rectum 102 (12)
T stage of primary tumour 
(clinical	stage	in	case	of	unknown	pathological	stage)
  T1 2 (0.2)
  T2 9 (1)
  T3 299 (33)
  T4 324 (36)
  Tx 270 (30)
N stage of primary tumour 
(clinical	stage	in	case	of	unknown	pathological	stage)
  N0 155 (17)
  N1,2 434 (48)
  Nx 315 (35)
Differentiation	grade	of	primary	tumour
  Well/moderate 337 (37)
  Poorly/undifferentiated 286 (32)
  Unknown 281 (31)
Extent	of	metastatic	disease
 Peritoneal carcinomatosis only 395 (44)
 Peritoneal carcinomatosis plus 
 other metastases
509 (56)
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Results
Between 1995 and 2008, 904 patients were diagnosed with synchronous PC in the registration 
area of ECR. The age-standardised incidence of synchronous PC in patients diagnosed with 
colorectal cancer remained stable over this time period. Patient and tumour characteristics 
are shown in table 1. 
The prescription of chemotherapeutic agents increased significantly over time from 16% 
of all patients diagnosed with PC in 1995 to 46% in 2008 (p<0.0001) (figure 1). In younger 
patients (<70 years), the percentage of patients treated with chemotherapy was even 
greater, increasing from 29% of patients to 64%. In total, 292 patients (32%) of the study 
population received chemotherapy. Details are shown in table 2.
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Figure 1. Percentage of patients who received chemotherapy per period.
Several factors influenced the probability of receiving chemotherapy. In multivariable 
analysis, patients diagnosed with PC between 2000 and 2004 were more likely to receive 
chemotherapy than patients diagnosed between 1995 and 1999 (Odds Ratio (OR) 2.1, 95% 
CI 1.37-3.15, p= 0.0005). This was even more pronounced in the most recent time period 
(OR=4.3, 95% CI 2.86-6.61, p<0.0001). 
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Table 2. Percentage of patients who received chemotherapy, by period and according to a number of 
relevant patient- and tumour characteristics.
1995-1999 2000-2004 2005-2008
Total Of	which	
chemo 
Total Of	which	
chemo 
Total Of	which	
chemo 
n (%) n (%) n (%)
Overall 272 21% 316 32% 316 43%
Age
  <70 years 151 29% 174 48% 149 64%
  70+ years 121 10%** 142 12%** 167 25%**
Gender
  Male 137 27% 160 36% 146 48%
  Female 135 14%* 156 27% 170 39%
Comorbiditya
  No 114 26% 95 45% 99 56%
  Yes 123 15%* 167 26%* 173 36%
Extent	of	metastatic	disease
  Peritoneal carcinomatosis only 137 18% 134 25% 124 35%
  Peritoneal carcinomatosis plus 
  other metastases
135 23% 182 36%* 192 48%
a Comorbidity unknown for 13%, 17%, and 14% of patients in the respective periods.
* P-value of Chi2 test (within period) <0.05
** P-value of Chi2 test (within period) <0.0001
Furthermore, patients diagnosed with rectal cancer were more often treated with 
chemotherapy (OR=1.6, 95% CI 1.05-2.39, p=0.03). Characteristics decreasing the probability 
of receiving chemotherapy treatment were older age (>70 years) (OR=0.2, 95% CI 0.15-0.30, 
p<0·0001), presence of comorbidities (OR=0.6, 95% CI 0.45-0.91, p=0.01), and female gender 
(OR=0.7, 95% CI 0.52-0.99, p=0.04) (table 3). Palliative surgery remained constant over time. 
(59% in 1995-1998 to 53% in 2003-2007, p=0.4). Cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy (HIPEC) for PC was introduced in the ECR registration area in 
2006. Between 2006 and 2008, 10 patients out of the presented population were treated 
with cytoreductive surgery and HIPEC.  
Overall survival of the total population of patients with PC did not increase significantly over 
time (table 4). However, a trend towards improvement in survival up to 66 weeks (95% CI 57-
91) was seen in patients treated with palliative systemic chemotherapy between 2005 and 
2008 (p=0.064). Crude survival curves of patients treated with and without chemotherapy 
in the three different time periods are shown in figure 2. 
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Table 3. Multivariable logistic regression analysis modelling the chance of treatment with 
chemotherapy among patients with colorectal cancer and synchronous peritoneal carcinomatosis, 
diagnosed between 1995 and 2008 in the south of the Netherlands. 
OR 95% CI P value
Age
  < 70 yearsa 1.0
  70+ years 0.2 0.15-0.30 <.0001
Gender
  Malesa 1.0  
  Females 0.7 0.52-0.99 0.04
Period of diagnosis
  1995-1999a 1.0   
  2000-2004 2.1 1.37-3.15 0.0005
  2005-2008 4.3 2.86-6.61 <.0001
Comorbidity
  Noa 1.0   
  Yes 0.6 0.45-0.91 0.01
Localisation
  Colon (incl. caecum and appendix)a 1.0   
  Rectum (incl. rectosigmoid) 1.6 1.05-2.39 0.03
T stage
  T1-2 1.0 0.22-4.52 0.9
  T3a 1.0   
  T4 1.0 0.72-1.39 0.9
N stage
  N0 0.9 0.53-1.39 0.5
  N1,2a 1.0   
Differentiation	grade	of	primary	tumour
  Well/moderatelya 1.0   
  Poorly/undifferentiated 0.8 0.54-1.08 0.1
Resection	of	primary	tumour
  Noa 1.0   
  Yes 1.3 0.91-1.85 0.1
Extent	of	metastatic	disease
  Peritoneal carcinomatosis onlya 1.0   
  Peritoneal carcinomatosis plus other metastases 1.4 0.99-1.88 0.06
Data are adjusted for all variables listed and differences between treatment hospitals. 
OR=odds ratio
CI=Confidence Interval
a Reference category
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Table 4. Median survival (in weeks) of patients with peritoneal carcinomatosis (n = 904), according to 
extent of disease and period.
1995-1999 2000-2004 2005-2008
n Survival	in	weeks	
(95% CI)
n Survival	in	weeks	
(95% CI)
n Survival	in	weeks	
(95% CI)
Overall 272 26 (20-33) 316 24 (19-30) 316 28 (22-36)
Chemotherapy
 Yes 56 52 (39-75) 100 50 (42-62) 136 66 (57-91)
 No 216 21 (16-27) 216 14 (11-17) 180 11 (8-15)
Age
 < 70 years 151 29 (22-39) 174 31 (27-39) 149 59 (48-72)
 70+ years 121 22 (18-34) 142 16 (11-21) 167 17 (12-21)
Gender
  Male 137 32 (22-41) 160 24 (17-31) 146 30 (21-47)
  Female 135 23 (18-28) 156 23 (17-34) 170 26 (19-35)
Comorbidity
  No 114 31 (22-41) 95 31 (23-39) 99 47 (28-69)
  Yes 123 22 (16-34) 167 19 (16-29) 173 25 (18-32)
Sites of metastases
  PC only 137 35 (24-43) 134 31 (19-43) 124 34 (25-54)
  PC plus other metastases 135 21 (15-27) 182 22 (17-28) 192 26 (18-33)
CI = Confidence Interval
PC = peritoneal carcinomatosis
Multivariable proportional hazards regression analysis modelling the risk of death for 
patients with colorectal cancer and synchronous PC is shown in table 5. A beneficial 
influence of time period on the risk of dying was observed in favour of patients diagnosed 
between 2005-2008 as compared with both earlier periods of time (HR 0.8, CI 0.64-0.92, 
p=0.004). The difference was not observed any more after adjusting for chemotherapy 
treatment. Comparison of the first two periods of time showed an equal risk of dying among 
patients with PC independent of chemotherapy treatment. Other beneficial prognostic 
factors identified by multivariable analysis were younger age (<70 years), absence of lymph 
node metastases, well or moderate differentiation grade of the primary tumour, and the 
performance of palliative surgery. 
PC was the only site of metastasis in 395 patients in this population (44%). This group 
showed a higher median survival than patients with PC and additional other metastases in 
all time periods. 
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Figure 2a. Crude survival of patients with peritoneal carcinomatosis not treated with chemotherapy, 
according to period of diagnosis. 
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Figure 2b. Crude survival of patients with peritoneal carcinomatosis treated with chemotherapy, 
according to period of diagnosis.
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Table 5. Multivariable proportional hazards regression analysis modelling the risk of death for patients 
with colorectal cancer and synchronous peritoneal carcinomatosis, diagnosed between 1995 and 2008 
in the South of the Netherlands. Data are adjusted for all variables listed and differences between 
treatment hospitals. 
HR 95% CI P value
Age
  < 70 yearsa 1.0
  70+ years 1.3 1.10-1.85 0.002
Gender
  Malesa 1.0  
  Females 1.0 0.86-1.14 0.8
Period of diagnosis
  1995-1999a 1.0   
  2000-2004 1.1 0.92-1.29 0.3
  2005-2008 1.0 0.83-1.20 0.9
Comorbidity
  Noa 1.0   
  Yes 1.0 0.87-1.20 0.8
Localisation
  Colon (incl. caecum and appendix)a 1.0   
  Rectum (incl. rectosigmoid) 0.9 0.76-1.11 0.4
T stage
  T1-2 1.1 0.59-2.11 0.7
  T3a 1.0   
  T4 1.0 0.88-1.18 0.8
N stage
  N0 0.6 0.51-0.79 <0.0001
  N1,2 a 1.0   
Differentiation	grade	of	primary	tumour
  Well/moderatelya 1.0   
  Poorly/undifferentiated 1.4 1.17-1.58 <0.0001
Resection	of	primary	tumour
  Noa 1.0   
  Yes 0.5 0.41-0.57 <0.0001
Extent	of	metastatic	disease
  Peritoneal carcinomatosis onlya 1.0   
  Peritoneal carcinomatosis plus other metastases 1.2 1.15-1.33 <0.0001
Chemotherapy
  Yes 0.4 0.34-0.47 <0.0001
  Noa 1.0
HR=hazard ratio
CI=Confidence Interval
a Reference category
Without adjustment for ‘chemotherapy’: period of diagnosis 2000-2004 HR 1.0 (CL 0.83-1.17, p=0.9); 
2005-2008 HR 0.8 (CL 0.64-0.92, p=0.004). 
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Figure 3a. Crude survival of patients with peritoneal carcinomatosis only, not treated with 
chemotherapy, according to period of diagnosis. 
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Figure 3b. Crude survival of patients with peritoneal carcinomatosis and other metastases, not treated 
with chemotherapy, according to period of diagnosis.
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Figure 3c. Crude survival of patients with peritoneal carcinomatosis only, treated with chemotherapy, 
according to period of diagnosis.
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Figure 3d. Crude survival of patients with peritoneal carcinomatosis and other metastases, treated 
with chemotherapy, according to period of diagnosis.
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Figure 4a. Crude survival of patients with synchronous liver metastases, not treated with chemotherapy, 
according to period of diagnosis.
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Figure 4b. Crude survival of pati nt  with synchronous liver metastases, treated with chemotherapy, 
according to period of diagnosis.
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Separate crude survival curves of patients with and without systemic metastasis in addition 
to PC are shown in figure 3, according to treatment with systemic palliative chemotherapy. 
As a comparison, survival data of patients with synchronous liver metastases as the only 
site of metastatic disease treated with chemotherapy in the same area and time interval 
were studied (figure 4). In this analysis, patients who underwent liver resection for their 
metastases were excluded. In these patients, an evident increase in survival was seen over 
time (p = 0.0016), in contrast to survival of patients with PC. Survival of patients with liver 
metastases who were treated with chemotherapy increased in each period of time, whereas 
survival of patients with PC remained stable between 1995 and 2004.  
Discussion
The peritoneal surface is a common site of metastasis in patients with colorectal cancer, 
occurring in 13% of patients8. PC has long been considered to be an incurable condition, 
with a poor prognosis with a median survival of approximately 6 months8;9;11.
Although the favourable effect of modern chemotherapy treatment on the survival of 
patients with metastatic disease in general has been well described, it remains unclear 
whether these systemic therapies have the same beneficial impact on the outcomes 
of the subset of patients diagnosed with PC. In recent years, the systemic treatment of 
metastasised colorectal cancer has rapidly evolved with the addition of oxaliplatin or 
irinotecan to 5-FU-based chemotherapy regimens2;13;14. New insights in carcinogenesis 
and angiogenesis contributed to the development of increasingly targeted and potentially 
more effective combinations of systemic treatment including agents like cetuximab and 
bevacizumab, resulting in a median survival of more than 20 months15-17. For this reason, 
systemic chemotherapy is now offered to an increasing number of patients with stage IV 
colorectal cancer, and this study shows that also in patients with PC, systemic chemotherapy 
use has significantly increased over time, from 21% in the period 1995-1999 to 43% in 
the period 2005-2008. Especially in patients <70 years, the prescription of chemotherapy 
increased: in the recent years, chemotherapy was used in 64% of the patients. 
5-FU-based chemotherapy was the mainstay of treatment in the first two periods. Despite a 
significant increase in the use of chemotherapy over the two time periods, survival did not 
improve in this large unselected population. The most recent time period evaluated in this 
study (2005-2008) reflects a time in which combination therapies including oxaliplatin or 
irinotecan in combination with a monoclonal antibody like cetuximab or bevacizumab were 
introduced and became standard of care in the Netherlands. In the present study, including 
a large population of 904 patients, a trend in improvement in overall survival was observed 
in the period 2005-2008 in comparison with the two earlier periods. Data from small 
pooled analyses also suggest that patients with PC may profit from addition of irinotecan 
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and oxaliplatin to 5-FU based chemotherapy treatment18;19. Although this benefit may be 
partially explained by patient selection, this observation strengthens the evidence for an 
effect of modern combination chemotherapy treatment on survival in patients with PC. 
In this study population, a marked difference in survival is seen between patients treated with 
or without systemic chemotherapy in all time periods in favour of chemotherapy treatment. 
The selection of patients receiving chemotherapy is mainly based on performance status, 
which indicates tumour load and co-morbidities. The observation that overall survival of 
patients who were not treated with chemotherapy in the last period of time has decreased 
to 11 weeks, even though more patients have been offered chemotherapy treatment, 
indicates a beneficial effect of palliative chemotherapy which cannot be explained by patient 
selection. Still, the effect is less pronounced than the effects observed in other localisations of 
metastatic disease like liver metastasis, and even with effective chemotherapy the prognosis 
of patients with PC remains worse than that of patients with metastases elsewehere20. 
There is no clear explanation for this observation. Yet, it might indicate that PC should be 
evaluated separately from systemic metastases. New insights in biological mechanisms 
cancer dissemination and the pathophysiology of PC from colorectal origin contributed to the 
understanding that PC can be regarded as a local-regional extension of disease, rather than 
a manifestation of systemic metastasis21-25. Furthermore, it has been suggested that gene 
expression patterns in the primary tumour determine not only the metastatic potential and 
the occurrence of peritoneal dissemination of colorectal cancer cells23;25;26 but also variation 
in response to treatment with chemotherapeutic agents27. According to this hypothesis, 
gene expression in peritoneal disseminated cells may differ from expression patterns in 
metastases localised elsewhere, thereby modulating the sensitivity and response of tumour 
cells to different kinds of systemic administrated chemotherapy. In addition, it is known 
that the microenvironment at the site of metastasis affects molecular and cellular aspects 
of tumour growth28. Interactions between cancer cells and the peritoneum may differ from 
those involved in hematogenous and lymphogenous spread and thereby react differently to 
the available chemostatic agents. From the results of the current study, it may be postulated 
that PC (as opposed to, e.g. liver metastases) is not sensitive to 5-FU monotherapy, while 
modern chemotherapy schedules seem more effective. 
The notion that a subgroup of patients presents with isolated intraperitoneal metastases 
without evidence of systemic disease contributed to the development of new locoregional 
treatment strategies consisting of cytoreductive surgery and HIPEC. In selected patients, this 
aggressive surgical approach combined with HIPEC results in a significant survival benefit29. 
Unfortunately, only a small and highly selected group of patients with limited disease 
confined to the peritoneal cavity is eligible for this treatment and so most patients suffering 
from PC are dependent on palliative surgery and/or systemic treatment. 
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The results of this study support the rationale for palliative treatment with the best 
available systemic chemotherapy schedules for patients with PC who do not meet the 
inclusion criteria for cytoreductive surgery and HIPEC. Still, the prognosis of patients with 
PC is worse than that of patients with other sites of metastases, even with the availability 
of more potent chemotherapy regimens. Future research should focus on developing the 
optimal combination of palliative chemotherapy regimens for patients suffering from PC of 
colorectal origin. 
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Abstract
Background 
Although systemic therapies have shown to result in a survival benefit in patients with 
metastatic colorectal cancer (mCRC), the outcome of this treatment in patients with 
peritoneal carcinomatosis (PC) is poor. No data are available on the outcome of current 
chemotherapy schedules plus targeted agents in mCRC patients with PC. We evaluated the 
efficacy and toxicity in mCRC patients with PC receiving systemic treatment in two phase III 
studies (CAIRO and CAIRO2). 
Methods  
Previously untreated mCRC patients treated with chemotherapy in the CAIRO study and 
with chemotherapy and targeted therapy in the CAIRO2 study were included in this analysis, 
and retrospectively analysed according to the presence or absence of PC at randomisation. 
Patient demographics, primary tumour characteristics, progression free survival (PFS) and 
overall survival (OS), and occurrence of toxicity were evaluated. 
Results 
Thirty-four patients with PC were identified in the CAIRO study, and 47 patients in the 
CAIRO2 study. In the CAIRO2 study patients with PC more often had a WHO classification 
1 than patients without PC. No other differences in baseline patient characteristics were 
observed between patients with and without PC. 
The median OS was significantly decreased for patients with PC compared with patients 
without PC, with 10.4 versus 17.3 months, respectively in the CAIRO study (p≤0.001) and 
15.2 versus 20.7 months, respectively, in the CAIRO2 study (p<0.001).
The median number of treatment cycles did not differ between patients with or without 
PC in both studies. The occurrence of major toxicity was more frequent in patients with PC 
treated with sequential chemotherapy in the CAIRO study as compared to patients without 
PC. However this was not reflected in the reasons to discontinue treatment in this study 
arm. In the CAIRO2 study, no differences in the occurrence of major toxicity were observed 
between patients with or without PC.  
Conclusion 
Our data demonstrate a decreased efficacy of the current standard chemotherapy with and 
without targeted agents in mCRC patients with PC. The median number of treatment cycles 
did not differ between patients with and without PC. This suggests that the poor outcome 
of these patients cannot be explained by undertreatment or increased susceptibility to 
toxicity, but rather by a relative resistance to treatment.
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Introduction	
Peritoneal carcinomatosis (PC) is frequently observed in patients with colorectal cancer and 
is notorious for its poor prognosis1-3. PC is found in approximately 5% of patients diagnosed 
with colorectal cancer, representing 24% of patients with synchronous metastasis at the 
time of diagnosis4. Another 8% of colorectal cancer patients develops PC during their course 
of disease1. 
Peritoneal spread is present in up to 15% of patients included in randomised trials 
investigating new palliative systemic treatment strategies for metastatic colorectal cancer 
(mCRC)5-9. Yet little is known about the effects of modern chemotherapy treatment and 
the effect of targeted agents in patients with PC, in contrast to patients with hepatic or 
pulmonary metastases10. 
There are no randomised trials evaluating the effect of systemic treatment in patients with 
PC. In retrospective studies investigating clinical determinants of outcome in patients with 
mCRC treated with chemotherapy, the presence of PC appears to be a negative prognostic 
factor11;12. Possible explanations for the reported poor median survival outcomes of 
patients with PC from these retrospective studies1;3;12-14 include an increased susceptibility 
to chemotherapy-induced toxicity causing an early discontinuation of treatment, or an 
unfavourable biological profile of tumours spreading to the peritoneal cavity. However, 
detailed data are scarce and no clear explanation is currently available. The chemotherapy 
regimens used in these studies mainly concern 5-fluorouracil and leucovorin (5-FU/LV), 
which was the standard of care at that time. With the development of novel cytotoxic 
agents and targeted antibodies the systemic treatment has changed over the years, and 
its outcome has significantly improved15;16. Therefore we analysed the outcome of mCRC 
patients with PC treated with current standard systemic treatments. 
Methods  
Patients
Data were obtained from mCRC patients enrolled in two phase III studies of the Dutch 
Colorectal Cancer Group (DCCG). In the CAIRO study17;18, 820 patients were randomised 
between sequential treatment (first-line: capecitabine, second-line: irinotecan, and third-
line: oxaliplatin plus capecitabine, arm A) and combination treatment (first-line: irinotecan 
plus capecitabine, second-line: oxaliplatin plus capecitabine, arm B) (ClinicalTrials.
gov NCT00312000). In the CAIRO2 study19;20, 755 patients were randomised between 
capecitabine, oxaliplatin, and bevacizumab (CB regimen), and the same regimen plus weekly 
cetuximab (CBC regimen) (ClinicalTrials.gov NCT00208546). 
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Eligibility criteria of both randomised trials were: age >18 years, histologically proven 
diagnosis of colon or rectum carcinoma, presence of metastatic disease not amendable 
to curative surgery, measurable or assessable disease parameters, no previous systemic 
chemotherapy for metastatic disease, World Health Organization (WHO) performance 
status 0-2 (CAIRO) or 0-1 (CAIRO2), and adequate bone marrow, liver and renal function. 
Tumour response was assessed every 3 cycles (9 weeks) according to Response Evaluation 
Criteria in Solid Tumours (RECIST) criteria21. 
For the current analysis patients were analysed according to the presence of PC at 
randomisation. Presence of PC was defined as reported presence of PC at previous 
laparotomy, the presence of ascites, or documented peritoneal tumour deposits by CT 
scanning at randomisation.
Statistical	analysis
Overall survival (OS) and progression-free survival (PFS) were determined according to the 
methods described in the original study reports17-20 and were estimated using the Kaplan–
Meier method and compared with the log-rank test. The comparison of baseline patient 
characteristics between patients with and without PC was done using Wilcoxon’s rank sum 
test or Chi square test where appropriate. 
SAS 8.2 software was used for the analyses. All tests were two-sided and P-values of less 
than 0.05 were considered statistically significant. 
Results
Baseline	patient	characteristics
In total, 803 eligible patients were enrolled in the in the CAIRO study and 736 patients in 
the CAIRO2 study. Thirty-four patients (4%) with PC at randomisation were identified in 
the CAIRO study cohort and 47 patients (6%) in the CAIRO2 study cohort. Baseline patient 
characteristics are shown in Table 1. In the CAIRO2 study patients with PC more often had a 
WHO performance status of 1 than patients without PC (as compared to WHO performance 
status 0). There were no other differences in patient characteristics between the patients 
with and without PC. 
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Table 1. Patient characteristics.
CAIRO CAIRO2
No PC PC No PC PC
n (%) n (%) P value n (%) n (%) P value
Overall 769 34 689 47
Mean age (SD) 62.5 (9.5) 60.6 (13.0) 0.500 61.9 (9.4) 59.6 (10.0) 0.133
Female 283 (37) 13 (38) 0.857 276 (40) 21(45) 0.532
WHO performance score
0.397  0.021
0 481 (63) 20 (59) 438 (64) 22 (47)
1 257 (33) 11(32) 250 (36) 25(53)
2 31 (4) 3 (9)
Prior adjuvant therapy
0.175 0.307Yes 107 (14) 4 (4) 95 (14) 9 (81)
No 662 (86) 30 (88) 594 (86) 38 (20)
No	of	organs	affected
0.0511 242 (35) 10 (21)
>1 445 (65) 37 (79)
Site of primary tumour
0.722 0.863
Colon 451 (59) 27 (79) 273 (45) 21 (48)
Rectum 255 (33) 5 (15) 172 (28) 11 (26)
Rectosigmoid 58 (8) 2 (6) 167 (27) 11 (26)
Multiple tumours 4 (1) 0 (0) 0 (0) 0 (0)
LDH
0.406 0.937
Normal 489 (64) 24 (71) 383 (56) 26 (55)
>UNL 280 (36) 10 (29) 302 (44) 21 (45)
Unknown 4
Primary tumour in situ
0.717 0.859
No 161 (21) 8 (24) 542 (79) 36 (77)
Yes 608 (79) 26 (74) 141 (20) 10 (21)
Unknown 6 (1) 1 (2)
Site of metastasis
PC only 4 (12) 5 (11)
PC plus other sites 30 (88) 42 (89)
UNL = Upper Normal Limit
Survival and toxicity outcomes 
CAIRO 
The median OS was significantly decreased for patients with PC compared to patients 
without PC, with 10.4 versus 17.3 months (p=<0.001) respectively. Kaplan Meier survival 
curves are shown in Figure 1. These differences were maintained when data were analysed 
per treatment arm. Detailed results on outcome are shown in Table 2. 
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Table 2. Overall survival (OS) and progression-free survival (PFS) of patients with and without PC in the 
CAIRO and CAIRO2 studies.
No PC PC P value
(PC vs. no PC) 
Median 
survival 
(months)
95% CI Median 
survival 
(months)
95% CI
CAIRO 
OS Arm A: Sequential chemotherapy 16.8 14.8-18.5 10.4 5.7-12.0 <0.001
Arm B: Combination chemotherapy 17.9 15.4-19.3 7.8 5.3-11.8 0.001
PFS Arm A: Sequential chemotherapy 5.8 5.1-6.3 4.6 3.2-6.0 0.044
Arm B: Combination chemotherapy 7.7 7.0-8.3 5.7 2.0-9.9 0.301
CAIRO2
OS Arm A: CB 21.4 18.9-24.8 15.2 7.2-17.9 0.002
Arm B: CBC 20.4 18.4-21.7 13.9 10.2-20.2 0.035
PFS Arm A: CB 10.8 9.8-12.5 6.6 5.3-12.8 0.048
Arm B: CBC 9.7 8.6-10.7 7.2 6.2-10.3 0.028
95% CI = 95% Confidence Interval
CB = Capecitabine + Oxaliplatin + Bevacizumab
CBC = Capecitabine + Oxaliplatin + Bevacizumab + Cetuximab
No significant differences in OS were observed between treatment arms for patients with 
PC (Arm A vs. Arm B, p =0.5499). In the sequential treatment arm patients with PC had 
a decreased median PFS on first-line treatment as compared to patients without PC (4.6 
months vs. 5.8 months, respectively, p=0.0443). 
The median number of treatment cycles given in the first line of treatment did not differ 
between patients with or without PC (Table 3a). In the combination arm, the occurrence 
of grade 3 or 4 toxicity did not differ between patients with and without PC (75% vs. 59% 
respectively, p=0.19). In the sequential arm major toxicity was observed in 67% of the 
patients with PC and in 43% of patients without PC (p=0.0489). This higher incidence of 
grade 3 or 4 toxicity was not reflected in the reason to discontinue treatment. 
In the combination arm, the most frequent reason to discontinue treatment was no further 
believed benefit or a poor performance status in patients with PC, and progression in 
patients without PC. In the sequential arm, acknowledgement of no further benefit was 
the main reason to discontinue treatment in both patients with and without PC (Table 3a). 
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CAIRO2 
OS of patients with PC treated in the CAIRO2 study was significantly decreased as compared 
to the OS of patients without PC (15.2 vs. 20.7 months, respectively (p<0.001). Kaplan Meier 
survival curves are shown in Figure 2. PFS was also significantly decreased in patients with 
PC as compared to patients without PC in both treatment arms. These differences were 
maintained when data were analysed per treatment arm (table 2).
No significant differences in OS were observed between treatment arms for patients with 
PC (Arm A vs. Arm B, p =0.981).
No differences were observed in the median number of cycles given. A summary of the 
main reasons for discontinuation of treatment is shown in Table 3b. Progression of disease 
was the most frequently reported reason for discontinuation of therapy in both treatment 
arms for patients with and without PC (75% vs. 55% in arm A, and 64 vs. 49 % in arm B, 
respectively). 
The incidence of grade 3-4 toxicity in both treatment arms did not differ between the 
patients with and without PC (40% vs. 24 % in the CB arm p=0.073 and 77% vs. 84% in the 
CBC arm, p=0.400), respectively).
1.0
0.8
0.6
0.4
0.2
0.0
+
0               20             40            60
+ Censored
Overall Survival (Months)
+
+
+
+
+
++
+
++++++++ ++ ++ ++++++++++++++++ +++ ++++++ ++ + + +
Figure 1. Kaplan-Meier curve for overall survival of metastatic CRC with and without PC at time of 
inclusion in the CAIRO trial.  
           Patients without PC. 
           Patients with PC
Median overall survival was 10.4 months for patients with PC versus 17.3 months in patients without 
PC (p≤0.001).  
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Table 3a. Number of treatment cycles given during the first line of treatment and primary reasons for 
treatment discontinuation for patients in the CAIRO trial, by treatment arm and presence of PC. 
Arm	A:	Sequential	chemotherapy	
arm
Arm	B:	Combination	chemotherapy	
arm
No PC PC P value
(PC vs. no PC)
No PC PC P value
(PC vs. no pc)
Number of treatment cycles 
given in 1st line of treatment
median 
(range)
median 
(range)
median 
(range)
median 
(range)
6.0 (0-53) 6.0 (1-14) 0.158 7.0 (0-42) 6.5 (1-18) 0.918
Reasons for treatment 
discontinuation
n (%) n (%)
0.873
n (%) n (%)
0.008
Progression 103 (27) 3 (17) 134 (35) 2 (13)
Toxicity 51 (13) 4 (22) 91 (24) 1 (6)
Patients refusal 46 (12) 2 (11) 40 (10) 3 (19)
Intercurrent death 32 (8) 3 (17) 25 (6) 2 (13)
Major protocol violation 3 (1) 0 (0) 2 (1) 0 (0)
No further benefit/poor 
performance status/other illness
107 (28) 5 (28) 53 (14) 5 (31)
Resection of metastases 2 (1) 0 (0) 8 (2) 0 (0)
Other 30 (8) 1 (6) 28 (7) 1 (6)
Missing data 0 (0) 0 (0) 5 (1) 2 (13)
Table 3b. Number of treatment cycles given and primary reasons for treatment discontinuation for 
patients in the CAIRO2 trial, by treatment arm and presence of PC. 
Arm A: CB Arm B: CBC 
No PC PC p value 
(PC vs. no PC)
No PC PC p value 
(PC vs. no PC)
Number of treatment cycles 
given 
median 
(range)
median 
(range)
median 
(range)
median 
(range)
9.0 (9-48) 8.5 (3-24) 0.388 9.0 (1-52) 9.0 (0-34) 0.732
Reasons for treatment 
discontinuation
n (%) n (%)
0.606
n (%) n (%)
0.571
Progression 175 (55) 18 (75) 164 (49) 14(64)
Toxicity 76 (24)
18 (6)
4 (17) 92 (28) 5 (23)
Patient refusal 0 (0) 17 (5) 2 (9)
Intercurrent death 7 (2) 0 (0) 2 (1) 0 (0)
Major protocol violation 2 (1) 0 (0) 12 (4) 1 (5)
Lost to follow-up 1 (0) 0 (0) 1 (0) 0 (0)
Other 40 (13) 2 (8) 44 (13) 0 (0)
Missing data 24 (7) 1 (0) 14 (4) 0 (0)
CB = Capecitabine + Oxaliplatin + Bevacizumab
CBC = Capecitabine + Oxaliplatin + Bevacizumab + Cetuximab
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Figure 2. Kaplan-Meier curve for overall survival of metastatic CRC with and without PC at time of 
inclusion in the CAIRO2 trial. 
           Patients without PC. 
           Patients with PC
Median overall survival was 15.2 months for patients with PC versus 20.7 months in patients without 
PC (p≤0.001).  
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Discussion 
We demonstrate that with the currently available standard systemic regimens the 
outcome for mCRC patients with PC remains poor as compared to patients without PC. 
The results of our analysis suggest an improved outcome in mCRC patients with PC when 
targeted agents are used, as the median OS of patients in the CAIRO2 study is longer 
than the median OS in the CAIRO study. However a formal comparison between the trials 
cannot be made due to differences in patient selection criteria, and caution is warranted 
with cross-study comparisons. Our data do not support inadequate treatment due to an 
increased susceptibility to systemic treatment-induced toxicity as an explanation for the 
poor outcome in mCRC patients with PC. Therefore a difference in biological behaviour of 
tumours spreading to the peritoneal cavity is more likely.
In the 1980s new treatment strategies have been introduced for patients presenting with PC 
in the absence of systemic metastases. These treatment strategies combine an aggressive 
surgical cytoreduction with the application of intraperitoneal chemotherapy, usually under 
hyperthermic conditions. In a randomised trial, the performance of cytoreductive surgery 
and hyperthermic intraperitoneal chemotherapy (HIPEC) has shown to result in a significant 
survival benefit as compared to systemic chemotherapy treatment with 5-fluorouracil/
leucovorin22. With the availability of novel chemotherapy regimens and targeted therapies, 
it may be questioned whether an aggressive surgical approach still prolongs survival as 
compared to systemic treatment. 
Another explanation for the scarce availability of data on outcomes of PC patients treated 
with chemotherapy is the lack of diagnostic tools. Despite technological developments, 
the accuracy of the currently available imaging techniques is insufficient for quantifying 
peritoneal tumour deposits. The small size of the tumour deposits, typically well below 
1 cm, and the characteristic appearance of peritoneal spread that layers the outline of 
normal structures in the abdomen negatively influences the sensitivity of abdominopelvic 
ultrasound and CT-scans23-25. Consequently, radiological findings often do not correlate with 
observations during surgery26. 
This also implies that a number of patients in the present study who were included in the 
group without macroscopic PC may have had peritoneal tumour deposits which have not 
been identified with radiological examination.
Furthermore, since peritoneal lesions are usually qualified as “non-measurable disease”, 
patients do not meet the inclusion criteria for response evaluation in randomised trials 
evaluating systemic treatment. 
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In conclusion, this subanalysis of two randomised controlled trials demonstrates a negative 
impact of the presence of PC on overall and progression-free survival in patients treated 
with currently available palliative chemotherapy with or without targeted therapy for mCRC. 
This study also suggests that the observed effect cannot be explained by undertreatment 
or increased susceptibility to toxicity. With the availability of both surgical and medical 
treatment options in this group of patients, a careful consideration of all options and an 
individual approach for each patient should be advocated. Further research should provide 
explanations for the different biologic behaviour of PC, and novel treatment approaches are 
warranted to improve the outcome in this subgroup of patients. 
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Abstract
Background
The detection of peritoneal carcinomatosis (PC) in colorectal cancer patients frequently 
results in a dilemma with regard to the optimal treatment strategy, especially when PC 
is encountered unexpectedly. Aim of this study was to evaluate outcomes of patients 
undergoing palliative surgery for colorectal carcinoma with synchronous PC. 
Patients	and	methods
Patients diagnosed with primary colorectal cancer and synchronous PC in three community 
hospitals were selected from the Eindhoven Cancer Registry database. Outcomes on post-
operative complications, in-hospital mortality and overall survival were analysed according 
to the type of intervention performed. 
Results
Between 1995 and 2009, 169 colorectal cancer patients were diagnosed with synchronous 
PC. Surgery was performed in 142 patients. PC was encountered unexpectedly in 130 
patients. Median survival was 14 weeks without surgery (n=22), 12 weeks after a derivative 
procedure (n=46) and 55 weeks after primary tumour resection (n=91). Derivative procedures 
resulted in a 30% complication rate and an in-hospital mortality of 41%. Performance of 
derivative procedures or no surgery were negative prognostic factors (Hazard ratio for dying 
2.33, p=0.0001 and 3.09, p=0.0007, respectively). Other factors increasing the risk of death 
were age (>70 years), second primary tumour, poor differentiation grade, and systemic 
metastases. 
Conclusion
PC is often encountered unexpectedly during surgery for colorectal cancer. Primary tumour 
resection can be safely performed with good outcomes, but some patients may have 
benefited from an even more radical approach. If possible, derivative surgery should be 
avoided given its high morbidity and mortality. Ideally, PC should be diagnosed prior to an 
operative procedure. 
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Introduction
The peritoneum is a commonly encountered site of metastasis in patients with colorectal 
cancer, being present in 4.8% of patients at the moment of diagnosis of the primary tumour1. 
Another 4 to 12% of patients will develop clinically evident peritoneal dissemination later in 
the course of their disease2. 
The presence of peritoneal carcinomatosis (PC) in patients with colorectal cancer represents 
a challenge for health care workers and for surgeons in particular. Currently, preoperative 
staging is inadequate to diagnose PC and it is therefore often discovered accidentally during 
surgery. 
Taking into account the relatively high incidence of peritoneal metastases in colorectal 
cancer patients, surprisingly few data are available reporting on the outcomes of the 
surgical procedures performed in these patients. As a result, the role of surgery in patients 
with PC is yet to be defined. One may postulate that surgical exploration should always be 
considered even with widespread systemic disease since it has been show that resection of 
the primary tumour has a beneficial influence on survival in patients with other metastasised 
malignancies3-6. On the other hand, the limited accessibility of the abdomen caused by 
peritoneal deposits and resulting in an increased risk for complications may deter a surgeon 
from operating, especially since PC is traditionally regarded as an incurable condition. 
Aim of this study was to report on the outcomes in terms of morbidity, mortality and 
survival of patients undergoing surgery for colorectal carcinoma with synchronous PC, in 
order to clarify the advantages and disadvantages of palliative surgical interventions. This 
may provide tools for clinical decision making in case of incidentally encountered PC during 
surgery or when PC is diagnosed during preoperative work-up.  
Patients	and	methods
Patients
The Eindhoven Cancer Registry (ECR) collects data on all patients with newly diagnosed 
primary colorectal cancer (C18.0-C20.9) in a large part of the south-eastern Netherlands, 
and maintains a population based cancer registry in an area with approximately 2.3 million 
inhabitants. The ECR is notified by 10 community hospitals at 17 locations, 6 pathology 
departments, and 2 large radiotherapy institutions. By means of an independent case 
ascertainment method, the Dutch cancer registries attain an estimated completeness of 
more than 95%7. 
Data on patient and tumour characteristics are routinely extracted on basis of information 
in medical files by specially trained administrators of the cancer registry, 6 to 9 months after 
diagnosis. Routinely extracted data include the subsites of metastasis present at the time of 
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diagnosis according to the International Classification of Diseases for Oncology (ICD-O). The 
tumour-node-metastasis (TNM) classification is used for stage notification of the primary 
tumour, according to the edition of the TNM classification by the International Union Against 
Cancer (UICC), valid at time of cancer diagnosis. 
For the analysis in the current study, patients diagnosed with primary colorectal cancer 
(C18.0– C20.9) and synchronous PC in three community hospitals between 1995 and 
2008 were selected from the ECR database (n=169), and additional data regarding surgical 
procedures and postoperative outcome were collected by a specially trained administrator 
of the ECR. 
Follow-up of vital status was complete until January 2009 in all patients as obtained from 
the Municipal Administrative Databases, containing data on all deceased and emigrated 
persons in the Netherlands. 
Surgery
The radicality of resection of the primary tumour was reported using the following 
classification. An R-0 score indicates microscopically radical resection, R1 indicates 
macroscopic resection of disease but evidence for microscopic residual disease during 
pathological examination, e.g. microscopic tumour present in the intersection plane, R2 is 
noted when residual macroscopic tumour was present after the removal attempt. 
Additional	Therapy
Decisions regarding chemotherapy regimens were made on an individual patient basis by 
the medical oncologists. In the first years of this study period, treatment with 5-fluoruracil 
and folic acid was the standard palliative treatment for metastasised colorectal cancer in 
the Netherlands. From 2004 on, irinotecan and oxaliplatin were incorporated in standard 
palliative treatment regimens. Targeted therapies like cetuximab and bevacizumab 
were introduced in the Netherlands in 2006 and have been added to the chemotherapy 
combination therapies since then. 
Statistical	analysis
In addition to follow-up via the hospitals, information on vital status was actively obtained 
from the Dutch municipal personal records database (Central Bureau for Genealogy). 
Survival time was defined as the time from diagnosis to death or 1 January 2010 for the 
patients who were still alive. Median survival rates were computed according to patient 
and tumour characteristics. Ninety-five percent confidence intervals were calculated. A 
multivariable proportional hazards regression analysis was used to discriminate independent 
risk factors for death. P-values < 0.05 were considered statistically significant. All analyses 
were performed using SAS/STAT statistical software (SAS system 9.1.3, SAS Institute, Cary, 
NC).
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Results
Patients
Between 1995 and 2009, 169 colorectal cancer patients (93 male) with a mean age of 
67.4 years were diagnosed with synchronous PC in the three community hospitals. Patient 
characteristics are shown in table 1. The majority of patients reported symptoms of disease 
at the moment of diagnosis. Only 4 patients were asymptomatic. Most common symptom 
was pain, followed by weight loss. 
In 22 patients it was decided not to perform surgery at all. The main considerations for this 
decision were the presence of wide-spread systemic disease and a poor performance status. 
Table 1. General characteristics of patients with peritoneal carcinomatosis, diagnosed between 1995 
and 2008 in the South of the Netherlands (n=169).
Mean age (yrs) 67.4
Male : Female 93:76
n (%)
Comorbidity
  Yes 50 (30)
  No 109 (64)
  Unknown 10 (6)
Localisation	of	primary	tumour*
  Caecum 33 (20)
  Appendix 3 (2)
  Colon 100 (58)
  Rectosigmoid 12 (7)
  Rectum 22 (13)
T	stage	of	primary	tumour	(cT	in	case	of	unknown	pT)
  T1 1 (1)
  T2 4 (2)
  T3 53 (31)
  T4 70 (41)
  Tx 41 (26)
N stage of primary tumour (cN	in	case	of	unknown	pN)
  N0 21 (12)
  N1,2 92 (55)
  Nx 56 (33)
Differentiation	grade	of	primary	tumour
  Well/moderate 73 (43)
  Poorly/undifferentiated 42 (25)
  Unknown 54 (32)
Extent	of	metastatic	disease
  Peritoneal carcinomatosis only 66 (39)
  Peritoneal carcinomatosis plus other metastases 103 (61)
* 5 patients were diagnosed with a synchronous primary tumour located in the colon and the rectum 
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Surgical procedures
In 142 patients, at least one surgical procedure was performed. Interestingly, the presence 
of PC was known before the operation in only 8 patients while in 130 patients PC was found 
unexpectedly during surgery. In 4 patients these data are missing. During surgery, ascites 
was noted in 37% of patients (n=62). A summary of the surgical decision making is shown 
in figure 1.
The primary tumour was resected in 91 patients. In most of these patients a microscopic 
(R-0) resection was achieved (n=66). In 4 patients, R1 resection was reported and in another 
4 patients macroscopic tumour was left behind; no information on completeness of resection 
was found in the medical files for the remaining 17 patients. 
In all other patients, the primary tumour was not resected. Main reasons for this decision 
were the knowledge that the patient was diagnosed with extensive synchronous metastases 
on other locations during preoperative work-up (n=21), irresectability of the primary tumour 
(n=16) or widespread peritoneal disease (n=11).
In five patients the abdomen was closed immediately after exploration without additional 
procedures.
In 46 patients a derivative procedure was performed, including an intestinal bypass in 11 
patients and stoma formation in 34 patients. In one patient both an intestinal bypass and a 
stoma were made. Table 2 shows the number of procedures performed in patients with PC, 
according to a number of relevant patient and tumour characteristics.
Patients diagnosed 
with synchronous PC
n = 169
No surgery
n = 22
Exploration only
n = 5
Surgery performed
n = 142
Resection primary
tumour
n = 91
Unknown
n = 5
Derivative procedure/
stoma
n = 46
Figure 1. Summary of procedures performed in colorectal cancer patients diagnosed with synchronous 
peritoneal carcinomatosis (PC).
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Adjuvant therapy
None of the 91 patients undergoing resection of the primary tumour received neoadjuvant 
chemotherapy. Six patients (7%) received preoperative radiotherapy. Resection of the 
primary tumour was followed by adjuvant chemotherapy in 45 patients (49%). Another 45 
patients did not receive adjuvant treatment, and in 1 patient these data were missing. 
None of the patients received postoperative radiotherapy. 
Table 2. Procedures and outcomes in patients with peritoneal carcinomatosis who underwent surgery, 
according to a number of relevant patient and tumour characteristics (n=142).
Exploration	only Resection	primary	
tumour
Derivative	procedure	
(incl stoma)
n (%) n (%) n (%)
Overall 5 (100) 91 (100) 46 (100)
Age
   <70 years 3 (60) 49 (54) 22 (48)
   70+ years 2 (40) 42 (46) 24 (52)
Gender
   Male 3 (60) 50 (55) 25 (54)
   Female 2 (40) 41 (45) 21 (46)
Comorbiditya
   Yes 2 (40) 56 (62) 30 (65)
   No 3 (60) 32 (35) 10 (22)
   Unknown 0 (0) 3 (3) 6 (13)
Extent	of	metastatic	disease
   Peritoneal carcinomatosis only 3 (60) 36 (40) 17 (37)
   Peritoneal carcinomatosis plus 
   other metastases
2 (40) 55 (60) 29 (63)
PC	known	before	operation
Yes 1 (20) 4 (4) 3 (7)
No 4 (80) 85 (94) 41 (89)
   Unknown 0 (0) 2 (2) 2 (4)
Median hospital stay (days) 5 10 11
Postoperative complications 1 (20) 13 (14) 14 (30)
In-hospital mortality 20% 14% 41%
Morbidity
Postoperative complications occurred in 14% of patients who underwent resection of the 
primary tumour (n=91), and 30% of patients with a derivative procedure (n=46). In the group 
with derivative procedures, in-hospital mortality was 41%, as opposed to 14% in patients in 
whom the primary tumour was resected. 
The most frequently reported complications in both the resection and the derivative group 
were prolonged ileus and systemic infections, such as pneumonia. In the resection group, 
this was followed by fascia dehiscence and wound infection. In the derivative group, renal 
failure was the next most frequent postoperative complication. 
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The performance of a derivative procedure was a significant negative prognostic factor as 
compared to resection of the primary tumour (Hazard ratio (HR) for risk of death 2.33, 95% 
CI 1.51-3.59). So was the performance of no surgery (HR 3.09, 95% CI 1.61-5.91). Other 
factors negatively influencing the risk of dying by multivariate analysis were age (>70 
years), presence of a second tumour, poor differentiation grade, and presence of systemic 
metastases. Results of the multivariate analysis are shown in table 3.  
Table 3. Multivariable proportional hazards regression analysis modelling the risk of death for patients 
with colorectal cancer and synchronous peritoneal carcinomatosis, diagnosed between in the south of 
the Netherlands between 1995 and 2008. Data are adjusted for all variables listed. 
HR 95% CI P value
Age
 < 70 yearsa 1.00
 70+ years 1.66 1.17-2.35 0.005
Gender
 Malea 1.00
 Female 0.95 0.68-1.34 0.8
Comorbidity
 Noa 1.00
 Yes 0.96 0.66-1.40 0.8
Localisation
 Colon (incl. caecum and appendix)a 1.00
 Rectum (incl. rectosigmoid) 0.86 0.55-1.33 0.5
Synchronous colon and rectal tumour
 No a 1.00
 Yes 2.28 1.02-5.13 0.046
T stage
 T1-2 1.50 0.49-4.58 0.5
 T3a 1.00
 T4 1.17 0.80-1.72 0.4
N stage
 N0 0.70 0.38-1.28 0.2
 N1,2 a 1.00
Differentiation	grade	of	primary	tumour
 Well/moderatea 1.00
 Poorly/undifferentiated 1.52 1.02-2.28 0.04
Operation	performed
 Resection of tumoura 1.00
 Derivative procedure 2.33 1.51-3.59 0.0001
 Exploration only 1.68 0.65-4.38 0.3
 No surgery 3.09 1.61-5.91 0.0007
Extent	of	metastatic	disease
 Peritoneal carcinomatosis onlya 1.00
 Peritoneal carcinomatosis plus other metastases 1.29 1.05-1.58 0.01
Ascites present?
Yesa 1.00
No 0.72 0.35-1.47 0.4
HR=hazard ratio
CI=Confidence Interval
a Reference category
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Survival
Median survival, calculated according to the surgical interventions that were performed 
is shown in table 4. Patients who did not undergo surgery had a median survival of only 
14 weeks (95% CI 4-34). In the group with a derivative procedure, median survival was 12 
weeks (95% CI 6-19). However in the group in which the primary tumour was resected, a 
median survival of 55 weeks (95% CI 46-70) was observed. 
Table 4. Median survival (in weeks) of patients with peritoneal carcinomatosis (PC) (n =164), All: 34 
weeks (23-46).
No surgery/ 
exploration	only
Resection	primary	
tumour
Derivative	procedure	
n Survival	in	weeks	
(95% CI)
n Survival	in	weeks	
(95% CI)
n Survival	in	weeks	
(95% CI)
Overall 27 14 (4-34) 91 55 (46-70) 46 12 (6-19)
Age
  < 70 years 13 23 (11-71) 49 76 (50-117) 22 12 (5-34)
  70+ years 14 5 (2-32) 42 46 (26-55) 24 14 (5-18)
Gender
  Male 14 28 (4-71) 50 55 (46-84) 25 13 (5-26)
  Female 13 5 (2-14) 41 54 (36-80) 21 11 (6-24)
Comorbidity
  No 12 12 (1-53) 32 47 (22-76) 10 12 (5-19)
  Yes 20 14 (4-49) 56 55 (47-84) 30 25 (5-39)
Sites of metastases
PC only 12 10 (2-71) 36 80 (55-135) 17 11 (4-34)
PC + other metastases 15 14 (4-34) 55 46 (26-50) 29 18 (6-24)
CI = Confidence Interval
Discussion
The presence of PC in colorectal cancer patients is frequently discovered unexpectedly 
during surgery. Also in this study, PC was unknown before surgery in no less than 130 
out of the 142 patients (91%) operated for PC. This causes the operating surgeon to be 
faced with a dilemma, since several surgical options are available: an attempt to resect the 
primary tumour with or without the peritoneal metastases, the performance of a derivative 
procedure or enterostomy, closure of the abdomen without further intervention. Currently, 
evidence from clinical studies to support one of these options is lacking. 
This study reports a high incidence of postoperative complications (30%) and in-hospital 
mortality (41%) associated with the performance of a derivative procedure. Prognosis 
in these patients is very poor with a median survival of only 12 weeks. Since survival is 
comparable to non-operated patients (14 weeks) one may speculate that it would have 
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been better not to operate on these patients at all. Instead, less invasive techniques such 
as stenting of enteral stenoses and drainage of ascites may have been more suitable to 
palliate symptoms. This however requires a more specific and reliable preoperative work-up 
in order to diagnose PC preoperatively. 
Patients in whom a resection of the primary tumour was performed achieved a median 
overall survival of 55 weeks with an acceptable morbidity and mortality. Although these 
survival outcomes remain unfavourable as compared to patients presenting with other 
sites of synchronous colorectal cancer metastases1, one may conclude that resection of 
the primary tumour should always be considered even in the presence of PC. However, 
recent developments give rise to the question whether all patients in this study were 
optimally treated by resection of the tumour alone. In the 1980’s, new treatment strategies 
have been introduced consisting of a combination of aggressive cytoreductive surgery 
with hyperthermic intraperitoneal chemotherapy (HIPEC). With this combined treatment 
modality, a significant increase in survival outcomes has been reported in clinical and 
experimental studies8-17. Eligibility criteria include fitness for major surgery, resectable 
peritoneal disease, limited extent of PC and absence of systemic metastases10;18-20. It is not 
unlikely that several of the patients with resectable tumours in the present study would 
have benefited from referral to a specialised HIPEC-center. Ideally, such referral is done 
before the performance of any operation since surgery induces the release of growth factors 
into the peritoneal cavity, which is thought to enhance the growth of peritoneal metastases. 
Once again, the preoperative discovery of PC is crucial in this respect since only then timely 
referral of the patient can be considered. 
The currently available imaging techniques that are used for preoperative staging in colorectal 
cancer are contrast-enhanced multi-sliced computed tomography (CT), magnetic resonance 
imaging (MRI), positron emission tomography (PET), and laparoscopy. The sensitivity of CT 
in detecting PC varies between 60 to 90% for lesions greater than 5 cm, but decreases to 
10-30% for lesions smaller than 1 cm21;22. In addition, the accuracy of detecting peritoneal 
tumour nodules depends on the quality of the image, the expertise of the radiologist and the 
abdominopelvic regions examined21-23. Functional imaging by PET has shown to be a valuable 
tool in detecting metastases from colorectal cancer, with an overall sensitivity of 97%24. Yet 
this technique also has the drawback of a limited sensitivity for small (<1 cm) lesions. Thus, 
especially in patients presenting with limited PC in whom treatment is most likely to be 
beneficial, the non-invasive imaging techniques CT and PET are not reliable. This was also 
demonstrated by a recent study reporting a discovery of macroscopic PC during systematic 
second look surgery in 23 out of 41 (56%) asymptomatic patients without radiological signs 
of peritoneal involvement25. MRI is not routinely used for abdominal imaging but may be a 
technique of interest with new developments like contrast enhancement and faster pulse 
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sequences26. The decision to use MRI for preoperative evaluation of PC will also depend on 
radiologist’s expertise, availability and costs. 
Although the sensitivity of the currently available imaging techniques is insufficient to 
accurately quantify PC lesions and radiological findings often do not correlate with surgical 
observations27-29, a high index of suspicion for the presence of PC should be raised with 
(often subtle) signs on imaging studies such as ascites, omental thickening and mesenterial 
implants. In the current study the presence of ascites –an indirect sign of PC - was mentioned 
in the operation notes in 37% of the patients in this study while PC was diagnosed 
preoperatively in only 5% of the patients. Part of this understaging may be explained by the 
fact that abdominal CT scans were not routinely performed for preoperative staging for a 
significant time-frame in the study period.
In case PC is suspected on preoperative imaging, an exploratory laparoscopy to provide 
more information on the presence and extent of PC may be considered. This has been 
shown to be feasible and safe but at the cost of an invasive procedure30-32. Nevertheless, 
since the present study reveals the great importance of being informed about the presence 
of PC prior to an operative procedure, a diagnostic laparoscopy should be part of the work-
up whenever signs of PC are present. By doing so futile operations may be avoided, patients 
with widespread and untreatable disease may be palliated less invasively with stenting of 
intestinal stenoses and drainage of ascites and selected patients with resectable disease 
may be offered a chance for long-term survival in specialised HIPEC-centers. 
As stated previously there is very little evidence from clinical studies investigating the effect 
of surgery in patients with PC. Bloemendaal et al. describe a series of 50 patients treated 
with conventional palliative care, of whom 8 patients underwent a bypass and 29 patients 
resection of the primary tumour33. Similar to the current study, median survival was better 
in patients in whom resection of the tumour was performed as compared to patients 
undergoing a derivative procedure or exploration only (17.3 versus 8.3 months respectively). 
No details were provided on postoperative morbidity and mortality. The better survival 
reported by these authors for both groups can be explained by the strict selection criteria 
in this study, including only patients with proven PC of colorectal origin without distant 
metastases, age 70 years or younger, and fit enough to undergo major surgery. 
The present study has a few limitations inherent to its retrospective design. First of all, a 
selection bias cannot be avoided as data are collected retrospectively, and the decision 
making process regarding surgery is influenced by the performance status of patients and 
the surgeon’s expertise and opinion. Furthermore, no description of the extent of PC that is 
found during laparotomy is available. This can be explained by the fact that exploration of the 
abdomen is not routinely performed, especially not if the surgical procedure is performed 
with palliative intent. Yet, the information presented here is unique since it describes (to our 
knowledge) the largest cohort of patients operated with palliative intent in the presence of 
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PC known in literature. Moreover, the cohort consists of an unselected group of consecutive 
patients and contains data on post-operative complications and in-hospital mortality. 
From these data it can be concluded that a careful and thorough preoperative staging is of 
crucial importance to improve the care for these patients. However, even then PC will be 
encountered frequently unexpectedly during surgery and despite the bad prognosis of PC 
on the long term, resection of the primary tumour should be considered whenever possible. 
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Abstract
Background 
The combination of cytoreductive surgery (CS) and hyperthermic intraperitoneal 
chemotherapy (HIPEC) is the treatment of choice for selected patients with peritoneal 
carcinomatosis (PC) of colorectal origin. However, it remains to be proven whether the 
addition of HIPEC to CS is essential for the reported survival benefit. 
Methods  
Sixty WAG/Rij rats were inoculated intraperitoneally with the rat colon carcinoma cell line 
CC-531. Animals were randomised into three treatment groups. Group 1: CS alone, group 2: 
CS followed by HIPEC (mitomycin 15 mg/m2), group 3: CS followed by HIPEC (mitomycin 35 
mg/m2). Survival was the primary outcome parameter.
Results  
Median survival of rats treated with CS alone was 43 days. Rats receiving HIPEC 15 mg/m2 
and HIPEC 35 mg/m2 both had a significantly longer median survival of 75 days (p=0.003) 
and 97 days (p<0.001), respectively. Rats receiving HIPEC showed a significantly lower 
tumour load at autopsy compared to rats treated with CS alone. 
Conclusions  
A combination of CS and HIPEC results in longer survival than CS alone in rats with PC of 
colorectal origin. 
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Introduction
Peritoneal carcinomatosis (PC) is an important cause of morbidity and mortality in patients 
with colorectal cancer. Synchronous peritoneal metastases are found in 7% of patients1 
and during follow-up a further 4-19% will develop PC2. Median survival in conservatively 
treated patients varies between 5.2 and 12.6 months3-5. PC has long been considered to 
be a manifestation of systemic metastasis with no curative treatment options. Recently, 
local treatment strategies have been developed combining cytoreductive surgery (CS) and 
Hyperthermic Intraperitoneal Chemotherapy (HIPEC). The only phase III randomised trial 
comparing CS and HIPEC with standard palliative care found median survival in the CS + 
HIPEC group to be 22.4 months, compared with 12.6 months patients treated with standard 
palliative care alone6. Although these results are certainly encouraging, it remains unclear 
whether the combination of CS and HIPEC is indeed required to achieve the survival benefit. 
Unfortunately, no experimental arm was included where patients were treated with CS 
alone. At this time, it cannot be ruled out that the gain in survival was mainly or entirely 
due to CS7. 
The addition of HIPEC to CS prolongs operating time and increases the risk of postoperative 
morbidity and mortality8;9. Therefore, the additional benefit of HIPEC should be demonstrated 
unequivocally before it is widely accepted as standard of care. 
Efforts to define the role of adjuvant intraperitoneal chemotherapy after CS in a randomised 
trial failed to attain the required number of patients, because of patient dissatisfaction with 
randomisation10. Thus, it seems unlikely that this issue will be resolved shortly in randomised 
clinical trials. Therefore, an experimental study was performed in rats with PC of colorectal 
origin, aiming to establish the benefit of HIPEC as adjuvant therapy after CS for PC. 
Materials and methods
Animals
Sixty male WAG/Rij rats, 10-12 weeks old and median weight 269 (range 236-303) g, were 
obtained from Harlan, Horst, The Netherlands. The animals were allowed to accustom to 
laboratory conditions for at least 1 week before experimental use. Rats were housed in 
filter-topped cages (three rats per cage) under clean, non-sterile standardised conditions 
(temperature 20-24⁰C; relative humidity 50-60%, 12h light/12 h dark cycle), with free access 
to food (ssniff®, Bio services, Uden, The Netherlands) and water. All experiments were 
approved by the Animal Welfare Committee of the Radboud University and carried out in 
accordance with the Dutch Animal Welfare Act of 1997. 
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Experimental design
PC was induced in all animals. Seven days after intraperitoneal tumour induction, animals 
were randomised into three groups of 20 animals each: exploration and CS alone (CS group), 
CS followed by HIPEC, total dose of mitomycin 0.5 mg (15 mg/m2) (HIPEC-15 group), and CS 
followed by HIPEC, total dose of mitomycin 1.2 mg (35 mg/m2) (HIPEC-35 group). Survival 
was the primary outcome parameter.
Induction	of	peritoneal	carcinomatosis
The tumour cell line used was the syngeneic rat colonic carcinoma cell line CC-531, originally 
induced in WAG/Rij rats by intravenous injection of 1,2-dimethylhydrazine11. The cell line 
was cultured and maintained as described previously12 and two ml of a cell suspension (106 
cells/ml) was injected intraperitoneally. 
Surgery
One week after tumour cell inoculation, CS was performed under general anaesthesia using 
isoflurane 3%, O
2
 and 1:1 nitrous oxide. For analgesia, rats were given carprofen (Rimadyl®; 
Pfizer Animal Health, Capelle aan de Ijssel, The Netherlands) 5 mg per kg per day 30 min 
before surgery and once daily until the third day after the operation. During surgery, rats 
were placed on a warmed mattress to limit body heat loss.
After laparotomy, the abdomen was carefully inspected for tumour growth at ten different 
sites, as shown in table 1. The tumour load at each site was scored semiquantitatively: 0, 
no macroscopic tumour; 1, limited tumour growth (diameter 1–2 mm); 2, moderate tumour 
growth (diameter 2–4 mm); or 3, abundant (diameter more than 4 mm). The sum of scores 
from all sites represented the Peritoneal Cancer Index (PCI) for that animal. 
Subsequently, CS including standard omentectomy was performed in all animals, aiming at 
complete removal of the macroscopic tumour deposits. Unresectable tumour deposits were 
cauterized using an electrocoagulation device. After CS the amount of residual tumour was 
scored using a system currently employed in clinical practice. Absence of residual tumour 
was recorded as R1, a residual tumour of 2.5 mm or less was scored as R2a, and a tumour 
larger than 2.5 mm as R2b. 
In the CS group, the abdomen was closed after surgery. In HIPEC-15 and HIPEC-35 groups, 
surgery was followed immediately by HIPEC. 
Hyperthermic Intraperitoneal chemotherapy 
Two multiperforated catheters were introduced into the abdominal cavity through the 
flanks, as described previously13. The catheters were connected to a closed perfusion 
system containing 250 ml 0.9% sodium chloride. The peritoneal perfusate was warmed in 
a tube coil using a thermostatically regulated water bath. Perfusion of the peritoneal cavity 
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was performed for 90 min at 10 ml/min. Mitomycin C (Nycomed Christiaens, Breda, The 
Netherlands) was dissolved in 0.9% sodium chloride to the appropriate concentration and 
added to the perfusate in three separate doses at 30-min intervals, each containing 50, 25 
and 25% of the total dose. During HIPEC, the abdomen was massaged gently to achieve a 
uniform heat distribution.  
After completion of the perfusion, the abdominal cavity was irrigated with warmed (42°C) 
saline during 5 min. The catheters were removed and the abdominal wall was closed in two 
layers using continuous polyglactin 910 (VicrylTM; Ethicon, Edinburgh, UK) sutures for the 
muscular layer and wound clips for the skin. All rats were given 10 ml 0.9% sodium chloride 
subcutaneously for rehydration. 
Follow-up
The primary endpoint of the experiment was survival. Rats were observed and weighed daily 
for the first 7 days following surgery, and three times a week thereafter. Body weight was 
expressed as relative body weight compared to the body weight on the day of operation, 
and taken to reflect toxicity of the treatment. 
When the humane endpoint was reached (physical inactivity, signs of intra-abdominal 
tumour growth with invalidating consequences or signs of massive haemorrhagic ascites), 
rats were killed by administration of carbon dioxide, and subjected to autopsy. Ultimately, 
the decision regarding the humane endpoint was made by an experienced biotechnician 
who was unaware of the experimental group to which the animal belonged. 
After autopsy, the intraperitoneal tumour load was scored as described above. In addition, 
the weight of ascites was measured. The study was terminated 140 days after surgery. 
Remaining rats were killed and subjected to autopsy. 
Statistical	Analysis
Statistical analysis was performed using Graphpad® Prism (Graphpad Software, San Diego, 
California, USA) and SPSS® version 16.0 (SPSS, Chicago, Illinois, USA) software. The primary 
objective of the study was to demonstrate an improvement in median survival from 48 days 
in the CS group to 90 days in the HIPEC groups. Sample size was calculated by lifespan analysis 
assuming exponential survival from day 35 onwards and using a power of 0.90, α = 0.05/2 
= 0.025 and an one-sided test. The various assumptions were based on data from previous 
studies using the same animal model and surgical cytoreductive procedures13-15. For the 
comparison of dichotomous values, chi square or Fisher’s Exact tests were used. One-way 
ANOVA or Kruskall-Wallis testing was used for comparison of continuous values. Survival 
outcomes were analysed and expressed using Kaplan–Meier curves, and compared with the 
log-rank test. Cox survival regression analysis was applied to correct for confounding factors. 
P < 0.050 was considered statistically significant. 
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Results
Surgical procedures
Sixty animals were randomised. Preoperative clinical condition and bodyweight did not 
differ between the groups. Findings at laparotomy and results of CS are shown in table 
1. Peritoneal tumour deposits were present in 59 animals (Figure 1). In the rat with no 
macroscopic tumour growth omentectomy and exploration were followed by HIPEC as 
determined by randomisation. The mean PCI score was similar in the three groups. There 
were no differences between groups regarding residual disease in situ after resection. 
The mean time taken for the CS procedures, without HIPEC, was 45 min and did not differ 
between groups.
One rat in the HIPEC-15 group died from respiratory failure immediately after the procedure, 
and one rat in the CS group died shortly after the surgical procedure as a result of excessive 
blood loss. On postoperative day 11, one rat from the HIPEC-35 group died with signs of 
peritonitis and sepsis. 
Table 1. Tumour score before cytoreduction, and results of cytoreductive surgery.
Group CS HIPEC-15 HIPEC-35
(n = 20) (n = 20) (n = 20)
Body	weight	(g) 270 (15) 269 (17) 271 (16)
Tumour score per site 
Subcutaneous 0 (0-3) 0 (0-2) 0 (0-2)
Injection site 1 (0-2) 1 (0-2) 1 (0-2)
Greater omentum 1 (1-1) 1 (1-1) 1 (0-1)
Liver hilum 1 (0-1) 1 (0-2) 1 (0-2)
Liver 0 (0-1) 0 (0-1) 0 (0-1)
Perisplenic 1 (0-2) 1 (0-1) 1 (0-1)
Mesentery 1 (1-1) 1 (0-2) 1 (0-2)
Gonadal fatpads 0 (0-3) 0 (0-2) 0 (0-2)
Diaphragm 0 (0-1) 0 (0-1) 0 (0-1)
Parietal peritoneum 0 (0-2) 0 (0-2) 0 (0-3)
Overall PCI 6 (1.9) 6 (1.4) 6 (3.0)
Splenectomy
Yes 5 5 6
No 15 15 14
Completeness	of	resection
R1 14 16 16
R2a 6 3 4
R2b 0 1 0
CS = cytoreductive surgery, HIPEC-15 = CS + hyperthermic intraperitoneal chemotherapy (HIPEC) with 
15mg/m2 mitomycin C, HIPEC-35 = CS + HIPEC with 35mg/m2 mitomycin C, PCI = Peritoneal Cancer 
Index; R1 = no macroscopic residual tumour after CS, R2a = residual tumour 2.5 mm or less after CS, 
R2b = residual tumour greater then 2.5 mm after CS. Tumour score per site is expressed as median 
(range). Body weight and overall PCI are expressed as mean (SD).
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Figure 1. Macroscopic aspect of peritoneal metastases found at laparotomy at (A) greater omentum 
and (B) abdominal wall.
Perfusion	characteristics
During the HIPEC procedure, the intra-abdominal temperature was similar in both groups, 
with a mean (SD) of 42.0 (0.9)°C. Mean (SD) rectal temperature at the start of the procedure 
was 32.8 (0.7)°C in the HIPEC-15 group and 32.7 (0.7)°C in the HIPEC-35 group (p=0.443). 
This increased to increased to 36.7 (1.9)°C in the HIPEC-15 group and 36.2 (1.4)°C in the 
HIPEC-35 group by the end of perfusion (p=0.372). The course of rectal and intra-abdominal 
temperatures during the HIPEC procedures is shown in Figure 2.
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Figure 2. Rectal and intra-abdominal temperatures during the hyperthermic intraperitoneal 
chemotherapy procedure. Values are means (SD) of all 40 procedures. 
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Clinical appearance
Figure 3 shows the course of mean body weight in the three groups during the first week 
after surgery. Rats in the CS group generally gained weight from the second postoperative 
day onwards. In the HIPEC groups, the lowest mean (SD) bodyweight was recorded on the 
third day after surgery: reduction of 4.1 (0.6) versus 5.2 (0.6) % in HIPEC-15 and HIPEC-35 
groups respectively. In the HIPEC-35 group, mean (SD) maximum weight loss was significantly 
higher than that in the CS group (5.2 (0.6) versus 3.0 (0.2) % respectively; p=0.042). 
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Figure 3. Course of mean body weight, relative to weight at operation, during the first week after 
surgery. Body weight is given relative to weight at operation. CS = cytoreductive surgery, HIPEC-15 = 
CS + hyperthermic intraperitoneal chemotherapy (HIPEC) with 15mg/m2 mitomycin C, HIPEC-35= CS + 
HIPEC with 35mg/m2 mitomycin C.
Survival 
Survival curves are shown in figure 4. During follow-up two rats died from non-tumour 
related causes. Median survival was 43 (95% confidence interval (CI) 39-64) days in the CS 
group and 75 (67-99) days in the HIPEC-15 group. The highest median survival of 97 (76-113) 
days was achieved in the HIPEC-35 group. This difference in survival outcome was significant 
for both HIPEC groups in comparison with the CS-group: p=0.003 versus HIPEC-15, hazard 
ratio for dying 0.42 (95% CI 0.22-0.78); p <0.001 versus HIPEC-35, hazard ratio 0.31 (95% CI 
0.16-0.59). Survival in the HIPEC-35 group tended to be higher than that in the HIPEC-15 
group (p = 0.197). After 20 weeks, 11 rats were still alive (1 CS, 3 HIPEC-15, 7 HIPEC-35). Three 
of these animals showed no macroscopic evidence of tumour growth (1 CS, 2 HIPEC-35). 
At autopsy, rats from the CS group were found to have a higher mean PCI than rats from the 
HIPEC-35 group (p < 0.001). One rat in the CS group had extensive lung metastases. Post 
mortem findings are shown in table 2. 
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In the rats treated with HIPEC, haemorrhagic ascites was the most common reason for 
reaching the humane endpoint. Rats in the CS group were most often removed from the 
experiment because of significant weight loss and palpable tumours in the abdomen. 
Differences in the mean ascites weight were observed between both HIPEC groups and the 
CS group, but, owing to massive variation, remained non-significant (p =0.355). 
In a multivariable analysis, the only other independent factor influencing survival was 
completeness of resection. Rats with a complete (R1) resection had a longer survival 
(median 75 days) than rats in which tumour had been left behind (R2a or R2b, median 49 
days), independent of treatment (hazard ratio 2.5, 95% CI 1.3-4.9, p=0.008). 
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Figure 4. Kaplan-Meier survival curves for the three treatment groups. CS = cytoreductive surgery, 
HIPEC-15 = CS + hyperthermic intraperitoneal chemotherapy (HIPEC) with 15mg/m2 mitomycin C, 
HIPEC-35 = CS + HIPEC with 35mg/m2 mitomycin C. CS versus HIPEC-15, p= 0.003; CS versus HIPEC-35, 
p<0.001 (log rank test). 
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Table 2. Tumour score and ascites weight at autopsy.
Group CS HIPEC-15 HIPEC-35
Tumour score per site 
Scar 2 (0-3) 1 (0-3) 0 (0-2)
Injection site 0 (0-3) 0 (0-3) 0 (0-0)
Greater omentum 3 (0-3) 3 (0-3) 3 (0-3)
Liver hilum 3 (0-3) 3 (0-3) 3 (0-3)
Liver 2 (0-3) 1 (0-3) 0 (0-3)
Perisplenic 3 (0-3) 3 (1-3) 1 (0-3)
Mesentery 3 (0-3) 3 (1-3) 2 (0-3)
Fatpad 1 3 (0-3) 3 (0-3) 3 (0-3)
Fatpad 2 3 (0-3) 2 (0-3) 2 (0-3)
Diaphragm 3 (0-3) 3 (0-3) 3 (2-3)
Parietal peritoneum 3 (0-3) 2 (0-3) 1 (0-3)
Overall PCI 24 (6) 23 (5) 17 (6)
Ascites	weight	(g) 24 (18) 38(19) 37 (20)
CS = cytoreductive surgery, HIPEC-15 = CS + hyperthermic intraperitoneal chemotherapy (HIPEC) with 
15mg/m2 mitomycin C, HIPEC-35 = CS + HIPEC with 35mg/m2 mitomycin C, PCI = Peritoneal Cancer 
Index. Tumour score is expressed as median (range). Overall PCI and ascites weight are expressed as 
mean (SD). 
Discussion
This is the first experimental study that demonstrates that HIPEC is an effective adjuvant 
intraoperative therapy after CS for PC of colorectal origin. Complete macroscopic removal 
of the tumour from the peritoneal cavity is a second independent factor that improves 
outcome. 
The experiments were performed using a validated and reproducible model of PC of 
colorectal origin that resembles the clinical situation. After inoculation of CC-531 syngeneic 
colonic carcinoma cells, PC without distant metastasis develops within three to five days12;16. 
As this cell line has been shown to be sensitive to mitomycin, the experimental model is 
attractive to determine the effect of HIPEC with this particular anticancer drug17. The model 
is also suitable for performing CS15 and the feasibility of performing HIPEC after CS has been 
demonstrated13;18. 
The present experimental HIPEC procedure was designed to mimic the procedure used in 
the only reported randomised clinical trial6 as closely as possible; the perfusion time was 
90 min and mitomycin was introduced into the flow system in 3 sequential doses. The total 
dose of 1.2 mg, equivalent to 35 mg/m2 body surface area, was similar to dosages used to 
treat patients with PC in the Netherlands. A second dose of 15 mg/m2 mitomycin was chosen 
as it has been reported to reduce intraperitoneal tumour growth in rats19. Increasing doses 
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appeared to be increasingly effective when used in the HIPEC procedures as performed in 
the current model. 
HIPEC proved to be highly effective in prolonging survival and in delaying outgrow of 
intraabdominal recurrence. A previous study carried out in the authors’ laboratory failed 
to demonstrate a significant gain in survival after HIPEC, although median survival time 
increased from 57 days following CS alone to 76 days with CS and HIPEC13. It is entirely 
conceivable that the toxicity resulting from the very high dose (120 mg/m2) of mitomycin 
used, delivered in a single administration, may have neutralised its potential benefits. 
Adaptation of the dose regimen resulted in a much lower toxicity in the present experiment, 
as indicated by a less severe loss of bodyweight, and a much improved outcome.
Rats treated by CS alone showed weight loss, palpable tumours in the abdomen and 
signs of bowel obstruction, most likely caused by rapid tumour growth. This is reflected 
by a significantly higher tumour load at autopsy than in either HIPEC group. In the latter 
groups the humane endpoint was based mainly on respiratory failure as a consequence of 
ascites. Most likely, tumour growth in these rats was inhibited and a fatal volume of ascites 
developed before tumour growth caused clinical symptoms. The beneficial effect of HIPEC 
on survival is therefore believed to be a result of tumour growth inhibition. 
An interesting observation from this study is that a macroscopically complete removal of 
tumour is an independent favourable prognostic factor determining outcome. This is in 
accordance with observations in clinical practice2;20;21. 
Effects of intraperitoneal treatment in addition to CS for PC in rats have been reported 
previously22-24. Postoperative intraperitoneal administration of cisplatin and adrenaline 
(epinephrine) improved survival, whereas CS alone did not22. In addition, intraperitoneal 
apoptogenic agents administered after CS diminished tumour growth and ascites after 
20 days23. Although these results support the rationale for performing HIPEC, the models 
used were not entirely relevant for dealing with questions concerning HIPEC because 
hyperthermia is not a component of treatment and chemotherapy is not applied during 
surgery. Recently, Raue and collegues24 showed that HIPEC with 15mg/m2 mitomycin after 
CS can indeed lead to reduced tumour weight 21 days after surgery. However, the effect of 
treatment on survival was not evaluated in this study. 
Although an experimental model, the results of the present study have provided an answer 
to the question whether the application of HIPEC is mandatory after CS to improve survival. 
This question has been under debate ever since publication of the only randomised trial 
currently available6. Although data on side effects remain limited, the available studies9;25 
report acceptable morbidity and mortality rates. Most common complications appear to 
be associated with CS rather than the addition of HIPEC9;25. These data, together with the 
results of the present study, show that HIPEC is a safe and effective intraoperative adjuvant 
to CS as therapy for PC of colorectal origin. 
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Abstract
Background
Hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C can improve survival 
if used as an adjunct to cytoreductive surgery (CS) for treatment of peritoneal carcinomatosis 
(PC). It remains unclear if both hyperthermia and chemotherapy are essential for the 
reported survival benefit. 
Methods 
Eighty WAG/Rij rats were inoculated intraperitoneally with the rat colon carcinoma cell line 
CC-531. Animals were randomly assigned to one of the four treatment groups (n=20): CS 
only, CS followed by HIPEC (mitomycin 35 mg/m2 at 41°C), CS followed by intraperitoneal 
mitomycin perfusion at 37°C, CS followed by intraperitoneal saline perfusion at 41°C. 
Survival was the primary outcome with a maximum follow up of 126 days. 
Results
Median survival was 62 days in rats treated with CS only and 57 days in rats treated with CS 
followed by hyperthermic saline perfusion. Rats receiving HIPEC had a median survival of 
121 days (p=0.022 when compared to CS only). In the group treated with chemotherapy at 
37oC, 13 of 20 animals were still alive at the end of the experiment so median survival was 
not reached (CS versus IPEC: p = 0.002). Rats treated with hyperthermic saline perfusion did 
not have an increased survival as compared to CS only. 
Conclusion 
The effectiveness of intraoperative intraperitoneal perfusion after CS is highly dependent 
on the presence of chemotherapeutic agents in the perfusate but not on hyperthermia. 
The need to include hyperthermia in the adjuvant intraoperative treatment after CS for PC 
should be further investigated.
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Introduction
The combination of cytoreductive surgery (CS) and hyperthermic intraperitoneal 
chemotherapy (HIPEC) is widely accepted as a treatment strategy for selected patients 
suffering from peritoneal carcinomatosis (PC) from colorectal origin who are considered to 
be fit for major surgery. With palliative treatment, these patients have a poor prognosis of 
approximately 6 months1-3. Results of a randomised controlled trial demonstrated a survival 
benefit in patients treated with CS and HIPEC, when compared to palliative treatment 
only4;5. Nevertheless, many questions remain unanswered regarding the optimal approach 
for this multimodality treatment6. 
In PC the presence of residual microscopic disease after cytoreductive surgical procedures 
is assumed to be inevitable due to the fact that tumour cells have entered the continuous 
volume of the peritoneal cavity. The adjuvant application of intraoperative intraperitoneal 
chemotherapy is aimed at the destruction of this residual microscopic disease. In most 
institutions performing surgical procedures for PC, hyperthermia is a standard component 
of the treatment7;8. Hyperthermia is defined as an increase of temperature in a tumour-
affected body region to 39-43°C by using an external energy source9. Next to a direct 
cytotoxic effect, hyperthermia is believed to enhance the antitumour effect of several 
cytostatic agents at markedly lower temperatures by increasing blood flow and oxygen 
content within tumours10;11. This phenomenon is thought to increase intratumoural drug 
concentrations and thereby the cytostatic efficiency. 
So far, no randomised controlled trials have been published comparing normothermic 
versus hyperthermic intraoperative chemotherapy for PC from colorectal origin. Moreover, 
the additional value of chemotherapeutic agents in the intraperitoneal perfusion fluid 
has never been assessed in prospective studies. For clinical practice, it is very relevant to 
ascertain the necessity of both elements being included in the treatment since performance 
of these procedures is technically demanding. Also, some of the of reported side effects 
resulting from HIPEC procedures are possibly associated with either the use of the relatively 
high dose of mitomycin C or the hyperthermic conditions during the perfusion12-14. Recently, 
an animal model for PC was established which allows the performance of CS and HIPEC15;16. 
It was shown that the adjuvant application of HIPEC after CS indeed significantly prolonged 
survival when compared to CS only17. This study was designed to evaluate the necessity of 
the separate elements hyperthermia and chemotherapy for the effectiveness of the HIPEC 
therapy as a whole on survival.   
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Methods
Experimental design
In all animals PC was induced seven days before the surgical procedures. Animals were 
randomly assigned to one of four treatment groups, consisting of 20 animals each: Group 
1: exploration and cytoreductive surgery only (CS), group 2: cytoreductive surgery followed 
by hyperthermic intraperitoneal perfusion with saline at 41°C (hyperthermic intraperitoneal 
perfusion: HIPE), group 3: cytoreductive surgery followed by normothermic intraperitoneal 
perfusion with mitomycin at 37°C (intraperitoneal chemotherapy: IPEC), group 4: 
cytoreductive surgery followed by hyperthermic intraperitoneal perfusion with mitomycin 
at 41°C (HIPEC). Primary outcome parameter was survival. 
Animals
Eighty 10-12 weeks old male WAG/Rij rats with a mean weight of 263 ± 13 grams were 
obtained from Harlan, Horst, The Netherlands. The animals were accustomed to laboratory 
conditions for at least one week before experimental use and housed under clean, non-
sterile standardised conditions (temperature 20-24°C; relative humidity 50-60%, 12h 
light/12 h dark) in filter-topped cages (three rats per cage). The animals were allowed free 
access to chow (Ssniff, Bio services Uden, The Netherlands) and water. All experiments were 
carried out in accordance with the Dutch Animal Welfare Act of 1997 and approved by the 
Animal Welfare Committee of the Radboud University Nijmegen Medical Centre. 
Induction	of	peritoneal	carcinomatosis
PC was induced by intraperitoneal injection of syngeneic rat colon carcinoma CC-531 cells 
as described before18. All animals were inoculated by intraperitoneal injection of 2ml of this 
cell suspension one week before surgical procedures. 
Surgery
CS was performed in all animals one week after tumour cell inoculation under general 
anaesthesia using isoflurane 3%, O
2
 and N
2
O 1:1. Carprofen (5 mg/kg/day) was given 30 
min before surgery and once daily until the third postoperative day for analgesia. Rats were 
placed on a warmed mattress during all procedures to limit body heat loss.
A complete midline laparotomy was performed in all animals. Subsequently, the abdominal 
cavity was inspected and the number of tumour deposits at 11 different sites was scored 
semiquantitatively with a score of 0 for no macroscopic tumour, 1 for limited tumour growth 
(diameter of 1–2 mm), 2 for moderate tumour growth (diameter of 2–4 mm), or 3 for an 
abundant presence of tumour nodules (diameter >4 mm or >10 deposits). The sum of scores 
from all sites represented the peritoneal cancer index (PCI) as described before15;17. 
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After inspection, CS was performed in all animals, aimed at radical removal of all macroscopic 
tumour deposits with standard resection of the greater omentum. In case of irresectable 
tumour deposits cauterisation using an electrocoagulation device was performed. Residual 
tumour load after CS was scored using the R1-R2a-R2b classification in accordance to current 
clinical practice: R1: Absence of residual tumour, R2a: a residual tumour smaller than 2.5 
mm, R2b: tumour mass larger than 2.5 mm left behind. 
In the CS group, the abdomen was closed after exploration and cytoreductive procedures. In 
all other groups, surgery was followed immediately by intraperitoneal perfusion during 90 
minutes according to the assigned treatment. 
Intraperitoneal perfusion procedure
While the abdominal cavity was still exposed, two multiperforated catheters were introduced 
through the flanks into the abdominal cavity to perform perfusion as described before15;17. 
In short, the peritoneal perfusate consisting of 250 ml NaCl (0.9%) was warmed and infused 
into the abdomen during 90 min at 10 ml/min using a roller pump (Ismatec, Idex corporation, 
Northbrook). In the IPEC and HIPEC group, Mitomycin-C (Nycomed Christiaens BV, Breda, 
The Netherlands) was dissolved in saline to the appropriate concentration. A dose of 35 mg/
m2 was added to the perfusate in three separate administrations at 30 min intervals, each 
containing 50%, 25% and 25% of the total respectively. The abdomen was gently massaged 
throughout the perfusion to achieve an equal fluid distribution throughout the peritoneal 
cavity. After 90 minutes, the abdominal cavity was perfused with saline during 5 min, the 
catheters were removed and subsequently the abdominal wall was closed in two layers 
using continuous Vicryl 3/0 sutures. Ten ml of NaCl 0.9% were given subcutaneously to all 
animals for rehydration. 
Follow-up
Survival was the primary endpoint of this study. Body weight and the general condition 
were assessed daily for the first week after surgical procedures, and at least twice a week 
thereafter. The humane endpoint was determined by an experienced biotechnician who 
was blinded for which treatment the animals had received. Bodyweight was used to 
evaluate toxicity of the treatment and expressed as relative bodyweight compared with the 
bodyweight on the day of surgery. 
When the humane endpoint was reached (physical inactivity, signs of intra-abdominal 
tumour growth with invalidating consequences or signs of massive haemorrhagic ascites), 
rats were killed by O
2
/CO
2
-asphyxation and autopsied. Postmortem, the same PCI scoring 
system as described above was used to record the intraperitoneal tumour load. In addition, 
the weight of ascites was measured. At 126 days post-operatively, the experiment was 
terminated and the remaining rats were euthanised and autopsied. 
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If no macroscopic tumour was found at autopsy, the greater omentum and diaphragm 
were removed for microscopic evaluation. Samples were stained with hematoxylin & eosin 
(H&E) and murine MG1 antibody in combination with a horseanti-mouse IgG antibody, HRP 
conjugated (Vector Laboratories Inc., Burlingame, CA). 
Statistical	Analysis
Graphpad Prism (version 4.0, 2003, Graphpad Software Inc., San Diego CA) and SPSS 
(version 16.0, 2007, Chicago, IL) software were used for all statistical analyses. Chi square or 
Fisher’s Exact test were used for the comparison of dichotomous values, and for comparison 
of continuous values one-way ANOVA testing or Kruskall-Wallis testing was used. Survival 
analysis was performed using Kaplan–Meier curves and compared by means of the log-rank 
test. Cox survival regression analysis was used to correct for confounding factors. 
Results
Surgical procedures
CS was performed on eighty animals. Preoperative clinical condition and mean body weight 
were similar in all treatment groups. 
All animals had macroscopic tumour deposits during laparotomy. Details are given in 
table 1 and examples of tumour deposits are shown in figure 1. Most frequently affected 
tumour sites were the greater omentum, perisplenic area, liver hilum, mesentery and 
intraabdominal site of tumour inoculation. At initial exploration during surgery, mean PCI 
did not differ between the treatment groups (p = 0.452). 
Complete macroscopic resection of tumour deposits (R1 resection) was achieved in 72 
animals (90%). In the animals with residual tumour, no deposits with a diameter larger than 
2.5 mm were left behind. The results of CS in terms of residual disease did not differ between 
the treatment groups (p = 0.918). The CS procedures took a mean time of 30 minutes in all 
groups.
Two rats (one each in the HIPE and IPEC groups) died during the perfusion procedures due 
to respiratory failure. One rat in the CS group died shortly after the surgical procedure due 
to hypovolemia as a consequence of extensive blood loss during surgery. An unexpected 
death occurred in the HIPEC group on day 13 after surgery. At autopsy a herniation of small 
bowel through a mesentery defect was found, causing obstruction. One rat from the IPEC-
treatment group died after 50 days due to an unknown cause. At autopsy, no evidence of 
tumour growth was found, nor any other signs which would explain the premature death. 
These rats were marked as censored in the survival analyses.  
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Figure 1. Examples of macroscopic tumour deposits found at spleen (A) and mesentery (B) during 
laparotomy. 
Table 1. Tumour score before cytoreduction and results of cytoreductive surgery.
Group CS HIPE IPEC HIPEC
Preoperative	weight	(g)	(mean,	SD) 264 (16) 265 (10) 264 (15) 261 (12)
Tumour score per site (median, range)
Subcutaneous 1 (0-1) 1 (0-2) 1 (0-1) 1 (0-3)
Inoculation site intraabdominal 1 (0-3) 1 (0-1) 1 (0-1) 1 (0-1)
Greater omentum 1 (1-1) 1 (1-2) 1 (1-1) 1 (1-1)
Liver hilum 1 (1-2) 1 (1-2) 1 (0-2) 1 (1-2)
Liver surface 0 (0-1) 0 (0-0) 0 (0-0) 0 (0-1)
Spleen 1 (0-1) 1 (0-1) 1 (0-2) 1 (1-1)
Mesentery 1 (0-2) 1 (0-2) 1 (0-2) 1 (0-2)
Fatpad left 0 (0-1) 0 (0-2) 0 (0-2) 0 (0-2)
Fatpad right 0 (0-3) 0 (0-1) 0 (0-1) 0 (0-1)
Diaphragm 0 (0-1) 0 (0-1) 0 (0-1) 0 (0-1)
Parietal peritoneum 0 (0-1) 0.5 (0-1) 0.5 (0-2) 0 (0-1)
Overall PCI (mean, SD) 5.9 (2.0)  6.6 (2.0) 5.8 (1.9) 6.1 (1.6)
Splenectomy (n)
Yes 0 1 2 2 
No 20 19 18 18
Completeness	of	resection	(n)
R1 18 17 18 19
R2a 2 3 2 1
R2b 0 0 0 0
CS = cytoreductive surgery, HIPE = CS + perfusion with NaCl at 41°C, IPEC = CS + perfusion with 
mitomycin at 37°C, HIPEC = CS + perfusion with mitomycin at 41°C. PCI = Peritoneal Cancer Index, 
R1 = no macroscopic residual tumour after cytoreduction, R2a = residual tumour <2.5mm after 
cytoreduction, R2b = residual tumour >2.5mm after cytoreduction. 
Chapter 6
106
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Perfusion	characteristics
During the perfusion procedures, the intraabdominal temperature at the inflow site 
was similar in both hyperthermic groups, with a mean of 41.3°C (figure 2A). Mean rectal 
temperatures during the experiment are shown in figure 2B. Rats in the IPEC group 
(normothermic perfusion) had a significantly lower rectal temperature at the end of 
perfusion than rats from both groups with hyperthermic perfusion (p<0.001). 
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Figure 2. A. Intra-abdominal temperatures at the site of inflow and B. rectal temperatures during 
perfusion procedures.
Data represent means ± SD (n=20) of all procedures. HIPE = CS + perfusion with NaCl at 41°C, IPEC = CS 
+ perfusion with mitomycin at 37°C, HIPEC = CS + perfusion with mitomycin at 41°C.
Clinical appearance
Apart from the surgery-related complications mentioned above, and one nontumour related 
death the procedures were well tolerated. In figure 3, the course of mean body weight in 
the various treatment groups is shown for the first week after operation. In the CS group 
the lowest postoperative body weight was recorded on the second day after surgery. In 
the other treatment groups rats generally gained weight from the fourth postoperative day 
onwards. After reaching a nadir, the rats gained weight again and recovered completely. The 
mean maximum weight loss was significantly higher in all groups that underwent peritoneal 
perfusion after CS than in rats in the CS group (CS versus HIPE, p = 0.034, CS versus IPEC and 
CS versus HIPEC, p <0.001). In addition, rats in the HIPEC group lost significantly more weight 
than rats in the HIPE group (p = 0.034). 
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Figure 3. Course of mean relative bodyweight during the first week after surgery.
CS = cytoreductive surgery, HIPE = CS + perfusion with NaCl at 41°C, IPEC = CS + perfusion with 
mitomycin at 37°C, HIPEC = CS + perfusion with mitomycin at 41°C.
Survival 
Kaplan-Meier survival analyses are shown in figure 4. In the group treated with CS only, 
median survival was 62 days (95% confidence interval (CI) 46-78) Median survival in rats 
receiving HIPE perfusion was 57 days (95% CI 50-64). In the group treated with HIPEC, 
median survival was 121 days. At the end of the follow-up, 13 rats in the IPEC-group were 
still alive and median survival was therefore not reached in this group. The difference in 
survival outcome when compared to the CS-group was significant for both the HIPEC group 
(p = 0.022, hazard ratio for dying 0.46, 95% CI 0.24-0.89) and the IPEC group (p = 0.002, 
hazard ratio 0.36, 95% CI 0.19-0.69). 
After the maximum follow-up of 126 days was reached, 27 rats were still alive. In 21 of these 
rats no ascites or macroscopic tumour deposits were found at autopsy (2/3 CS, 2/2 HIPE, 
10/13 IPEC, 7/9 HIPEC). In one of the rats from the IPEC-group, microscopic tumour deposits 
were found in a coagulated tumour. In the other rats, no residual tumour tissue was found 
at microscopic evaluation.  
In rats from the CS group that reached their humane endpoint during the follow-up, a higher 
mean PCI was found when compared to the postmortem PCI of rats in the HIPEC-group (p = 
0.050). A similar trend was observed when comparing the HIPEC group with the rats treated 
with HIPE, but this remained non-significant (p = 0.070). The amount of ascites present at 
autopsy did not differ between groups (p = 0.083). Post mortem findings are given in table 2. 
No predictors of outcome other than treatment group were identified in multivariate 
analysis. 
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Figure 4. Kaplan Meier survival curves, per group.
CS = cytoreductive surgery, HIPE = CS + perfusion with NaCl at 41°C, IPEC = CS + perfusion with 
mitomycin at 37°C, HIPEC = CS + perfusion with mitomycin at 41°C.
CS versus HIPEC: p = 0.022, CS versus IPEC: p = 0.002, CS versus HIPE: nonsignificant. 
Table 2. Post mortem findings.
Group CS HIPE IPEC HIPEC
Overall PCI (mean, SD) 26 (5) 25 (6) 21 (3) 20 (7)
Ascites	weight	(g)	(mean,	SD) 31 (28) 34 (23) 37 (13) 47 (15)
CS = Cytoreductive Surgery, HIPE = CS + perfusion with NaCl at 41°C, IPEC = CS + perfusion with 
mitomycin at 37°C, HIPEC = CS + perfusion with mitomycin at 41°C. PCI = Peritoneal Cancer Index
Discussion
This study shows that the effectiveness of intraoperative intraperitoneal perfusion after CS 
is highly dependent on the presence of chemotherapeutic agents in the perfusate but not 
on hyperthermia. 
Although most procedures for PC nowadays are performed under hyperthermic conditions, 
the additional effect of hyperthermia as a component of the combined treatment for 
patients with PC from colorectal origin has never been demonstrated. Only one randomised 
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trial comparing intraoperative intraperitoneal perfusion with mitomycin C and cisplatin 
under normothermic and hyperthermic conditions has reported a survival benefit in 
the hyperthermic group19. However, this trial was performed in patients with advanced 
gastric cancer after curative gastrectomy without macroscopic peritoneal involvement, 
and treatment was applied in a prophylactic setting to prevent recurrent disease. The 
addition of hyperthermia to standard malignancy treatment strategies like radiotherapy or 
chemotherapy has been associated with improved tumour control and survival in patients 
with locally advanced cervix carcinoma20, breast cancer21, and soft tissue sarcoma22. However 
the available evidence is very limited, warranting further research to establish the value of 
hyperthermia in clinical practice. 
Preclinical studies report conflicting results regarding the effect of hyperthermia on several 
outcome parameters varying from no effect on pharmacokinetics and pharmacodynamic 
outcomes23-25 to a significant increase in concentration of chemotherapeutic agents in 
tumour cells or tissue under hyperthermic conditions26. Pelz et al. evaluated the histological 
response of PC in rats treated with hyperthermic perfusion with or without mitomycin, 
or with an intraperitoneal mitomycin injection under normothermic conditions. In all 
locoregional treatment groups a delay of tumour growth was observed as compared with 
sham operated animals, which was most pronounced in the group treated with HIPEC27. Yet 
in none of these preclinical studies CS was performed and overall survival was not used as 
an outcome parameter. 
In this study, the application of hyperthermic saline did not have a beneficial effect on 
survival as compared to CS only. Moreover, no difference in postmortem PCI scores was 
found between the CS only and HIPE group, whereas the rats in the IPEC and HIPEC group 
showed a lower tumour load as expressed by PCI scores at autopsy. This inhibition of 
tumour growth by HIPEC is in accordance with results from a previous study performed 
in our laboratory17, but was not seen in the group treated with hyperthermia only in this 
experiment. It should be taken into account that in the current study the temperature used 
for hyperthermic conditions was 41°C, which is used in the only completed randomised 
clinical trial evaluating the effect of HIPEC5;15. It cannot be ruled out that the application 
of higher temperatures (exceeding 42°-43°C) would have resulted in a decrease in tumour 
growth, as these temperatures have been demonstrated to have a direct cytotoxic effect 
on to both normal and tumour cells under experimental conditions9;10. However, in this 
study we aimed to evaluate the separate components of the clinical multimodality HIPEC 
treatment, which is routinely performed at a temperature of 41°C. 
At the end of the follow up period of this study, 10 animals in the IPEC group and 7 animals 
in the HIPEC-group were alive without any microscopic evidence of disease, which compares 
favourably to 2 animals in both the CS and HIPE group. This study demonstrates that the 
application of normothermic chemoperfusion can successfully eliminate microscopic tumour 
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cells after cytoreductive procedures, and that normothermic intraperitoneal chemotherapy 
certainly does not lead to inferior results as compared to hyperthermic treatment. This is an 
important finding as application of hyperthermic circumstances in intraperitoneal perfusion 
may result in additional toxicity in clinical practice12;14. Indeed, in the current experiment the 
mean weight loss in the first week which is considered to be a marker of treatment-related 
toxicity was most pronounced in the HIPEC group. Furthermore, in clinical practice the 
heating of chemotherapy is time-consuming, increases the technical demands to operating 
room personnel and raises costs. Thus, the observation that normothermic application 
of intraperitoneal chemotherapy may be equally effective in the treatment of PC should 
stimulate further research in this area, to critically assess the necessity of hyperthermia. If 
feasible, a simplification of the current multimodality treatment may benefit the patients 
with PC.
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Abstract
Background 
Perioperative intraperitoneal chemotherapy is used as an adjunct to cytoreductive surgery 
(CS) for peritoneal carcinomatosis (PC) in order to prolong survival. Worldwide, hyperthermic 
intraperitoneal chemotherapy (HIPEC), early postoperative intraperitoneal chemotherapy 
(EPIC) and combinations of the two are used. It remains unclear which regimen is most 
beneficial. 
 
Methods
The rat colon carcinoma cell line CC-531 was injected into the peritoneal cavity of eighty 
WAG/Rij rats to induce PC. Animals were randomised into four treatment groups (n=20): CS 
only, CS followed by HIPEC (mitomycin 35 mg/m2 at 41.5°C), CS followed by EPIC during 5 
days (intraperitoneal injection of mitomycin on day 1 and 5-fluorouracil on day 2-5), and CS 
followed by HIPEC plus EPIC. Primary outcome was survival. 
Results
In rats treated with CS only, median survival was 53 days (95% confidence interval (CI) 49-
57). In rats treated with CS followed by HIPEC, survival was significantly (p = 0.001) increased 
(median survival 94 days, 95% CI 51-137). In the group treated with EPIC after CS, 12 out of 
20 rats were still alive at the end of the experiment (p<0.001 as compared with CS only). In 
the group receiving both treatments, eleven rats died of toxicity, and therefore this group 
was not included in the survival analysis. 
Conclusion  
Both EPIC and HIPEC were effective in prolonging survival. The beneficial effect of EPIC on 
survival seemed to be more pronounced than that of HIPEC. Further research is indicated 
to evaluate and compare the possible benefits and adverse effects associated with both 
treatments.
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Introduction
The combination of cytoreductive surgery (CS) and perioperative intraperitoneal 
chemotherapy is the only available curative option for patients with peritoneal carcinomatosis 
(PC) from colorectal cancer. By now, it has been widely accepted as the treatment of choice 
for patients with limited peritoneal carcinomatosis who are fit for major surgery. The aim of 
this treatment is to radically remove all visible tumour deposits from the peritoneal cavity, 
and to eradicate residual microscopic disease by adjuvant application of intraperitoneal 
chemotherapy. Promising results have been shown by several centres, achieving a median 
survival which compares favourably to the outcomes of patients treated with palliative care 
in whom life expectancy is usually limited to approximately 6 months1-5.
The adjuvant intraperitoneal chemotherapy can be applied directly after cytoreduction 
under hyperthermic conditions (hyperthermic intraperitoneal chemotherapy, HIPEC) as a 
part of the surgical procedure, or can be started on the first postoperative day and continued 
for several (usually five) days (early postoperative intraperitoneal chemotherapy, EPIC). 
Both techniques are currently offered to patients with colorectal PC, either as separate 
treatments or in combination, depending on the preference of the center and surgeon. 
The choice for HIPEC and/or EPIC has major consequences for the scheduling of procedures 
and the capacity of the treatment centre. This becomes relevant as growing awareness 
among physicians about the availability of treatment possibilities for PC results in increasing 
numbers of patients being referred to specialised centres. 
No randomised controlled trials have been published comparing the survival outcomes after 
EPIC and HIPEC. Furthermore, it is unclear whether the combination of both HIPEC and EPIC 
results in superior outcomes.
In a recent experimental study, it was shown that the adjuvant application of HIPEC after 
CS can prolong survival as compared with CS only6. A second study demonstrated beneficial 
results for both adjuvant normothermic and hyperthermic intraoperative perfusion7.  
In the present study, the effectiveness of HIPEC and EPIC as adjuvant treatment after CS was 
evaluated in a well-established model for PC in rats. In addition, the combination of the two 
treatments was investigated. Survival was the primary outcome parameter.   
Methods
Experimental design
PC was induced in all animals seven days before the surgical procedures. Rats were assigned 
to one of four treatment groups (n=20 each) by randomisation. Treatment per group was as 
follows: Group 1 (CS): exploration followed by cytoreductive surgery only; group 2 (HIPEC): 
Chapter 7
116
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
cytoreductive surgery plus hyperthermic intraperitoneal perfusion with mitomycin at 41°C 
for 90 minutes; group 3 (EPIC): cytoreductive surgery followed by early postoperative 
chemotherapy from the first day postoperatively using mitomycin on the first day and 
5-fluorouracil (5-FU) on day 2 -5; group 4 (HIPEC+EPIC): cytoreductive surgery followed by 
HIPEC and EPIC. Primary outcome parameter was survival.
Animals
Eighty male WAG/Rij rats (10-12 weeks old, mean weight 267 ± 8.2 g) were obtained from 
Harlan, Horst, The Netherlands. The animals were housed in filter-topped cages (three rats 
per cage) under clean, non-sterile standardised conditions (temperature 20-24°C; relative 
humidity 50-60%, 12h light/12 h dark) with free access to water and chow (Ssniff, Bio 
services Uden, The Netherlands). Accustomization to laboratory conditions was allowed for 
at least one week before the start of the experiment. All experiments were approved by the 
Animal Welfare Committee of the Radboud University Nijmegen Medical Centre and carried 
out in accordance with the Dutch Animal Welfare Act of 1997.
Induction	of	peritoneal	carcinomatosis
Two ml of a suspension containing a concentration of 106 cells/ml of the syngeneic rat 
colon carcinoma cell line CC-531 were injected intraperitoneally in all animals as described 
elsewhere to induce peritoneal carcinomatosis8. 
Surgery
One week after tumour cell inoculation, CS was performed in all animals under general 
anaesthesia using isoflurane 3%, O
2
 and N
2
O 1:1. Carprofen (5 mg/kg/day) was given for 
analgesia 30 min prior to surgery and once daily until the third postoperative day. To limit 
body heat loss, all rats were placed on a warmed mattress during the procedure.
The abdominal cavity was opened and exposed by a complete midline laparotomy, and 
all abdominal regions were systematically inspected for tumour deposits. The peritoneal 
cancer index (PCI) representing the extent of PC was recorded as the sum of all scores, as 
described previously6;7.
All animals underwent CS with standard resection of the greater omentum aiming at radical 
removal of all macroscopic tumour deposits. CS may include resection of fatpads, spleen, 
parts of the mesentery and peritonectomy. No bowel resections are performed in this 
experimental model and no anastomoses are made. Due to the small size of the animals, 
some tumour localisations are impossible to reach for performing surgical resection. Small 
lesions that are not suitable for resection due to their localisation are cauterised using an 
electrocoagulation device. These cauterised deposits are considered as completely treated, 
as no visible vital tumour tissue is left behind. After the best achievable cytoreduction, the 
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amount of residual tumour was scored in accordance to current clinical practice using the 
R1-R2a-R2b classification: R1, no macroscopic disease left; R2a, tumour smaller than 2.5 
mm left behind; R2b, residual tumour mass larger than 2.5 mm. 
In both the CS and EPIC groups the abdomen was closed. In the HIPEC and HIPEC+EPIC 
groups, surgery was followed immediately by heated intraperitoneal perfusion. 
HIPEC
Perfusion of the abdomen was performed with a closed technique as described before6;9. 
The peritoneal perfusate consisting of 250 ml NaCl (0.9%) was warmed to 41.5°C and 
infused into the abdomen at 10 ml/min during 90 min. Mitomycin-C (Nycomed Christiaens 
BV, Breda, The Netherlands) was dissolved in saline and added to the perfusate in three 
separate administrations at 30 min intervals, each containing 50%, 25% and 25% of the total 
dose of 35 mg/m2 mitomycin. During the perfusion, gentle massage of the abdomen was 
applied to equalise fluid distribution in the peritoneal cavity. Subsequently the abdominal 
wall was closed in two layers using continuous Vicryl 3/0 sutures. All animals received a 
subcutaneous injection with ten ml of NaCl 0.9% for rehydration. 
EPIC
Intraperitoneal chemotherapy was administered with a single daily intraperitoneal injection 
(0.75 ml). On the first day following surgery, mitomycin was given in a dose of 10 mg/m2 
(1.36 mg/kg). From the second postoperative day onwards a dose of 15 mg/kg 5-fluorouracil 
was given to each rat intraperitoneally. The last dose of 5-fluorouracil was administered on 
day five. 
Follow-up	and	Autopsy
During the first week after surgery, general condition and body weight of the animals was 
assessed daily. After the first week, general condition and bodyweight were recorded at 
least twice weekly and more often if symptoms of discomfort were present. Survival was the 
primary endpoint of this study. 
Humane endpoints were chosen to minimise or terminate the pain or distress of the 
experimental animals via euthanasia rather than waiting for their deaths as the endpoint. 
The following humane endpoints were used: 
The animal refuses intake of food and fluids, shows rapid weight loss, severe circulation 
or breathing problems, strongly abnormal behaviour, severe clinical symptoms or disabling 
consequences of ascites or tumour growth, or the expectation is raised that the animal will 
die shortly. 
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Whether these endpoints were reached was determined by an experienced biotechnician 
blinded to the animals’ assigned treatment groups. 
When the humane endpoint was reached, rats were killed by O
2
/CO
2
-asphyxation and 
autopsied. 
At autopsy, the weight of ascites (if present) was measured and the extent of intraperitoneal 
tumour load was recorded using the same PCI scoring system as described above. The 
experiment was terminated at 168 days post-operatively (24 weeks). The rats that were still 
alive at that time were euthanized and autopsied. 
In case no macroscopic tumour deposits were found at autopsy, the greater omentum and 
diaphragm were removed and microscopically examined for presence of tumour growth. 
Hematoxylin & eosin (H&E) staining and murine MG1 antibody in combination with a 
horse anti-mouse immunoglobin G (IgG) antibody, horseradish peroxidise (HRP) conjugated 
(Vector Laboratories Inc., Burlingame, CA, USA) were used for microscopic evaluation of the 
samples. 
Statistical	Analysis
Statistical analysis was performed using Graphpad Prism (version 4.0, 2003, Graphpad 
Software Inc., San Diego CA) and SPSS (version 17.0, 2007, Chicago, IL) software. One-way 
analysis of variance (ANOVA) testing was used for comparison of continuous values. The 
comparison of dichotomous values was performed with Chi-square or Fisher’s Exact test. 
Kaplan–Meier curves were used for survival analysis and compared by means of the log-
rank test. To correct for confounding factors, Cox regression analysis was performed. 
Results
Surgical procedures
All animals underwent CS. No differences were observed between groups regarding 
preoperative clinical condition or mean bodyweight. 
Macroscopic PC was present in all animals. An example of macroscopic tumour growth is 
shown in figure 1a. The greater omentum, perisplenic area, liver hilum, mesentery and intra-
abdominal site of tumour inoculation were the most commonly affected sites of tumour 
growth. Detailed PCI is given in table 1. Median PCI before cytoreduction was similar in all 
treatment groups (p = 0.429). 
No difference in results of CS in terms of residual disease were observed between the 
treatment groups (p = 0.343). Mean time of the CS procedures was 26 (standard deviation, 
SD 6) min without differences between groups (p=0.221).
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Table 1: Tumour score before cytoreduction and results of cytoreductive surgery.
Group CS EPIC HIPEC HIPEC+EPIC
Preoperative	weight	(g)	(mean,	SD) 267 (7) 265 (9) 268 (9) 267 (8)
Tumour score per site (median, range)
Subcutaneous 1 (0-2) 1 (0-1) 1 (0-1) 1 (0-2)
Inoculation site intraabdominal 1 (0-3) 1 (0-3) 1 (0-2) 1 (0-3)
Greater omentum 1 (1-1) 1 (0-2) 1 (1-3) 1 (1-1)
Liver hilum 1 (0-1) 1 (0-1) 1 (1-3) 1 (1-2)
Liver surface 0 (0-0) 0 (0-0) 0 (0-1) 0 (0-0)
Spleen 1 (0-1) 1 (0-1) 1 (1-2) 1 (0-2)
Mesentery 1 (1-3) 1 (0-3) 1 (1-2) 1 (0-3)
Fatpad left 0 (0-1) 0 (0-1) 0.5 (0-1) 0 (0-1)
Fatpad right 0 (0-2) 0.5 (0-2) 1 (0-2) 0 (0-2)
Diaphragm 0 (0-2) 0 (0-1) 0 (0-1) 0 (0-2)
Parietal peritoneum 0 (0-3) 0 (0-2) 0 (0-3) 0 (0-3)
PCI (mean, SD) 8.0 (2.9)  7.3 (2.0) 8.3 (1.8) 7.4 (2.0)
Splenectomy (n)
Yes 1 1 3 3 
No 19 19 17 17
Completeness	of	resection	(n)
R1 16 19 18 18
R2a 2 1 2 2
R2b 2 0 0 0
CS = cytoreductive surgery, EPIC = early postoperative intraperitoneal chemotherapy, HIPEC = 
hyperthermic intraperitoneal chemotherapy, PCI = Peritoneal Cancer Index
Perfusion	characteristics
Mean intra-abdominal temperature at the inflow site was 41.5°C (SD 0.44). Mean rectal and 
intra-abdominal temperatures during the perfusion are shown in figure 2. The perfusion 
characteristics were similar in both HIPEC and HIPEC+EPIC groups. 
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Figure 1. Examples of macroscopic tumour deposits found at during initial exploration of the abdomen 
on the kidney (a) and during autopsy at liver (b), omentum (c) and mesentery (d). 
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Figure 2. Rectal and intra-abdominal temperatures during perfusion procedures. Data represent means 
± SD of temperature measurements during HIPEC in all animals from both HIPEC and HIPEC+EPIC 
groups (n=40). 
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Early	follow-up
Figure 3 shows the course of bodyweight during the first 14 days after surgery in the four 
groups. 
Rats in the CS group generally gained weight from postoperative day 2 onwards. In the HIPEC 
group, rats started gaining weight after day 6. Rats receiving EPIC (with or without HIPEC) 
reached their minimum weight on day 7. In both groups receiving EPIC, the maximum 
weight loss was higher than in the CS group (CS versus HIPEC, p = 0.056, CS versus EPIC and 
CS versus HIPEC+EPIC, p <0.001).
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Figure 3. Postoperative course of mean relative body weight. 
Eight deaths occurred in the early postoperative course (two HIPEC, three HIPEC+EPIC, two 
CS and one EPIC) unrelated to tumour growth. In the CS group, one rat died of postoperative 
ileus after 4 days. The other rat died of unknown reasons after 3 days. In the EPIC group, 
one rat died after 12 days because of obstruction caused by herniation of the ileum through 
a mesentery defect. In the HIPEC group, two unexpected deaths occurred, one after 7 
days because of an abscess in the upper abdomen, and one caused by respiratory failure 
immediately following the surgical procedure, possibly related to excessive blood loss 
during CS. In the HIPEC+EPIC group, deaths were caused by bowel perforation and necrosis 
after 2 days and abscess formation in the liver hilum resulting in obstruction and progressive 
icterus after 15 days. One rat was found dead after 8 days, and the cause of death remained 
unclear. 
In the HIPEC+EPIC group, a late unexpected death occurred after 86 days. At autopsy, 
herniation of the small bowel was found. All rats mentioned above were marked as censored 
in the survival analysis.  
Rats in the HIPEC+EPIC group initially recovered from the procedures and gained weight 
from day 8 onwards. However, after several weeks rats started to lose weight again to die 
eventually from excessive weight loss. This course was observed in eleven rats. At autopsy, 
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no tumour was found in these animals, nor any evidence for another cause of death. Only 
four rats died from the consequences of tumour growth. At the end of the experiment, two 
rats were alive. Given the large amount of rats dying from not tumour related causes in 
this group, the effect of treatment on survival could not be evaluated and therefore it was 
decided not to include this group in the survival analysis. 
Survival	and	post	mortem	findings
Figure 4 shows the Kaplan-Meier survival analysis for each group. Median survival in the 
group treated with CS only was 53 days (95% confidence interval (CI) 49-57 days). In the 
group of rats receiving HIPEC perfusion, a median survival of 94 days (95% CI 51-137 days) 
was observed. In the EPIC-group, 12 animals were still alive when the experiment was ended 
and therefore median survival could not be recorded, but it was at least 168 days. 
Survival outcomes were compared between groups, correcting for completeness of 
resection and pre-operative PCI. Survival outcomes in both adjuvant treatment groups were 
significantly better as compared to the CS-group: HIPEC versus CS (p = 0.001, hazard ratio 
for dying 0.24, 95% CI 0.10-0.55) and EPIC versus CS (p < 0.001, hazard ratio 0.10, 95% CI 
0.04-0.28). 
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Figure 4. Kaplan-Meier analysis of overall survival, per group. 
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Nineteen rats were still alive at the time of the maximum follow-up of 168 days. At autopsy 
11 of these rats appeared to be macroscopically free of tumour and ascites (1/2 CS, 3/5 
HIPEC, 7/12 EPIC). In all of these rats, the remaining omentum and diaphragm were removed 
and stained for histological examination. No microscopic evidence of disease was found. 
Rats from the CS group that reached their humane endpoint during follow-up showed a 
higher mean PCI at autopsy than rats treated with HIPEC (p=0. 004) or EPIC (p<0.001). The 
differences in the amount of ascites present at autopsy remained statistically insignificant 
for both adjuvant treatment groups as compared with the CS group. Post mortem findings 
are summarised in table 2. 
In multivariate analysis, the influence of PCI and completeness of resection on survival 
outcomes did not reach significance (p=0.065 and p=0.164, respectively). 
Table 2: Post mortem findings.
Group CS EPIC HIPEC p-value
PCI (mean, SD) 27 (4) 14 (10) 19 (6) <0.001
Ascites	weight	(g)	(mean,	SD) 27 (23) 40 (26) 43 (20) 0.136
CS = Cytoreductive Surgery, EPIC = Early Postoperative Intraperitoneal Chemotherapy, HIPEC = 
Hyperthermic Intraperitoneal Chemotherapy, PCI = Peritoneal Cancer Index
Discussion
In this experimental study, both EPIC and HIPEC were effective in prolonging survival when 
applied as adjuvant treatment after CS. Always keeping in mind the difference between 
rodents and humans, this finding may have important implications for clinical practice. 
The scheduling of EPIC treatment has several logistical advantages when compared with 
HIPEC. For the performance of a HIPEC procedure, a careful and punctual scheduling of 
the surgical procedure is essential. Intraoperative administration of heated chemotherapy 
requires the availability of the chemotherapeutic agent in the operating room, safety 
precautions for both the patient and the personnel involved in the procedures, specialised 
technical equipment which is adequately cleaned and/or sterilised and the presence of an 
experienced perfusionist. In contrast, for administration of EPIC, insertion of a peritoneal 
port at the end of a surgical procedure is an easier and less time consuming procedure. 
The intraperitoneal treatment itself can be performed at an intensive care unit or even 
hospital ward. Furthermore, EPIC can be offered ad hoc to patients in whom peritoneal 
carcinomatosis is discovered incidentally during laparotomy, which is a common way 
of diagnosing this disease. However, performance of EPIC has been associated with an 
increased risk of complications after extensive abdominal surgery in some retrospective 
studies10;11. 
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This theoretically may be a consequence of the prolonged contact of chemotherapy with 
newly performed anastomoses and operated surfaces, thereby delaying wound healing and 
recovery. Indeed, experimental studies have shown that both HIPEC and intraperitoneal 
injection of chemotherapy have a negative influence on wound strength12;13. 
Other disadvantages of EPIC may be a less equal distribution of fluid in the abdomen and 
patients experiencing physical discomfort (nausea, impaired mobility) associated with the 
intraabdominal presence of the chemotherapy for 5 days. However, other studies reported 
no differences in complications between HIPEC and EPIC14;15. Currently no randomised 
controlled trials have been reported comparing the two techniques in this respect. 
Previously published animal experiments have shown that the timing of intraperitoneal 
chemotherapy treatment after tumour cell application is a relevant factor influencing 
the effectiveness of treatment. It has been described that administration of anticancer 
agents immediately after tumour cell inoculation can eliminate all disease, whereas late 
administration (later than 3 days after tumour inoculation, when usually macroscopic disease 
is present) may slow down tumour growth but cannot be used with curative intent16-20. The 
current study shows, in accordance with the experimental literature mentioned, that the 
application of intraperitoneal chemotherapy 1 day after surgery is still effective to eliminate 
microscopic tumour cells after cytoreductive procedures, without the use of hyperthermic 
circumstances. Twelve animals from the EPIC group and 5 animals from the HIPEC group 
were alive at the end of the follow-up period of 24 weeks. Three animals from the HIPEC and 
7 from the EPIC group were free of microscopic tumour. 
Due to the experimental design of this study, choices such as the HIPEC conditions applied 
had to be made, which always constitute a certain degree of bias. Although the flow rate in 
rats may be lower than in the human situation, it is thought unlikely that this would explain 
the survival outcomes of this study. To our knowledge, the flow rate is not a commonly 
reported prognostic factor in patients treated with HIPEC. In the rats receiving EPIC, 
chemotherapy was given as a low volume intraperitoneal injection, resulting in no flow or 
pressure at all. 
A direct cytotoxic effect of higher temperatures (exceeding 42°C–43°C) on both normal and 
tumour cells has been observed under experimental conditions21;22. In HIPEC treatment, 
however, direct cytotoxicity by hyperthermia is not a primary goal. The hyperthermia 
applied in this treatment is aimed at a synergetic effect with chemotherapy. Therefore in 
this animal model, lower temperatures are used, based on the HIPEC technique that was 
described in the only completed randomised phase III trial evaluating the effectiveness of 
HIPEC using an inflow temperature of 41-42°C1. 
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The necessity of hyperthermia in the treatment of peritoneal carcinomatosis has never been 
proven. Although mild hyperthermia as applied in HIPEC is thought to increase blood flow 
and oxygen content within tumours, thereby increasing drug concentrations and enhancing 
the antitumour effect, the presumed beneficial effect on patient survival has never been 
investigated in randomised trials22;23. In retrospective studies, no difference between 
normothermic and hyperthermic administration of mitomycin followed by EPIC was found24. 
In a recent experimental study normothermic and hyperthermic intraoperative perfusion 
were both effective in prolonging overall survival in rats with peritoneal carcinomatosis 
and with both treatments several animals remained free of disease until the end of the 
follow-up period7. In a study by Zeamari et al., similar results were obtained, although no CS 
was performed25. Also in the current study, the performance of EPIC (under normothermic 
conditions) showed to be at least equally effective to the treatment including hyperthermia. 
Therefore, further research into the necessity of hyperthermia should be performed to 
investigate if indeed simplification of the current multimodality treatment for peritoneal 
carcinomatosis is possible.
In theory, EPIC and HIPEC may be combined to obtain optimal oncologic outcome. However, 
a risk of toxicity of the high dose of chemotherapy should always be taken into account 
when considering the combination of treatments. In the current study most rats treated 
with HIPEC+EPIC suffered from severe toxicity as illustrated by the weight loss during the 
first two postoperative weeks. In the end most rats died after several weeks with symptoms 
suggesting late toxicity. For further evaluation of the combination of HIPEC and EPIC in 
experimental studies, it may be useful to use only 5-fluorouracil in the EPIC regimen in order 
to decrease toxicity. 
In conclusion, both HIPEC and EPIC prolonged survival when used as adjuvant therapy 
after cytoreductive surgery for peritoneal carcinomatosis from colorectal cancer in an 
experimental model. Further research is required to evaluate and compare the possible 
beneficial and adverse affects associated with both treatments in daily clinical practice. In 
this way the optimal treatment strategy for patients suffering from peritoneal carcinomatosis 
of colorectal origin will be further improved. 
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Abstract
Background 
Failure to respond to systemic chemotherapy is considered an exclusion criterion by some 
institutions for treatment with cytoreductive surgery and hyperthermic intraperitoneal 
chemotherapy (HIPEC). However, it is unknown if these patients benefit from HIPEC 
treatment. This study aimed to report on outcomes of HIPEC in patients who failed to 
respond to adjuvant systemic chemotherapy. 
Methods
Patients were selected from a prospective database containing data on all patients who 
underwent HIPEC, using the following criteria: (1) Metachronous peritoneal carcinomatosis 
(PC) from colorectal origin, (2) adjuvant chemotherapy after primary tumour resection, 
(3) development of PC or local recurrence within 18 months after start of chemotherapy. 
Treatment and survival data were retrospectively collected. 
Results
Twenty-one patients (29% male, mean age 57 years) were included. Median time to 
recurrence of disease was 9 months (range 2-15) after first chemotherapy administration. 
Median survival was 28 months (range 3-100). One-year and 2-year survival were 71% and 
43%, respectively. 
Conclusion
Patients who initially failed to respond to systemic adjuvant treatment showed a survival 
after HIPEC similar to results reported in literature in patients with unknown responsiveness. 
Failure to respond to previous adjuvant systemic treatment should therefore not be 
considered an exclusion criterion for HIPEC treatment.
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Introduction
Peritoneal carcinomatosis (PC) originating from colorectal tumours has long been considered 
to be an incurable condition. Patients have therefore been treated in palliative support 
programs. Median survival is less than 13 months in patients receiving leucovorin and 
5-fluorouracil (5-FU)-based chemotherapy schedules and might reach survival rates up to 
18 months with combination therapies1;2. Recently, treatment of patients suffering from PC 
from colorectal origin has gained new interest because PC without visceral metastases is now 
considered as regional spread of disease rather than systemic metastasis. The availability 
of new local treatment strategies like cytoreductive surgery, hyperthermic intraperitoneal 
chemotherapy (HIPEC) and early postoperative intraperitoneal chemotherapy (EPIC) has 
been based on this disease concept3;4. Multiple institutions have reported promising results 
with these techniques5-14.
A careful patient selection for this complex treatment is essential to prevent unnecessary 
toxicity. There is currently no uniformity in selection criteria worldwide, but good clinical 
performance status, age <75 year, absence of visceral and retroperitoneal lymph node 
metastasis and no massive peritoneal disease. One of the controversies is the inclusion 
of patients in whom previous systemic therapy has failed, as it is unclear whether or not 
this group benefits from HIPEC. Response to systemic chemotherapy has been suggested 
as a selection criterion in patients in whom cytoreductive surgery and HIPEC is considered 
as a therapy, as this may allow selection of patients with biologically favourable tumour 
characteristics15. Patients who fail to respond to systemic chemotherapy, are excluded from 
intraperitoneal treatment in some studies reporting on treatment effects13;16. However, 
there is no evidence available in literature to date discussing whether or not these patients 
could derive benefit from treatment with HIPEC. 
Aim of this study is to report on the outcomes of cytoreductive surgery and HIPEC in patients 
who failed to respond to adjuvant systemic chemotherapy after primary resection preceding 
HIPEC procedures. 
Methods
Patient	selection	and	data	collection
Data were obtained from a prospective database, including all patients who underwent 
cytoreductive surgery and HIPEC between 1997 and 2008 in the Netherlands Cancer 
Institute, Amsterdam. In our institute, cytoreductive surgery in combination with HIPEC has 
been performed in patients with colorectal carcinoma since 1996. Eligibility of patients is 
based on performance status and resectability of the tumour. Data on previous treatments 
are recorded, but response to systemic chemotherapy is currently not used as a patient 
selection criterion17.
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Patients were selected by using the following criteria: (1) diagnosis of PC from colorectal 
origin, (2) metachronous presentation of disease, (3) treatment with adjuvant chemotherapy 
after primary resection, (4) presentation of recurrence of disease or development of PC 
within 18 months after start of adjuvant systemic chemotherapy, (5) treatment with 
cytoreductive surgery and HIPEC. A total of 21 patients was identified according to these 
inclusion criteria. 
The time to recurrence of disease was defined as the period between the start of 
chemotherapy treatment and the first evidence of local recurrence or discovery of PC during 
follow-up. 
Data on patient and tumour characteristics, HIPEC procedures and survival were retrieved 
from the database. Additionally, data on the time of diagnosis of recurrence of disease 
and development of PC and information on chemotherapy schedules was registered 
retrospectively. If necessary, reports from surgical procedures, laboratory tests and imaging 
studies were reviewed. 
Operative	procedures
Cytoreduction followed by HIPEC with mitomycin C was performed in the Netherlands 
Cancer Institute in all patients. After laparotomy, the number of regions involved was 
assessed and recorded by use of a simplified peritoneal cancer index (PCI)17. Stripping of 
the parietal peritoneum was routinely performed as described by Sugarbaker et al18. In 
all patients the greater omentum was removed. The construction of anastomoses was 
performed after HIPEC. 
Completeness of cytoreduction was recorded using the following score system: absence 
of macroscopic residual tumour after completion of cytoreduction was recorded as R-1, 
macroscopic residual tumour nodules smaller than 2.5 mm as R-2a and a tumour residue in 
any region larger than 2.5 mm as R-2b. 
After cytoreductive procedures, lavage of the abdominal cavity with mitomycin C (35 mg/
m2 for 90 min at 41°C) was carried out using an open technique as described in detail 
elsewhere17. 
Statistical	analysis
Survival time was calculated from the date of diagnosis of PC to the time of death or last 
follow up. Patients alive at the time of analysis were marked as censored in the analysis at 
the date of their last follow-up contact. Data were analysed by Kaplan Meier analysis using 
SPSS 17.0 (Chicago, IL, 2008) software. 
Cytoreductive surgery and HIPEC after early failure of adjuvant systemic chemotherapy
133
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Results
Twenty-one patients (6 male), with a mean age of 57 years (standard deviation, SD 11) were 
included in this study. Tumour characteristics are shown in table 1. 
Table 1: Tumour characteristics (n = 21).
Localisation	 n (%)
Rectum 2 (9.5%)
Sigmoid 1 (4.8%)
Left colon 6 (28.6%)
Transverse colon 2 (9.5%)
Right colon 2 (9.5%)
Caecum 8 (38.1%)
T stage of primary tumour 
  T3 12 (57.1%)
  T4 9 (42.9%)
N stage of primary tumour 
  N0 3 (14.3%) 
  N1 10 (47.6%)
  N2 8 (38.1%)
Diagnosis of PC
The median time between the primary tumour resection and the development of PC was 
11 months (range 5-81). In two patients, PC was diagnosed more than 18 months after 
the primary tumour resection (23 and 81 months, respectively). In these patients, systemic 
chemotherapy was applied in a palliative setting. During this treatment these patients 
developed PC as sign of progression of disease and were referred for cytoreductive surgery 
and HIPEC. In all other patients, chemotherapy treatment was given in an adjuvant setting 
directly following resection of the primary tumour.
During chemotherapy treatment, follow-up routinely included assessment of tumourmarkers, 
in particular CEA, and CT scans. In addition, PET-CT was used if indicated. In all patients, a 
rise in CEA levels or a changing aspect of the abdomen on CT scans raised the suspicion of 
peritoneal disease. Diagnosis was confirmed in all patients by histological examination of 
the specimens resected during explorative laparotomy or cytoreductive surgery procedures. 
Systemic chemotherapy treatment
Adjuvant systemic chemotherapy regimens used following resection of the primary tumour 
(but before HIPEC treatment) are shown in table 2. Most frequently used chemotherapy 
regimen was 5-fluorouracil combined with leucovorin. Median time of chemotherapy 
treatment was 21 weeks (range 3-27 weeks). Fourteen patients (67%) completed their 
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intended chemotherapy treatment. Toxicity was the reason of discontinuation in four 
patients, progression of disease in two patients and one patient oluntary withdrew from 
continuation of adjuvant systemic chemotherapy treatment. Mean time to recurrence of 
disease was 9.3 months from the first administration of chemotherapy. 
Table 2: Details on adjuvant chemotherapy treatment following primary tumor resection before HIPEC 
procedures.
Adjuvant systemic chemotherapy 
schedules
n (%)
5-FU and leucovorin 13 (62%)
5-FU and leucovorin and oxaliplatin (FOLFOX) 4 (19%)
Oxaliplatin and capecitabine 4 (19%)
Reasons	for	discontinuation	
chemotherapy
Completed 14 (67%)
Progression during chemotherapy 2 (9%)
Toxicity/Fever 4 (19%)
Voluntary withdrawal 1 (5%)
Mean	(SD)	time	from	start	chemo	to	
diagnosis to recurrence of disease, 
preceding HIPEC treatment
Months 9.3 (3.4)
5-FU = 5-fluorouracil
HIPEC procedures
Simplified PCI scores are shown in table 3. In four patients (19%), more than 5 of the regions 
were involved. In most patients (76%) a complete macroscopic resection of PC was achieved 
(R1). All other patients underwent R2a resection.
Adjuvant systemic chemotherapy after HIPEC was routinely offered to all patients in 
whom physical condition was sufficient within 6-12 weeks after the surgical procedures. 
Three patients (14%) received 5-FU/leucovorin, four patients (19%) received capecitabin/
oxaliplatin, and one patient received irinotecan as adjuvant treatment after HIPEC. All these 
patients completed 6 months of adjuvant treatment except for one case. This patient showed 
severe toxicity to the adjuvant treatment after HIPEC and did not continue the course after 
one cycle of chemotherapy. Twelve patients (57%) were not eligible for adjuvant treatment 
after their HIPEC procedure. Main reason for not starting chemotherapy after HIPEC was the 
occurrence of complications from surgery prolonging recovery. One patient moved overseas 
and details of treatment could not be retrieved. The outcomes of this patient were censored 
at the time of last known follow-up. 
Another five patients received palliative chemotherapy treatment for recurrent disease 
diagnosed during follow up after their HIPEC procedure. 
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Table 3: Findings and results during cytoreductive surgery procedures. 
n (%)
Simplified	PCI	before	surgery
Number of regions involved
0 2 (9%)
1 2 (9%)
2 5 (24%)
3 5 (24%)
4 3 (14%)
5 0 (0%)
6 3 (14%)
7 1 (6%)
Radicality	of	cytoreductive	surgery
R1 16 (76%)
R2a 5 (24%)
R2b 0 (0%)
PCI = Peritoneal Cancer Index
Survival
Kaplan-Meier analysis of survival data is shown in figure 1. Two patients moved abroad and 
therefore these follow-up data were incomplete. Median overall survival was 28 months 
(range, 3-100 months) One-year and 2-year survival were 71% and 43%, respectively. 
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Figure 1. Kaplan-Meier analysis of survival in the presented study population. 
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Discussion
This study shows that patients with recurrence of disease or development of PC during or 
within 18 months after the start of adjuvant systemic chemotherapy after curative resection 
for colorectal cancer may benefit from HIPEC procedures. Their median survival of 28 months 
is similar to the overall median survival reported in the literature and, more specifically, to 
the result of a randomised controlled trial from our institute comparing HIPEC plus systemic 
chemotherapy with systemic chemotherapy alone. In that trial the median survival was 22.2 
months17 in an intention-to-treat analysis. 
In general, treatment strategies for stage IV colon carcinoma are applied independent of 
the localisations of metastases. All possible different dissemination patterns, including liver, 
lung, bone or peritoneum have been treated with systemic chemotherapy as a standard 
of care for a long time. There has been a shift in this paradigm to a more anatomic and 
surgical approach since the successful introduction of liver resections. During the inclusion 
period of the study presented here, both adjuvant and palliative treatment of colorectal 
cancer underwent a rapid development. In the first years of this study period, 5-fluorouracil 
combined with leucovorin was the only available chemotherapy for patients with colorectal 
cancer. Since 1998-2000, irinotecan and oxaliplatin have been introduced and oxaliplatin has 
been incorporated in standard combination schedules. Oxaliplatin for adjuvant treatment 
has been used since 2004. These developments explain the differences in adjuvant 
chemotherapy schedules applied in this study. 
Although overall survival of patients with metastasised colorectal cancer has increased over 
time with the availability of combination therapies and the more recent introduction of 
targeted monoclonal antibodies19-22, the effect of these developments in patients with PC 
remains unclear. This group of patients is known to have a reduced response rate to systemic 
chemotherapy as compared to patients without peritoneal metastases2. Currently no data 
from randomised trials are available that evaluate the effect of new palliative chemotherapy 
treatment strategies. Elias et al.16 reported a median survival of 24 months in 48 highly 
selected and relatively young (mean age 51 years) PC-patients with limited disease, treated 
with combination schedules including oxaliplatin and irinotecan. However, in the same 
study a median survival of 62.7 months was reported in patients who underwent HIPEC. 
A retrospective study from our institution showed a median survival of 12.6 months in 
patients with PC treated with 5-fluorouracil or irinotecan1. 
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The development of new treatment strategies including HIPEC has been based on the 
hypothesis that PC could be considered as a regional dissemination pattern rather than 
as a sign of systemic disease23-25. This supports the possible beneficial effect of a regional 
treatment using the combination of cytoreductive surgery and HIPEC.
Although the performance of cytoreductive surgery and application of intraperitoneal 
chemotherapy is nowadays more widely accepted as a treatment strategy in patients with 
PC, patient selection for these procedures remains an important subject of discussion. Well-
known and commonly used selection criteria for HIPEC procedures include good performance 
status, a limited extend of PC, and absence of systemic metastases. In a review by Yan et 
al.15 it is acknowledged that response to preoperative chemotherapy could potentially be 
a useful criterion for selecting patients with biologically favourable tumour characteristics. 
Indeed in patients with metastatic disease, evidence indicates that genomic profiling may 
be related to chemotherapeutic treatment response26. Nevertheless, this study shows that 
failure of systemic adjuvant chemotherapy is not associated with an unfavourable outcome 
in patients treated with intraperitoneal chemotherapy. This suggests that the susceptibility 
to systemic chemotherapy treatment, at least in an adjuvant setting, in patients with PC 
cannot be associated with outcomes after local application of chemotherapy. A possible 
explanation for this could be that systemic administration of chemotherapy fails to reach 
the peritoneal metastases in a therapeutic concentration. In contrast, during HIPEC a 
direct contact between chemotherapy and the presumed presence of loose tumour cells 
is established. This contact is independent of blood supply of the metastasis and depends 
on direct penetration up to a depth of 2.5 mm and diffusion. In addition, the dose of 
chemotherapeutic agents that can be applied in intraperitoneal administrations is higher 
than the maximum systemic dose tolerated. Furthermore heating of the chemotherapy is 
presumed to enhance the cytotoxic effect of chemotherapeutic agents used27. As stated 
before, no data are currently available considering the effects of modern chemotherapy 
schedules, and therefore it remains unclear whether the results of chemotherapy reported 
in this study represent a failure of systemic treatment in general, or a failure in adjuvant 
chemotherapy treatment. 
Some limitations of this study should be taken into account. Although data presented in this 
study were collected prospectively, this report has a retrospective design. Furthermore, only 
a small number of patients was included resulting in a wide range of data. Yet the fact that the 
results achieved in this highly selected patient group do not differ from the overall outcomes 
of the previous randomised clinical trial from our institute suggests that patients who fail 
to respond to systemic adjuvant treatment may still benefit from locoregional treatment. It 
also supports the hypothesis that PC should be considered as a local dissemination rather 
than a subgroup of systemic metastasis. 
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No evidence was found to support the exclusion of patients who failed to respond to systemic 
adjuvant chemotherapy from treatment with HIPEC. In the group of patients presented 
here, a median survival of 28 months was achieved after performing cytoreductive surgery 
and HIPEC, at least comparable to reported results of HIPEC in patients with an unknown 
response. Therefore, failure to respond to systemic adjuvant chemotherapy treatment 
should not be regarded as a selection criterion when assessing patient eligibility for HIPEC 
procedures. 
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Abstract
Background
The combined treatment of cytoreductive surgery (CS) and perioperative chemotherapy 
(PIC) for colorectal peritoneal carcinomatosis (PC) is a rigorous surgical treatment most 
suited for fit and young patients. With technical maturity and improved perioperative care, 
we examined the outcomes of elderly patients undergoing CS and PIC for colorectal PC. 
Methods
All consecutive patients treated in two tertiary centres for PC of colorectal cancer who were 
70 years of age or older at the time of surgery were included. Data on patient characteristics, 
concomitant diseases, operation details, perioperative course and follow-up were retrieved 
from medical charts. Primary outcomes were perioperative morbidity and mortality. 
Secondary outcomes were disease-free and overall survival. 
Results
Twenty-four patients (11 male) were included in this study (mean age 73.5 years). In 
eight patients major complications occurred. In six patients the postoperative course was 
complicated by minor adverse events. There was no perioperative mortality. Median overall 
survival was 35 months with a 6-, 12- and 18-months survival rate of 94%, 83% and 68%, 
respectively. 
Conclusion
CS and PIC for colorectal PC may be safely performed with acceptable morbidity in selected 
elderly patients. When considering patients for surgery, performance status and the disease 
extent should be used as eligibility criteria rather than age. 
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Introduction
The incidence of colorectal cancer increases with age. With the increase in life expectancy, 
the ageing population is expected to rise. A considerable number of patients presenting 
with colorectal cancer are aged 75 or older. To offer a safe and appropriate treatment to 
elderly patients with colorectal cancer represents a challenge for health care resources 
with surgery in particular. As age is traditionally associated with more frequently occurring 
comorbidities and a reduced physical capacity to recover from adverse events1;2, it is 
questionable whether elderly patients will tolerate aggressive surgery. Fortunately, over 
the last few years, there have been advances in the perioperative care of colorectal cancer 
surgery leading to a decrease in morbidity and mortality rates in elderly patients treated, 
and a good quality of life after surgery3-5. Several recent studies have shown that age alone 
does not influence the outcomes of surgery for colorectal cancer, and cancer-specific 
survival in these patients is similar to that of younger patients6-9. For example, hepatectomy 
for colorectal liver metastases has been shown to achieve reasonable 3-year survival at an 
acceptable morbidity in octogenarians10. 
The combination of cytoreductive surgery (CS) and perioperative intraperitoneal 
chemotherapy (PIC) has been established as a treatment strategy for patients with 
peritoneal carcinomatosis of colorectal origin. Traditionally, this condition has been 
regarded as a terminal disease that is often managed palliatively. Nowadays, many patients 
are treated worldwide with extensive surgical procedures including CS combined with PIC 
aiming for cure. Encouraging disease-free and overall survival results have been reported. 
In the few randomised trials that were performed, age was used as a selection criterion, 
including only patients younger than 71 or 65 years of age, respectively11;12. Yet, the majority 
of patients who present with synchronous peritoneal carcinomatosis as the only site of 
metastatic disease is 70 years of older at the time of diagnosis13. The risks and benefits of 
cytoreductive surgery and PIC in elderly patients have not been clearly defined. In a multi-
institutional study, age over 65 years appeared to be an unfavourable prognostic factor in 
both univariate and multivariate analysis14. Many surgeons are therefore reluctant to offer 
these procedures to patients who are above 70 years of age. Given that surgical techniques, 
anaesthetic management and perioperative medical care have improved with increased 
experience over the years, we are now observing lower complication rates, improved 
selection of patients and anticipation to perioperative factors that may influence morbidity 
and mortality15. With these advances in the management of patients undergoing CS and PIC, 
it remains to be seen whether these procedures, being the only curative option available for 
peritoneal carcinomatosis, should only be reserved for younger patients. Using prospectively 
collected data from two tertiary institutions with specialised interest in peritoneal surface 
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malignancies, we examined the outcomes of elderly patients who underwent CS and PIC for 
PC from colorectal cancer. 
Patients	and	Methods	
Patients 
All patients with a histologic diagnosis of PC from colorectal adenocarcinoma who underwent 
CS and PIC in two tertiary referral centres in Australia and the Netherlands at an age of 70 
years or older were included in this study. The evaluation process to determine eligibility 
for CS and PIC procedures consists of physical examination by the surgeon who performs 
the procedures and discussion of the cases during a weekly multidisciplinary team meeting 
attended by representatives of surgical oncology, medical oncology, radiology, cancer care 
nurses and research staff.
Data regarding baseline patient characteristics, surgical procedures, perioperative outcomes 
and survival outcomes were prospectively collected and included in an electronic database. 
Regular follow-up was performed at monthly intervals for the first 3 months and at 6-monthly 
intervals thereafter. Additional details regarding the primary tumour, comorbidities and 
blood test results were retrieved from the medical charts. Redo CS and PIC procedures were 
excluded from the analysis. 
Preoperative	management
As per protocol, all patients underwent physical examination and double contrast-enhanced 
computed tomography (CT) scans of the chest, abdomen, and pelvis. 
In addition, positron emission tomography (PET) was performed to assess the extent of 
disease if necessary. Subcutaneous heparin is given routinely as thrombosis prophylaxis in 
both institutions. 
Mechanical bowel preparation was performed in all patients. All patients received an 
intrajugular or subclavian central venous catheter. Prophylactic antibiotic treatment 
consisted of metronidazole 500 mg every 6 hours during surgery in both institutes combined 
with a pre-operative gift of cefotaxime 1000 mg (Australia) or cefalozine 2000mg (the 
Netherlands). Patient position was supine. 
Cytoreductive	surgery
In both institutions (STG and CHE), procedures were performed by a specialised surgical 
team, led by a single surgeon (D.L.M and I.H.J.T.H.). Midline laparotomy was performed in 
all patients, followed by assessment of the extent of disease by use of the Peritoneal Cancer 
Index (PCI)16. The PCI involves an assessment combining thickness of lesion size (LS) (LS 0: 
no macroscopic tumour; LS 1: tumour <0.5 cm; LS 2: tumour 0.5–5 cm; and LS3: tumour >5 
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cm) with distribution of tumour deposits in different abdominal regions (abdominopelvic 
region 0–12), resulting in a numerical score which represents a quantification of the extent 
of disease (PCI 0–39). 
All surgical procedures were aimed at complete removal of all visible tumour deposits from 
the abdominal cavity. CS was performed using Sugarbaker techniques17 in both centres. 
CS may include total anterior parietal peritonectomy, greater omentectomy, splenectomy, 
right and left subphrenic peritonectomy, pelvic peritonectomy, lesser omentectomy, 
cholecystectomy, rectosigmoidectomy, right colectomy, total abdominal colectomy, 
hysterectomy, salpingoovariectomy, and small bowel resection, depending on the presence 
of macroscopically visible tumour deposits. Furthermore, dissection of ureters and bladder 
may be required in order to achieve complete cytoreduction. Additionally, electrocoagulation 
was used. The macroscopic result of cytoreduction was assessed and recorded by means 
of the completeness of cytoreduction (CCR) score15. A score of CC0 represents no residual 
macroscopic tumour deposits; CCR1, remaining tumour does not exceed 2.5mm; CCR2, 
tumour nodules between 2.5 mm and 2.5 cm in diameter remain; and CCR3, nodules of 
more than 2.5 cm in diameter are present after best achievable cytoreduction.
Hyperthermic intraperitoneal chemotherapy
After cytoreduction, but prior to bowel anastomoses or repair of seromuscular tears, 
HIPEC was performed in a subset of patients by instillation of a heated chemoperfusate 
into the abdomen using the coliseum technique at approximately 42°C for 90 minutes. The 
chemoperfusate was made up of the cytotoxic drug diluted in 3 L of 1.5% dextrose peritoneal 
dialysis. To improve drug distribution, stirring of the abdomen was performed throughout 
the perfusion. The intraperitoneal temperature was monitored by a thermometers placed 
in the abdominal cavity.
After perfusion, the cytotoxic drugs were removed from the abdominal cavity and 
anastomoses were performed consequently. Two axion sump drains (on each side of the 
hemidiaphragm) were inserted before closure of the abdomen. If diaphragmatic resection 
was performed, 2 chest drains were placed. 
Early	postoperative	intraperitoneal	chemotherapy
Early postoperative intraperitoneal chemotherapy (EPIC) on postoperative day 1 to 5 was 
offered to selected patients who underwent CS. EPIC was not considered in case of leakage 
of the intraperitoneal chemotherapy system, early postoperative complications, or major 
organ failure. Furthermore, patients should be tolerating the increased intraabdominal fluid 
volume, as evaluated by an adequate urine output. During the years, a dose reduction of 
EPIC was introduced for patients with extensive prior treatment, long duration of surgery 
(>12 hours), unprotected bowel anastomoses and suboptimal preoperative conditions. 
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EPIC was administrated in the intensive care unit (ICU) or high dependency unit (HDU) 
through a peritoneal catheter port that was placed during surgery. Perfusion fluid consisted 
of 5-fluorouracil (650–800 mg/m2 per day) in 1 L of 1.5% dextrose peritoneal dialysis 
solution, which remained intraperitoneally for 23 hours. After this time, the intraperitoneal 
chemotherapy was removed by closed suction drains over the course of 1 hour. During EPIC 
treatment, sump drains were clamped. Once all the perfusion fluid was removed, the next 
instillation was commenced.  
Postoperative	Management
All patients were given subcutaneous heparin for deep venous thrombosis prophylaxis. 
All patients who had a splenectomy were given pneumococcal polysaccharide vaccine. 
Clinical suspicions of deep venous thrombosis were assessed by Doppler ultrasound, and 
ventilation/perfusion scan or CT pulmonary angiogram was performed when pulmonary 
embolus was suspected. For the assessment of intra-abdominal collections or abscesses, 
oral contrast-enhanced abdomen and pelvic CT was performed in symptomatic patients. 
Total parenteral nutrition was only started on indication, including prolonged gastroparesis 
or inadequate intake for several days. 
Statistical	Analysis
Perioperative morbidity and mortality were the primary outcomes of this study. Survival 
was evaluated using Kaplan-Meier survival analysis. Overall survival was defined as time 
between the CS and PIC and the date of death or last follow-up. Disease-free survival was 
defined as time between the CS and PIC and the date of recurrence or death. Survival 
curves of subgroups were assessed by means of the log rank test. SPSS for Windows version 
17.0 (SPSS, 2008) was used for all statistical analyses. A p-value of <0.05 was considered 
statistically significant. 
Results
Patient	demographics
Between January 1996 and August 2010, 106 CS procedures for peritoneal carcinomatosis 
of colorectal carcinoma were performed in STG and 41 in CHE. Twenty-four patients (13 
female) of 70 years or older underwent combined treatment of CS and PIC, with a mean 
age of 73.5 years. Eight patients were 75 years or older at the time of surgery. Details on 
concomitant diseases and medical history are given in table 1. 
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Table 1. Patient characteristics (n=24).
n
Gender M/F 11/13
Age (years) 
Mean (SD)
73.5 (3.4)
70-74 16
75-79 7
>80 1
Concomitant diseases/Medical history
None 2
Metabolic
Hypercholesterolaemia 3
Diabetes 3
Hypothyroidism 1
Cardiovascular
Hypertension 6
Abdominal Aorta Aneurysm 2
Peripheral Arterial Disease 1
Ischaemic heart disease 1
Wolff-Parkinson-White syndrome 1
Transient ischaemic attack/Cerebrovascular accident 1
Malignancies
Breast cancer 1
Prostate cancer 1
Bronchus carcinoma 1
Other
Peptic ulcer disease 3
Deep venous thrombosis/pulmonary embolus 2
Parkinson 1
Primary tumour
Caecum 4
Ascending colon 5
Hepatic flexure 1
Transverse colon 1
Splenic flexure 2
Sigmoid 7
Rectosigmoid 1
Rectum 1
Unknown 1
Time between primary tumour resection and CS + PIC in months
Median (range)
13 (0-214)
CS = cytoreductive surgery, PIC = perioperative intraperitoneal chemotherapy
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Clinical	characteristics
In 14 patients, PC was discovered during follow-up for their primary tumour. In 9 patients PC 
was present at the time of the resection of the primary tumour. 
Median time between the primary tumour resection and CS was 13 months (range 0-214) 
The median PCI was 8 (1-22), with a mean of 8.3. Three patients had a PCI of 15 or higher. 
In 16 patients, PCI was lower than 10. A complete removal of the peritoneal tumour (CCR0) 
was achieved in 22 patients (92%). In 2 patients, residual tumour deposits of less than 
2.5mm were present after cytoreduction (CCR1). 
In twelve patients CS was directly followed by the administration of HIPEC, and in 6 patients 
EPIC was given during the first postoperative days. Five patients received both treatments 
after CS. 
Morbidity and mortality
The median duration of the procedure was 5 hours and 45 minutes (range 2-7), with a mean 
of 5.7 (standard deviation, SD 2) hours. The median number of resections performed per 
patient was 4 (range 2-8), with a median of 1 anastomosis per patient (range 0-3). Twelve 
patients required blood transfusion during surgery, with a median of 4 units of blood per 
patient (range 2-16). Details on the CS procedures are shown in table 2. 
Table 2: Cytoreductive surgery procedures.
n
CCR
CCR0 22
CCR1 2
CCR2 0
CCR3 0
Stoma
None 17
Colostomy 2
Ileostomy 4
Unknown 1
Number	of	resections Mean (SD)
4 (1)
Median (range)
4 (2-8)
Number of peritonectomy sites Mean (SD)
1 (1) 
Median (range)
1 (0-3)
PIC
HIPEC 12
EPIC 6
HIPEC+EPIC 5
Drugs used for HIPEC perfusion
Mitomycin 13
Oxaliplatin 4
CCR = completeness of cytoreduction score, PIC = perioperative intraperitoneal chemotherapy, 
HIPEC = hyperthermic intraperitoneal chemotherapy, EPIC = early postoperative intraperitoneal 
chemotherapy. 
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Patients were admitted to the ICU as per protocol and had a median stay in this unit of 2 
days (range 1-6), with a mean of 2 (SD 1) days. Thereafter, some patients were admitted 
to the HDU, staying there for a mean of 2 (SD 4) days. Patients were discharged from the 
hospital after a median total stay of 15 days (range 8-74), with a mean of 20 (SD 14) days. 
In nine patients (38%) the procedures were uncomplicated. In six patients, postoperative 
complications were observed which could be managed conservatively or with medical 
intervention. In five patients (21%), radiological intervention was required and three 
patients (13%) required surgical intervention or admission to the ICU to deal with major 
complications. 
Details regarding the complications and their management are shown in table 3. In the 
3 patients (13%) requiring surgical intervention to deal with severe complications, no 
predisposing factors could be identified. They were aged 70, 71 and 77, respectively, and 
did not suffer from major concomitant diseases. Furthermore, their PCI scores were 8, 10 
and 11 respectively, representing a moderate amount of peritoneal tumour. 
The median time to the occurrence of morbidity was 14 days (range 2-26). No deaths 
occurred within 30 days after treatment, represented by a mortality rate of 0%. Twelve 
patients received adjuvant chemotherapy after their surgical treatment. 
Table 3. Complication details.
Required management Complication	
n
None 9
Conservatively treated 4 Ileus
3 Atrial fibrillation
1 Renal impairment
Medical intervention 1 Ileus requiring total parental nutrition
3 Hypertension
2 Pulmonary embolism
1 Seizure
1 Pneumonia
1 Diabetic keto-acidosis
1 Urinary tract infection causing delirium
1 Fever without focus
Radiological intervention 5 Drainage intra-abdominal collection
1 Drainage pulmonary fluid
Surgical intervention 1 Pancreatic leakage/necrotic pancreas fistula
1 Splenic infarction
1 Big subcutaneous abcess
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Survival outcomes
Median follow-up time was 10.5 months (range 1-52). Median overall survival was 35 
months (95% Confidence Interval 20.0-49.9), with a 6-, 12- and 18-months survival rate of 
94%, 83% and 68%, respectively. Kaplan-Meier survival analysis for overall survival is shown 
in figure 1. Median disease-free survival was 12 months (95% confidence interval 7.7-16.3). 
In 13 patients, recurrent disease was discovered during follow-up after the CS. Most frequent 
site of recurrent disease was the liver (n=6), followed by the peritoneal surface (n=4) and 
lung (n=2). Median time to recurrence after the CS in these patients was 9 months (range 
3-21). 
Univariate analysis was performed to assess the influence on overall survival of the following 
factors: Age >75 years, histologic type of tumour (mucinous adenocarcinoma versus 
adenocarcinoma), completeness of cytoreduction score, amount of blood transfused, 
completeness of cytoreduction as represented by CCR, performance of HIPEC, administration 
of EPIC, and occurrence of a postoperative complication requiring radiological drainage or 
surgical intervention. None of these factors influenced overall survival. 
Time aer surgery (months)
Su
rv
iv
al
 (%
)
0 10 20 30 40 50 60
100
80
60
40
20
0
Censored
Figure 1. Kaplan-Meier survival analysis of overall survival in patients aged 70 years or older 
undergoing cytoreductive surgery and perioperative chemotherapy for colorectal cancer peritoneal 
carcinomatosis. 
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Discussion
The ageing population and the associated rise in prevalence of malignancy lead to an 
increase in demand for oncological surgery. In 2004, it was estimated that about 13% of the 
total Australian population was aged 65 years or older. It is expected that the proportion of 
elderly people will increase over time to 26% in 2051, and to 27% in 210018;19. Furthermore, 
life expectancy grows up to ages over 80 years in children born in this decade. These 
developments together with the availability of specialised centres offering high standards 
of anaesthetic and perioperative care may allow a reconsideration of the use of age as a 
selection criterion. 
This study shows that CS and PIC can be performed safely in patients aged 70 years or older 
without compromising the perioperative mortality rate and with an acceptable morbidity. 
Two patients who developed recurrence during follow up were also treated with a second 
cytoreductive procedure and recovered without complications. Although long term results 
could not be reported at this time due to a limited follow-up, the estimated median 
survival of 35 months is encouraging and comparable with results reported in the available 
randomised trials that included younger patients11;20 and in a meta-analysis of the results of 
multiple centres worldwide by Yan et al21.
To optimise the outcomes of elderly patients undergoing CS and PIC, it is important to avoid 
unnecessary resections to prevent potential added morbidity and mortality. It should be 
noted that the patients included in the current study represent a highly selected group, 
considered fit for major surgery and without any absolute contraindications for general 
anaesthetics. 
Especially in elderly patients, the value of a detailed and careful counseling of patients 
being referred to a specialised centre for assessment for the combined procedures should 
be acknowledged. Truly, elderly patients often have less functional reserve when compared 
with a younger patient. The insult of an extensive surgical effort may therefore be potentially 
fatal in a poorly selected patient with significant comorbidities. Detailed explanation of 
the risks and benefits of the combined treatment modality and the awareness that major 
surgery, ICU stay, and the existence of comorbidities may potentially complicate the recovery 
and increase the morbidity and mortality is of utmost importance.
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However, it can be concluded from the results of this study that eligibility assessment for CS 
and PIC should be based on performance status and the presence of concomitant diseases 
that may potentially increase the risks of anaesthesia and compromise the recovery process, 
rather than focus on age as a single factor. 
Age has traditionally been regarded as a limiting factor towards the pursuit of curative 
therapies. Current data emerging in the surgical literature of metastasectomy suggest a need 
for change in this opinion. In other malignancies in which major abdominal surgery is the only 
curative option, selection criteria regarding age have been critically assessed. Recent reports 
have shown acceptable outcomes in terms of morbidity and mortality in patients older than 
70 years of age undergoing pancreatectomy for pancreatic cancer22-25 or gastrectomy for 
gastric cancer26-30. Further, clinical studies have shown that elderly patients undergoing 
chemotherapy treatment for colorectal cancer often receive suboptimal chemotherapy and 
are not offered modern effective polychemotherapy regimens and adjuvant therapy as a 
result of poorer tolerance towards chemotherapy toxicities31;32. Hence, if surgery may be 
safely performed in elderly patients, it may potentially be an appropriate therapy. 
To our knowledge, this is the first study reporting on the outcomes of CS and PIC in elderly 
patients. Previous studies have evaluated the feasibility, safety and effectiveness of other 
metastasectomy procedures for colorectal cancer in the elderly population. Several centers 
have reported their results of liver resections for colorectal metastases in an elderly patient 
population (65 or older), repeatedly showing a low mortality and acceptable morbidity33-35. 
Even in octogenarians, the performance of liver surgery has been shown to be feasible and 
safe with a careful patient selection process36;37. 
The application of PIC worldwide is variable. The effectiveness of the combined approach 
of aggressive CS and HIPEC as compared to palliative care has been shown in both 
experimental studies and a randomised controlled trial12;38;39. The additional value of EPIC as 
early adjuvant after CS is less clear. Some studies suggest no additional effect of EPIC after 
cytoreduction11, other studies have shown prolongation of survival with the combination of 
CS and EPIC as compared to standard care40-42. Also a trend towards prolonged survival has 
been described when hyperthermia is applied43, whereas others do not show a difference 
between normothermic and hyperthermic treatment41. 
Unfortunately, data on quality of life in this elderly patient group were not available. 
Nonetheless, in this highly functional group of patients who are selected for surgery and 
expected to make a reasonable recovery, the ability to impact on life extension may be 
considered significant. Therefore, CS and PIC should not be withheld for elderly patients in 
whom a potential to prolong a good quality of life is to be expected. Further studies with 
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larger numbers of patients are needed to assess the quality of life after CS and PIC, and to 
identify factors of influence on morbidity, mortality and long-term survival in elderly patients. 
In addition, it may be useful to investigate quality of life outcomes of patients receiving CS 
combined with adjuvant systemic rather than intraperitoneal chemotherapy treatment. This 
modification of the current standard of care would aim to reduce complications associated 
with the intraperitoneal chemotherapy and shorten hospital stay, if the beneficial effects in 
terms of survival appear to be similar.  
In conclusion, the results of this study should encourage surgeons to judiciously select 
elderly patients aged 70 years for potentially curative surgery for colorectal PC. Furthermore, 
these data should stimulate the inclusion of well selected elderly patients in clinical trials to 
determine the best treatment modality for patients with colorectal PC. 
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Abstract
Background
Primary cytoreductive surgery (CS) and peri-operative intraperitoneal chemotherapy (PIC) is 
the only curative option for patients with colorectal cancer peritoneal carcinomatosis (PC). 
A significant proportion of patients develop peritoneal recurrence despite the aggressive 
treatment. Outcomes of patients undergoing secondary CS and PIC for recurrent PC were 
examined.
Methods
All patients undergoing second procedures with curative intent for recurrent colorectal 
cancer PC in three centres, one in Australia and two in the Netherlands, were included. 
Relevant data were retrieved from medical charts. Morbidity and mortality, overall survival 
and disease-free survival were primary outcomes. 
Results
The study included eighteen patients (13 female, mean age 47 years). At primary CS, mean 
Peritoneal Cancer Index (PCI) was 9.1, and in 13 patients (72%) complete resection was 
achieved. Median time to recurrence was 14 months (range: 1-33). At secondary CS, mean 
PCI was 6.3 and CS was complete in 13 patients. In one patient severe adverse events 
occurred requiring surgical intervention. There was no mortality in the first 30 days after 
surgery. One-year and two-year survival after secondary CS were 74% and 50%, respectively. 
However, fourteen patients showed recurrence after the second procedure with a median 
disease-free survival of only 4.5 months. 
Conclusion
A secondary CS for recurrent colorectal cancer PC is safe and feasible, however, relapse is 
frequent. Further investigations are required to critically assess the efficacy of a secondary 
procedure and to define optimal patient selection criteria in the era of effective modern 
chemotherapy. 
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Introduction
Peritoneal carcinomatosis (PC) from colorectal cancer is often considered an incurable 
disease associated with a poor prognosis and a median survival of approximately 6 months1;2. 
Since the 90’s of the last century, new treatment strategies have been developed aiming 
for cure, combining cytoreductive surgery (CS), including peritonectomy procedures, with 
perioperative intraperitoneal chemotherapy (PIC). The effectiveness of this therapy was 
evaluated in a randomised trial, showing a median survival of 24 months in patients treated 
with CS and HIPEC, which compared favourably to median survival of 12 months reported in 
the patients treated with palliative care3. Since then many centers worldwide have reported 
positive results with these techniques in terms of survival with acceptable morbidity and 
mortality rates. Although CS and PIC are performed with a curative intent, a considerable 
number of patients develop disease recurrences during follow-up4-7. The abdominal cavity 
is the most common site of recurrence, often without evidence of systemic metastasis. This 
raises the question of whether this group would benefit from a second surgical procedure 
to extirpate recurrent disease and repeated use of PIC. Recently, it was shown that 
repeated peritonectomy procedures are feasible in patients with different gastrointestinal 
malignancies8. It remains unclear whether this aggressive approach to managing recurrence 
is justifiable. Using the peritoneal surface malignancy databases of three major referral 
centers, we identified consecutive patients with PC of colorectal origin who underwent 
secondary CS and PIC to evaluate its oncologic efficacy and feasibility. 
Methods
Selection	criteria
Between June 2000 and October 2010 eighteen consecutive secondary CS procedures 
were performed for recurrent colorectal metastases. In all these patients hyperthermic 
intraperitoneal chemotherapy (HIPEC) and/or early postoperative intraperitoneal 
chemotherapy (EPIC) was administered. Informed consent was obtained from all patients 
prior to the procedures. The suitability of patients for an iterative procedure was assessed 
and discussed during a weekly multidisciplinary team consisting of treating surgeons, 
radiologists and medical oncologists. All patients underwent preoperative investigations 
consisting of complete history, physical examination, contrast enhanced abdominal, pelvic 
and chest CT and blood tests including tumour markers. Eligibility criteria for the procedures 
were age <80 years, a good performance status (World Health Performance Status ≤2), 
absence of haematological abnormalities and adequate hepatic and cardiac functioning. 
Patients with extra-abdominal metastases were excluded.
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Preoperative	management
All patients were admitted on the day before surgery and received thrombosis prophylaxis. 
One hour prior to surgery cefotaxime 1000 mg (Australia) or cefalozine 2000mg (the 
Netherlands) was given as prophylactic antibiotic treatment, followed by metronidazole 500 
mg every 6 hours during surgery in both institutes. 
Cytoreductive	surgery
Cytoreductive procedures were performed by a team supervised by a single experienced 
surgeon in each centre (D.L.M., V.J.V. and I.H.J.T., respectively). The extent of peritoneal 
disease was recorded using the peritoneal cancer index (PCI) as described elsewhere9, and 
CS was performed using Sugarbaker’s peritonectomy techniques10. The completeness of 
cytoreduction score (CCR score) was used to record the amount of residual tumour after the 
cytoreductive procedures9. 
Perioperative	intraperitoneal	chemotherapy
Following CS, HIPEC with mitomycin using the coliseum technique was initiated in a subset of 
patients, according to availability of the technique at the time of surgery. In the Netherlands, 
oxaliplatin is standardly used for hyperthermic perfusion in the second procedure. In 
Australia, mitomycin was used for all procedures. 
Bowel anastomoses and repair of serosal defects were performed after perfusion. 
Selected patients received EPIC containing of 5-fluorouracil (650–800 mg/m2 per day) in 
1 L of 1.5% dextrose peritoneal dialysis solution, in the intensive care unit (ICU) or high 
dependency unit (HDU) on postoperative day 1 to 5. EPIC was only available in Australia 
and was applied as adjuvant treatment after CS in the first years of the inclusion of patients. 
Patients were considered eligible for EPIC treatment in addition to HIPEC if they recovered 
from the surgery without early postoperative complications or major organ failure. 
Postoperative	management
Subcutaneous heparin was administered to all patients per protocol for deep venous 
thrombosis prophylaxis. In symptomatic patients the presence of intraabdominal collection 
or abscesses was evaluated by oral contrast-enhanced abdomen and pelvic CT scan. Total 
parenteral nutrition was reserved for patients with prolonged gastroparesis or inadequate 
intake for several days. 
Adjuvant chemotherapy was offered to all patients who recovered well from surgery and 
were fit enough to receive this treatment.
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Follow-up
Data regarding baseline patient characteristics, surgical procedures, perioperative outcomes 
and survival outcomes were prospectively collected and included in an electronic database. 
Additional details regarding the primary tumour, comorbidities and blood test results were 
retrieved from the medical charts. For the assessment of complications, postoperative 
complications were registered according to their severity in terms of required management. 
Regular follow-up was performed at monthly intervals for the first 3 months and at 6-monthly 
intervals thereafter, including clinical examination, assessment of tumour markers and CT 
scans. 
Study methods
The time between the first incision and closure of the abdomen was recorded as the 
operation time. Data regarding surgical and anaesthetic procedures including intraoperative 
administration of fluids and blood products were prospectively recorded in operative 
anaesthetic charts. 
Grade I/II adverse events were defined as events managed with conservative or medical 
interventions. Moderate complications requiring radiological drainage of collections or fluid 
under CT- or ultrasound-guidance were recorded as grade III, whereas a severe complication 
(grade IV) was registered if a patient required reoperation or return to the intensive care 
unit (ICU). Perioperative death was defined as death occurring within 30 days after the CS or 
during the primary hospital admission. 
Statistical	analysis
All analyses were performed using SPSS software (Version 17.0). Data are reported as mean 
(standard deviation, SD) or median (range). Survival outcomes were assessed with Kaplan 
Meier survival analysis. 
Results
Patient	demographics
In total, 604 procedures combining CS and PIC for PC of colorectal carcinoma were 
performed between January 1996 and August 2010 in the three centers. Eighteen secondary 
procedures were performed for recurrent PC after prior primary CS and PIC treatment 
(seven in Australia and eleven in the Netherlands: ten in the NKI and one in the CHE). The 
study cohort comprised of 5 male and 13 female, with a mean age of 47 (SD 3.8) years at the 
time of the first CS. In two patients, an additional third procedure for recurrence after the 
second operation was performed. 
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Clinical	characteristics
Relevant pathological characteristics of the primary tumours are shown in table 1. In 
4 patients, PC was present at diagnosis of the primary tumour. Eleven patients received 
adjuvant chemotherapy after the resection of their primary tumour. 
At the time of the primary CS and PIC, the mean PCI was 9.1 (SD 4.8) with a median of 10 (1-
19). Five patients had incomplete cytoreduction (4 patients with CCR2 and one with CCR3) 
at primary CS and PIC. The median time to peritoneal recurrence after the primary CS and 
PIC was 14 months (1-33), and the median time interval between primary and secondary 
cytoreduction was 22 months (range 8-125). At the secondary CS and PIC, a complete 
removal of the peritoneal tumour (CCR0) was achieved 13 patients. In 2 patients a CCR2 
resection was recorded, and in 3 patients a CCR3 resection. 
Table 1. Primary tumour characteristics (n=18).
Primary tumour n
Location
Ascending colon 4
Transverse colon 1
Descending colon 1
Sigmoid 3
Recto sigmoid 3
Appendix 5
Unknown 1
T-stage
T2 1
T3 10
T4 3
Unknown 4
N-stage
0 9
1 2
2 2
Unknown 5
Differentiation	grade
Poor 4
Moderate 2
Well 10
Unknown 2
Previous adjuvant chemotherapy
No 6
Yes 11
Unknown 1
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The administration of PIC after the primary CS consisted of HIPEC in 12 patients, EPIC for five 
postoperative days in 3 other patients and a combination of both treatments was given to 
3 patients. During the second treatment, 14 patients received HIPEC, 3 patients were given 
EPIC only and 1 patient received a combination of the treatments. 
From the three patients receiving only EPIC after their secondary CS procedure, the first 
procedure was combined with HIPEC in two of these patients. The third had EPIC only in 
both procedures.
Morbidity and mortality
The first procedures had a median duration of 7 hours (2.0-12.5), with a mean of 6.8 (3) 
hours. During the second procedure the median operating time was 6.5 (2.5-9.5) hours with 
a mean of 6.3 (1.9) hours. The median number of resections performed per patient during 
the first CS and PIC was 3 (1-10), and 2 (0-5) during the second procedure. Details on the CS 
procedures are shown in table 2. 
Table 2. Details of cytoreductive surgery and perioperative intraperitoneal chemotherapy. 
1st CS + PIC procedure 2nd CS + PIC procedure
Operating	hours Mean (SD)
6.8 (3)
Median (range)
7.0 (2-12.5)
Mean (SD)
6.3 (1.9)
Median (range)
6.5 (2.5-9.5)
Blood transfusions Mean (SD)
2.4 (3.6)
Median (range)
0.5 (0-14)
Mean (SD)
1.4 (2.2)
Median (range)
0 (0-7)
CCR
CCR0 13 13
CCR1 0 0
CCR2 4 2
CCR3 1 3
No	of	resections Mean (SD)
3.4 (2.1)
Median (range)
3 (1-10)
Mean (SD)
1.9 (1.3)
Median (range)
2 (0-5)
PCI Mean (SD)
9.1 (4.8)
Median (Range)
10.0 (1-19)
Mean (SD)
6.3 (3.3)
Median (Range)
6.5 (1-13)
PIC
HIPEC 12 14
EPIC 3 3
HIPEC+EPIC 3 1
CS = cytoreductive surgery, PIC = Peri-operative Intraperitoneal Chemotherapy, CCR = Cytoreduction 
Completeness Score, PCI = Peritoneal Cancer Index
All patients were admitted to the ICU after the surgical procedures as per protocol. Median 
time of stay was 2 (1-21) days for the first procedure and also 2 (0-6) days for the second 
CS and PIC. Some patients in Australia were transferred to the High Dependency unit (HDU) 
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before going to the surgical ward, staying in this unit for a mean of 2.1 (2.7) days during the 
first admission, and 2.7 (3.9) days during the second. The median time of total hospital stay 
was 16 days for the first procedure (8-45), and 15.5 (8-61) days for the second procedure. 
Table 3. Perioperative course.
1st CS + PIC 2nd CS + PIC
ICU days Mean (SD)
3.9 (5.1)
Median (Range)
2 (1-21)
Mean (SD)
2.5 (1.5)
Median (Range)
2 (0-6)
HDU days Mean (SD)
2.1 (2.7)
Median (Range)
0.5 (0-6)
Mean (SD)
2.7 (3.9)
Median (Range)
0 (0-10)
Total days of hospital 
admission
Mean (SD)
19.9 (10.3)
Median (Range)
16.0 (8-45)
Mean (SD)
18.5 (12.4)
Median (Range)
15.5 (8-61)
Severity of morbidity 
per	patient	(n)
None 15 11
Conservatively treated 2 4
Medical intervention 1 0
Radiological intervention 0 2
Surgical intervention 0 1
CS = cytoreductive surgery, PIC = Peri-operative Intraperitoneal Chemotherapy, ICU = Intensive Care 
Unit, HDU = High Dependency Unit
The perioperative course of the initial CS and PIC procedure was uncomplicated in 15 patients. 
In 3 patients, mild adverse effects occurred, which could be managed with conservative or 
medical treatment. The first CS and PIC procedure was followed by adjuvant chemotherapy 
treatment in 9 patients. 
During the second procedure, conservatively manageable complications occurred in 4 
patients. In two patients, a collection had to be drained under radiological guidance. One 
patient required surgical intervention because of small bowel obstruction and sepsis. No 
deaths occurred within 30 days after treatment, represented by a mortality rate of 0%. 
Details about the complications observed are shown in table 4. 
In 3 patients adjuvant chemotherapy was given after the second CS and PIC procedure. 
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Table 4. Details on adverse events during the postoperative courses of procedures.
1st procedure 2nd procedure
Required management Adverse event
n n
Uneventful recovery 15 None 11
Conservatively treated 1 Ileus 0
0 Lesion N. femoralis 1
1 Pneumothorax 0
1 Pleural effusion 2
1 Fistula 1
0 Intra-abdominal collection 2
Medical intervention 0 Wound infection 1
1 Pericarditis 0
Radiological intervention 0 Drainage intra-abdominal collection 2
Surgical intervention 0 Small bowel obstruction and sepsis 1
Survival outcomes
Median follow-up time was 33 months (15-157) after the first CS and PIC procedure, with a 
2-year and 3-year survival rate of 83% and 72%, respectively. 
Median follow up after the second CS was 10 months (range 1-76). After the secondary 
procedure, 1-year survival was 74% and 2-year survival was 50%. Kaplan Meier survival 
analysis for overall survival from the primary and secondary CS and PIC is shown in figure 1 
and figure 2. Fourteen out of eighteen patients showed relapse of disease after the second 
CS and PIC procedure, with a median time to recurrence of 4.5 months (range 1-22). Most 
frequent sites of recurrence were intra-abdominal (n=7), hepatic (n=3), and pulmonary 
(n=2). At the time of analysis, the four patients that remained disease-free had a follow-up 
of 1, 3, 4 and 76 months, respectively, after the second procedure. 
The patient receiving EPIC treatment only after both CS procedures had a survival of 25 
months after the second procedure. Lung metastases were diagnosed 5 months after the 
second CS and PIC. In one of the patients receiving EPIC only after the second procedure, 
survival was 21 months in which liver metastases developed 2 months after the last CS and 
PIC. The third patient developed local recurrence of disease 9 months after the secondary CS 
and EPIC treatment. This patient is currently alive with disease 10 months after the second 
procedure and decided not to undergo further surgery. 
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Figure 1. Kaplan-Meier survival analysis of patients undergoing secondary cytoreductive surgery, as 
assessed from primary cytoreduction. 
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Figure 2. Kaplan-Meier survival analysis of patients undergoing secondary cytoreductive surgery, as 
assessed from secondary cytoreduction. 
Secondary cytoreductive surgery and peri-operative intraperitoneal chemotherapy 
167
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Discussion
Repeat surgery via secondary cytoreduction appears to be a feasible option for managing 
patients with isolated peritoneal recurrence from colorectal cancer PC following previous 
primary CS with acceptable morbidity and no mortality. The findings of our study suggest 
that secondary cytoreduction is able to prolong the survival of patients who would otherwise 
succumb to disease. However, the results may require further evaluation to determine its 
efficacy. Fourteen patients developed disease recurrence after secondary CS and PIC. 
Recurrent disease after a CS and PIC is a frequently encountered problem. Verwaal et al. 
describe a recurrence in 69 out of 106 patients (65%) after CS and PIC6. In 39 of these patients, 
the recurrent disease remained limited to the abdominal cavity. These patients were treated 
with surgery if possible, but no intraperitoneal chemotherapy was applied for a second time. 
Bijelic et al. reported recurrent disease in 49 out of 70 patients with complete cytoreduction 
and PIC7. Survival of patients with localised recurrence was significantly better than survival 
with diffuse peritoneal recurrence (p=0.018) and isolated distance metastases (p=0.002). 
A diagnosis of recurrence within 6 months after CS was associated with a significantly 
shorter survival than late recurrent disease (17 vs. 36 months, p=0.001). In this study, 26 
patients underwent a second operation and in 18 of these patients a complete secondary 
cytoreduction was achieved. Fourteen patients received intraperitoneal chemotherapy. The 
median survival in complete secondary CS was 42 months as compared to 30 months for 
whole recurrence group. In a study by Kianmanesh, secondary procedures were performed 
in 11 out of 43 patients (26%) undergoing CS and HIPEC for PC of colorectal origin. Overall 
median survival was 38.4 months, but unfortunately, outcomes of these patients were not 
analysed separately from those of patients treated with a single procedure11. Brouquet et 
al report on a series of 20 patients treated with repeated CS and PIC, four of which were 
treated for PC from colorectal origin. Strict inclusion criteria were used, e.g. an interval of 
>12 months between the first procedure and recurrence, limited extent of recurrence and 
complete cytoreduction at the repeated procedure. A median survival of 32 months was 
reported in these patients12. Gomez Portilla et al reported a median survival of 20 months in 
18 patients undergoing a second procedure for recurrent PC, with six patients being disease-
free three years after their initial CS and PIC treatment5. 
The comparison of survival results of patients undergoing a secondary CS versus palliative 
chemotherapy is difficult. It should be noted that the median disease-free survival time 
after second procedures for PC as reported in the literature and also in the current study 
is comparable to the progression-free survival reported in patients treated with modern 
chemotherapy regimens13-15. Yet, median follow-up time of the patients included in this study 
is relatively short. The follow-up of these patients should be continued to draw conclusions 
on long-term survival benefits. 
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Although the occurrence of adverse events associated with the secondary CS and PIC 
procedures in the present study is acceptable for a major oncological surgical procedure, 
the survival results and the risks of surgical complications question its role when compared 
to conservative medical treatment using palliative chemotherapy. 
Surgery offers eradication of disease that may be the source of symptoms that impact on 
quality of life. In the setting of metastatic disease, issues of maximizing survivorship are 
an objective goal of treatment. With the variety of options available through local options 
including surgery and radiotherapy to systemic therapies comprising of chemotherapy 
and biological therapy, the decision-making process to select the optimal and appropriate 
choice is complex. It requires tailoring based on degree of tumour-related symptoms, 
peritoneal tumour burden, competing performance status, age and the acceptability of 
treatment-induced toxicities. Importantly, the estimates of duration of survival based on 
an understanding of tumour biology and the patient’s disease behaviour together with the 
expected gains from treatment must be balanced in choosing optimal therapies.
The clinical behaviour of disease recurrence varies and holds a heterogenous pattern 
unique to each patient. There are variations in the extent and location of relapse that may 
be important in deciding on the ability to offer a secondary CS. In addition, the presence of 
systemic metastasis not only excludes many patients from a secondary CS procedure, but is 
also known to be an independent negative prognostic factor16. It is therefore inevitable that 
the group of patients that is considered eligible for a secondary CS procedure is a subset of 
patients with limited disease and favourable prognostic baseline characteristics, introducing 
a selection bias when comparing these patients with patients who have not been offered a 
second procedure.
The only way in which a surgical procedure could be beneficial in patients with recurrent 
disease is in case of the possibility of a curative treatment. Although our multidisciplinary 
tumour board may support a secondary CS and PIC through carefully selected young 
patients with a low PCI and favourable tumour biology, the current preliminary analysis of 
this management strategy have yielded results that require a re-evaluation given that the 
potential for long term survival is low. Although long term survivors after secondary CS and 
PIC have been described7, the number of patients in whom this is achieved is limited and it is 
not clear which characteristics are of beneficial influence. It would be interesting to evaluate 
these patients in more detail to identify characteristics that influence long term outcomes 
after secondary procedures. 
Owing to the high recurrence rates, some authors have advocated standard second-look 
surgery after CS and PIC5. The early discovery of recurrent disease (before this reaches the 
extent which is visible on imaging or causes symptoms) in patients after CS and PIC may 
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provide some advantages if a second procedure will be offered, for example limited extent 
of disease. The PCI is a well known prognostic factor in CS and PIC for colorectal PC. However, 
in the current study (in which PC was diagnosed during standard follow-up without second 
look procedures) the median PCI at the second procedure was 6.5 with a range of 1-13, and 
complete cytoreduction was achieved in most patients. Before offering standard second 
look procedures after CS and PIC, it should be clarified whether this has advantageous over 
standard follow up and can result in long term survival without evidence of disease, as it 
involves additional surgical procedures. Furthermore early discovery of disease also implies 
a shortening of the experienced disease-free life of patients. 
In conclusion, secondary CS and PIC to treat isolated peritoneal recurrence of colorectal 
cancer PC following primary cytoreduction appears to be feasible with an acceptable 
morbidity and in this study without mortality. Unfortunately, early relapse from secondary 
CS is observed frequently. The optimal treatment strategy to manage recurrence after 
primary CS requires an individualised approach. Should secondary CS be pursued, it should 
be offered to patients who respond following a trial of systemic therapy, who are fit and 
have minimal and completely resectable disease.
A multi-disciplinary approach is essential to select patients who would benefit from 
secondary cytoreduction based on technical feasibility of further surgery, performance 
status and response to chemotherapy in an era when systemic therapies have shown to 
achieve survival prolongation17.
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Peritoneal metastases are frequently diagnosed in patients with colorectal cancer. Due to 
the fact that peritoneal carcinomatosis (PC) is thought to be relatively resistant to systemic 
chemotherapy and is associated with an inevitably fatal outcome, this pathology has received 
little interest in the past. The introduction of aggressive surgical treatments, combining 
cytoreductive surgery with intraperitoneal chemotherapy, has lead to a change in this 
attitude. With these techniques, an increased overall survival was achieved with even long-
term disease-free survival in some patients. In order to optimise these treatment strategies, 
data regarding the natural course of disease, results of palliative treatment and insight into 
patient-dependent factors influencing outcome are of utmost importance. The lack of such 
data has stimulated research in this area and renewed the interest in information regarding 
different aspects of PC. 
This thesis describes population-based, experimental and clinical studies. Aims of the thesis 
were to report the outcomes of patients with PC treated with systemic chemotherapy and 
palliative surgery, to clarify the role of several components of surgical treatment including 
cytoreductive surgery and intraperitoneal chemotherapy, and to evaluate patient selection 
criteria for this treatment.
Part	I	Treatment	with	palliative	intent
The primary goal of the study described in chapter 1 was to provide reliable population-based 
data on the incidence of synchronous PC. Including all patients diagnosed with synchronous 
PC of colorectal origin between 1995 and 2008 in the south of The Netherlands, relevant 
patient and tumour characteristics were related to incidence data to identify predictors 
for the development of synchronous PC. In addition, data on the overall survival of these 
patients were provided. In the study period, 904 colorectal cancer patients were diagnosed 
with synchronous PC (4.8% of all patients diagnosed with colorectal cancer, constituting 
24% of patients presenting with metastatic disease). The risk of synchronous PC appeared 
to be increased in case of advanced T stage, advanced N stage, poor differentiation grade, 
younger age, mucinous adenocarcinoma and right-sided localisation of the primary tumour. 
The prognosis of synchronous PC remained poor especially compared to the improvements 
that have been reported for patients with liver metastases from colorectal origin. Median 
survival was 8 months and even worse if concomitant metastases in other organs were 
present. This underlines the importance of initiating studies on new treatment strategies 
for this population. The results of this study may help to understand the natural history of 
the disease and contribute to identifying subgroups of patients at risk for PC.
The beneficial effect of systemic chemotherapy in patients diagnosed with PC is questionable. 
The limited size of peritoneal tumour deposits precludes response evaluation of systemic 
treatment and therefore these patients are often not included or not separately analysed in 
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randomised trials, because they are qualified as presenting with “non-measurable” disease. 
In spite of any evidence as to its efficacy, it is entirely conceivable that in daily clinical 
practice, patients suffering from PC are considered as ‘regular’ metastatic colorectal cancer 
patients to whom palliative chemotherapy should be offered. In chapter 2 the trends in 
usage of palliative chemotherapy and its effect on survival in a large unselected population 
of patients with PC in the south of the Netherlands were studied retrospectively. It was 
shown that the administration of chemotherapy gradually increased over time, from 16% of 
all patients diagnosed with PC in 1995 to 46% in 2008 (p=0.001). In younger patients (<70 
years), the percentage of patients treated with chemotherapy was even greater, increasing 
from 29 to 64%.
However, median survival did not increase despite increasing usage of palliative 
chemotherapy and availability of new agents like oxaliplatin and irinotecan. Median overall 
survival was 35 weeks for patients with PC without other metastases diagnosed in 1995–
2000 and 34 weeks in 2005-2008. Interestingly, a trend towards improvement in survival up 
to 66 weeks was seen in patients treated with palliative systemic chemotherapy between 
2005 and 2008. Also, in multivariable regression analysis the use of chemotherapy showed 
a beneficial influence on survival only in 2005–2008. In previous periods, chemotherapy 
treatment did not reduce the risk for death. This study shows that even with effective 
chemotherapy the prognosis of patients with PC remains worse than that of patients with 
metastases elsewhere. From 2005 onwards, targeted agents were routinely included in 
palliative treatment for patients with metastasised colorectal carcinoma. This coincides with 
the increase in survival observed in this population. Yet, no data from randomised trials 
are available reporting on the outcome of chemotherapy plus targeted agents in stage IV 
colorectal cancer patients with PC. 
To further evaluate the effects of the most recent chemotherapy regimens, the efficacy and 
toxicity in metastatic colorectal cancer patients with PC receiving systemic treatment were 
evaluated in two large phase III studies (CAIRO and CAIRO2). These results are presented 
in chapter 3. Patients with previously untreated metastatic colorectal cancer were treated 
with chemotherapy in the CAIRO study and with chemotherapy and targeted therapy 
in the CAIRO2 study. All patients were included in this analysis, and the outcomes were 
retrospectively analysed in relation to the presence or absence of PC at randomisation. 
Patient demographics, primary tumour characteristics, occurrence of toxicity and survival 
outcomes were evaluated. 
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Thirty-four patients with PC were identified in the CAIRO study, and 47 patients in the 
CAIRO2 study. In the CAIRO2 study patients with PC more often had a WHO classification 1 
(as opposed to classification 0) than patients without PC. No other differences in baseline 
patient characteristics were observed between patients with and without PC. 
The median overall survival was significantly decreased for patients with PC compared 
to patients without PC, with 10.4 versus 17.3 months, respectively in the CAIRO study 
(p=<0.001) and 15.2 versus 20.7 months, respectively, in the CAIRO2 study (p<0.001). 
The median number of treatment cycles did not differ between patients with or without 
PC in both studies. The occurrence of major toxicity was more frequent in patients in PC 
treated with sequential chemotherapy in the CAIRO study as compared to patients without 
PC. However this was not reflected in the reasons to discontinue treatment in this study 
arm. In the CAIRO2 study, no differences in the occurrence of major toxicity were observed 
between patients with or without PC.  
These data demonstrate a decreased efficacy of the current standard chemotherapy with 
and without targeted agents in metastatic colorectal cancer patients with PC. The median 
number of treatment cycles did not differ between patients with and without PC. This 
suggests that the poor outcome of these patients cannot be explained by undertreatment 
or increased susceptibility to toxicity, but rather by a relative resistance to treatment.
The detection of PC in colorectal cancer patients frequently results in a dilemma with regard 
to the optimal treatment strategy, especially when PC is encountered unexpectedly. It is 
unclear whether any surgical interventions of any kind should be advocated in patients with 
colorectal cancer and synchronous PC or if a non-invasive palliative treatment policy should 
be preferred. Several surgical options are available: an attempt to resect the primary tumour 
with or without the peritoneal metastases, the performance of a derivative procedure or 
enterostomy, closure of the abdomen without further intervention. 
In chapter 4 the morbidity, mortality and survival of patients undergoing palliative surgery 
for colorectal carcinoma with synchronous PC were evaluated, in order to clarify the 
advantages and disadvantages of different surgical approaches.
For this purpose, patients diagnosed with primary colorectal cancer and synchronous PC 
between 1995 and 2009 in three community hospitals were selected from the Eindhoven 
Cancer Registry database. Between 1995 and 2009, 169 colorectal cancer patients were 
diagnosed with synchronous PC. Surgery was performed in 142 patients. PC was encountered 
unexpectedly in 130 patients. Median survival was 14 weeks without surgery (n=22), 12 
weeks after a derivative procedure (n=46) and 55 weeks after primary tumour resection 
(n=91). Derivative procedures resulted in a 30% complication rate and an in-hospital 
mortality of 41%. Performance of derivative procedures or no surgery were negative 
prognostic factors (Hazard ratio for dying 2.33, p=0.0001 and hazard ration 3.09, p=0.0007, 
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respectively). Other factors increasing the risk of death were older age (>70 years), the 
presence of a second primary tumour, poor differentiation grade, and systemic metastases. 
This study shows that PC is often encountered unexpectedly during surgery for colorectal 
cancer. Primary tumour resection can be safely performed with good outcomes, but some 
patients may have benefited from an even more radical approach. If possible, derivative 
surgery should be avoided given its high morbidity and mortality. Ideally, PC should be 
diagnosed prior to an operative procedure. 
Part	II	Surgical	combination	therapies	with	curative	intent	in	experimental	studies	
The only phase III randomised trial comparing cytoreductive surgery and hyperthermic 
intraperitoneal chemotherapy (HIPEC) with standard palliative care found median survival in 
the cytoreductive surgery and HIPEC group to be 22.4 months, compared with 12.6 months 
in patients treated with standard palliative care alone. Although these results are certainly 
encouraging, it remains unclear whether both cytoreductive surgery and HIPEC are indeed 
required to achieve the survival benefit. Unfortunately, no experimental arm was included 
with cytoreductive surgery alone. It is unlikely that a clinical trial will be able to resolve this 
issue since patients are not willing to participate in such studies. Instead an experimental 
study was performed in rats with PC of colorectal origin, aiming to establish the benefit of 
HIPEC as adjuvant therapy after cytoreductive surgery for PC. The results of this study are 
presented in chapter 5. The experiments were performed using a validated and reproducible 
model of PC of colorectal origin that resembles the clinical situation. After inoculation of 
CC-531 syngeneic colonic carcinoma cells, PC without distant metastasis develops within 
one week. One week after tumour cell inoculation, cytoreductive surgery was performed 
followed by no further treatment in the first group, and perfusion with hyperthermic 
mitomycin in a concentration of 15 or 35 mg/m2 bodysurface in the second group and third 
group, respectively. Perfusion of the peritoneal cavity was performed for 90 min at 10 ml/
min at a temperature of 41°C. Mitomycin C was dissolved in 0.9 per cent sodium chloride to 
the appropriate concentration and added to the perfusate in three separate doses at 30-min 
intervals, each containing 50, 25 and 25 per cent respectively of the total dose. 
The median survival of rats treated with cytoreductive surgery alone was 43 days. Rats 
receiving HIPEC 15 mg/m2 and HIPEC 35 mg/m2 both had a significantly longer median 
survival of 75 days (p = 0.003) and 97 days (p < 0.001) respectively. Rats receiving HIPEC 
showed a significantly lower tumour load at autopsy compared with rats treated with 
cytoreductive surgery alone. Complete macroscopic removal of the tumour from the 
peritoneal cavity was identified as a second independent factor that improves outcome, 
similar to observations in clinical practice.
Concluding, HIPEC in both concentrations proved to be highly effective in prolonging survival 
and in delaying intra-abdominal recurrence when applied after cytoreductive surgery. 
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The HIPEC treatment consists of two factors, chemotherapy and hyperthermia. Next to 
a direct cytotoxic effect, hyperthermia is believed to enhance the antitumour effect of 
several cytostatic agents at markedly lower temperatures by increasing blood flow and 
oxygen content within tumours. This phenomenon is thought to increase intratumoural 
drug concentrations and thereby the cytostatic efficiency. Yet it remains unclear if both 
hyperthermia and chemotherapy are essential for the reported survival benefit.
In chapter 6, the necessity of the separate elements hyperthermia and chemotherapy for 
the effectiveness of the HIPEC therapy as a whole on survival was evaluated in the same 
experimental model as described above.
In this study, eighty WAG/Rij rats with PC were randomly assigned to 1 of the 4 treatment 
groups (n = 20): cytoreductive surgery only, cytoreductive surgery followed by HIPEC 
(mitomycin 35 mg/m2 at 41°C), cytoreductive surgery followed by intraperitoneal mito-
mycin-C perfusion at 37°C and cytoreductive surgery followed by intraperitoneal saline 
perfusion at 41°C. Survival was the primary outcome with a maximum follow up of 126 days. 
Median survival was 62 days in rats treated with cytoreductive surgery only and 57 days in rats 
treated with cytoreductive surgery followed by hyperthermic saline perfusion. Rats receiving 
HIPEC had a median survival of 121 days (p=0.022 when compared with cytoreductive 
surgery only). In the group treated with chemotherapy at 37°C, 13 of 20 animals were still 
alive at the end of the experiment so median survival was not reached. (cytoreductive 
surgery versus normothermic perfusion: p=0.002) Rats treated with hyperthermic saline 
perfusion did not have an increased survival as compared with cytoreductive surgery only.
It is concluded that the effectiveness of intraoperative intraperitoneal perfusion after 
cytoreductive surgery is highly dependent on the presence of chemotherapy in the perfusate 
but not on hyperthermia. 
Currently, the factor hyperthermia is not integrated in all treatment protocols for PC 
including cytoreductive surgery and intraperitoneal chemotherapy. The two most widely 
used treatment regimens for application of intraperitoneal chemotherapy are HIPEC and 
normothermic Early Postoperative Intraperitoneal Chemotherapy (EPIC). It remains unclear 
which regimen is most beneficial. In the experimental study described in chapter 7, the 
effectiveness of both treatment strategies was compared to treatment with cytoreductive 
surgery only. In addition, the effect of a combination of both therapies on survival outcomes 
was investigated. 
PC was induced in Wag/Rij rats as described before, and the animals were randomised into 
four treatment groups (n=20): cytoreductive surgery only, cytoreductive surgery followed by 
HIPEC (mitomycin 35 mg/m2 at 41°C), cytoreductive surgery followed by EPIC during 5 days 
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(i.p. injection of mitomycin 10 mg/m2 on day 1 and 5-fluorouracil 15mg/kg on day 2-5), and 
cytoreductive surgery followed by HIPEC plus EPIC. 
In rats treated with cytoreductive surgery only, median survival was 53 days. In rats treated 
with CS followed by HIPEC, survival was significantly increased to a median survival of 94 
days (p = 0.001). In the group treated with EPIC after cytoreductive surgery, 12 out of 20 rats 
were still alive at the end of the experiment (p<0.001 as compared to cytoreductive surgery 
only). In the group receiving both treatments, eleven rats died of toxicity and therefore this 
group was not included in the survival analysis.
Both EPIC and HIPEC were effective in prolonging survival after cytoreductive surgery for 
PC from colorectal cancer. The beneficial effect of EPIC on survival seemed to be more 
pronounced than that of HIPEC. Further research is indicated to evaluate and compare the 
possible benefits and adverse effects associated with both treatments. 
Part	III	Clinical	aspects	of	surgical	combination	therapies	with	curative	intent
In order to optimise the outcome of cytoreductive surgery and perioperative intraperitoneal 
chemotherapy, a careful patient selection remains one of the most important determinants. 
Well-known selection criteria are a physical condition fit enough for extensive surgery, 
resectable disease, absence of extensive hematogenous metastases and a limited extent 
of PC. Other criteria are applied on a theoretical basis only and therefore the selection of 
patients is still very much dependent on individual experience and preference of the surgical 
oncologist who performs the surgery. 
In chapter 8 the question is addressed whether patients who developed intraperitoneal 
recurrent disease during or shortly after the use of adjuvant systemic chemotherapy, and 
thus showed a relative resistance against systemic chemotherapy, should be eligible for 
local treatment with cytoreductive surgery and HIPEC. For this purpose, the outcomes 
of twenty-one consecutive patients who had an early recurrence after adjuvant systemic 
chemotherapy were analysed. Median time to recurrence of disease was 9 months after the 
first chemotherapy administration. Median survival after diagnosis of PC was 28 months. 
One- and 2-year survival was 71% and 43%, respectively. These results are similar to data 
reported in the literature on patients treated with HIPEC in whom data on response to 
previous chemotherapeutic treatment were not provided. No evidence was thus found to 
support the exclusion of patients who failed to respond to systemic adjuvant chemotherapy 
from treatment with HIPEC. Therefore, previous chemotherapy treatment should not be 
regarded as a selection criterion when assessing patient eligibility for HIPEC procedures.
Another group of patients where the indication for an aggressive surgical approach is 
debatable is the group of elderly patients. With advances in surgical techniques, anesthetic 
management and perioperative medical care complication rates of patients undergoing 
cytoreductive surgery and intraperitoneal chemotherapy have lowered considerably. It 
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remains to be seen whether these procedures, being the only curative option available for 
PC, should only be reserved for younger patients. This issue was addressed in chapter 9. 
In this chapter, morbidity, mortality and survival are reported for patients aged over 70 
years at the time of surgery. Twenty-four patients were included with a mean age of 74 
years. In eight patients major complications occurred. In six patients the postoperative 
course was complicated by minor adverse events. There was no perioperative mortality. 
Median overall survival was 35 months with a 6-, 12- and 18-months survival rate of 94, 
83 and 68%, respectively. Thus, cytoreductive surgery and perioperative intraperitoneal 
chemotherapy can be safely performed with acceptable morbidity in elderly patients with 
PC from colorectal origin. When selecting patients for surgery, performance status and the 
disease extent should be used as eligibility criteria rather than age. This should encourage 
surgeons to consider elderly patients aged 70 years and older for cytoreductive surgery and 
perioperative intraperitoneal chemotherapy if indicated. 
Despite aggressive treatment with cytoreductive surgery and intraperitoneal chemotherapy, 
a significant proportion of patients develops peritoneal recurrence. This raises the question 
whether a repeat procedure consisting of cytoreductive surgery and peri-operative 
intraperitoneal chemotherapy should be offered to these patients. In chapter 10, a study 
is described evaluating the oncologic efficacy and feasibility of repeat procedures including 
cytoreductive surgery and intraperitoneal chemotherapy for recurrent disease. The study 
included eighteen patients. During the repeat procedure, severe adverse events requiring 
surgical intervention occurred in one patient. There was no mortality in the first 30 days 
after surgery. One-year and two-year survival after repeat cytoreductive surgery were 74 
and 50 %, respectively. However, fourteen patients developed a recurrence after the repeat 
procedure with a median disease-free survival of only 4.5 months. It was concluded that 
repeat cytoreductive surgery for recurrent colorectal cancer PC appears feasible, with 
an acceptable morbidity and without mortality. Unfortunately, early relapse from repeat 
cytoreduction is observed frequently. Further research and long-term follow up to explore 
the option of repeat cytoreduction for recurrent colorectal PC is required. 
Should secondary cytoreduction be pursued, it should be offered to patients who respond 
following a trial of systemic therapy, who are fit and have minimal and completely resectable 
disease. A multi-disciplinary approach is essential to select patients who would benefit from 
secondary cytoreduction based on technical feasibility of further surgery, performance 
status and response to chemotherapy in an era when systemic therapies have shown to 
achieve survival prolongation. 
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Conclusion	and	future	perspectives
Part	I	Treatment	with	palliative	intent
Traditionally, patients with PC have been treated with palliative systemic chemotherapy for 
stage IV colorectal cancer. The introduction of cytoreductive surgery and intraperitoneal 
chemotherapy treatment has increased the need for data describing the results of palliative 
treatment, in order to compare this “standard” palliative care with aggressive surgical 
approaches. Furthermore, the presence of systemic metastases, extensive irresectable 
peritoneal involvement, or a poor physical performance status excludes patients from 
aggressive surgery. The majority of patients with PC thus remains dependent on palliative 
treatment. 
The choices available to medical oncologists for the palliative treatment of patients with 
metastatic colorectal cancer have increased over the last few years with the approval 
of irinotecan and oxaliplatin, and with the introduction of targeted agents suppressing 
angiogenic growth factors. Although the presence of PC is associated with a worse prognosis 
as compared to other sites of metastasis, the data reported in this thesis show that the 
introduction of targeted agents may be beneficial in this group of patients. Also, it appears 
that the traditional chemotherapeutic agents have only a minor impact on this disease. 
Therefore, new developments in the systemic palliative treatment of peritoneal metastases 
should focus on pathways involved in tumour growth other than working mechanisms of 
conventional chemotherapy. The process of tumour induced neoangiogenesis may be a 
pathway of interest. 
An individualisation of care is important to select those patients who will most likely benefit 
from different systemic treatment regimens. With an increasing number of cytotoxic and 
targeted agents available, the need is growing for selection parameters like tumour markers 
or mutational status to offer an appropriate and individualised treatment to every patient. 
Response evaluation studies investigating the predictive value of tumour related parameters 
in this group of patients are required to achieve more accuracy in treatment strategies, and 
to avoid unnecessary toxicity. 
Finally, future studies should focus on quality of life in patients with PC to optimise treatment, 
and palliative care in particular. 
Part	II	Surgical	combination	therapies	with	curative	intent	in	experimental	studies	
From the preclinical experiments described in this thesis, it can be concluded that the 
addition of intraperitoneal chemotherapy after cytoreduction is an essential component 
of HIPEC in the combination treatment to achieve a survival benefit. There is no evidence 
for an additional value of hyperthermic over normothermic intraperitoneal treatment after 
cytoreduction. Also, EPIC after cytoreductive surgery certainly seems a treatment option 
worthwhile to pursue. 
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Animal studies remain important for studying cancer in humans, but caution is always 
warranted with extrapolation and application to the clinical situation. Although similarities 
among animal models and human clinical practice in terms of responses to hazardous 
exposures are well known, differences between species may be of influence on tumour 
pathogenesis and response to treatment. Yet, the possibilities for simplification of the 
procedures including intraperitoneal chemotherapy may be worthwhile to explore further. 
The results obtained in these experimental studies should stimulate further investigation 
in clinical phase III trials. A comparison between HIPEC and EPIC would be an interesting 
issue to address. Primary goals should be to evaluate differences in morbidity and mortality 
associated with these procedures. Secondly, long term survival benefits should be 
compared. Interesting groups of patients to include in this trial would be patients in whom 
PC is encountered unexpectedly during surgery, or patients considered to be at high risk for 
developing peritoneal metastases and in whom PC is found during a planned second look 
laparoscopy. Randomisation between direct application of EPIC and rescheduling for HIPEC 
treatment would be a possibility to compare these treatments. 
Next to clinical evaluation of experimental conclusions, the availability of the animal model 
allows further investigation of questions regarding HIPEC techniques. Other questions that 
may be examined in this animal model are the influence of the concentration of the perfusate 
as compared to the dose used in an undefined volume of perfusion fluid. Furthermore, the 
duration of perfusion time is not standardised worldwide, and the perfusion time in HIPEC 
procedures varies between 30 and 90 minutes. No clear rationale for one of these variations 
exists, although the time needed for perfusion has important implications with regards 
to operating time scheduling, duration of anaesthesia and control of body temperature. 
In addition, it would be interesting to develop an animal model with an open (coliseum) 
technique HIPEC perfusion, to compare open and closed perfusion techniques. 
Promising results have been reported with the application of adjuvant radioimmunotherapy 
after cytoreductive surgery in experimental studies. With this technique, monoclonal 
antibodies directed against tumour-associated antigens are labeled with radionuclides for 
targeted radiation. This may be a worthwhile alternative to chemotherapy and requires 
additional evaluation in phase I trials. 
Part	III	Clinical	aspects	of	surgical	combination	therapies	with	curative	intent
A careful selection process of patients remains one of the most important factors in 
the effectiveness of surgical combination treatment. New insights into the biological 
mechanisms of cancer dissemination and the pathophysiology of PC from colorectal 
origin have contributed to the understanding that PC can be regarded as a locoregional 
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extension of disease, rather than a manifestation of systemic metastasis. Yet, the exact 
pathophysiological mechanisms and differences between patients in the behaviour of 
the disease remain to be clarified. It has been suggested that gene expression patterns in 
the primary tumour determine not only the metastatic potential and the occurrence of 
peritoneal dissemination of colorectal cancer cells, but also the variation in response to 
treatment with chemotherapeutic agents. According to this hypothesis, gene expression in 
peritoneal disseminated cells may differ from expression patterns in metastases localised 
elsewhere, thereby modulating the sensitivity and response of tumour cells to different 
kinds of systemically administrated chemotherapy. This would explain the observation that 
the prognosis of patients with PC is worse than that of patients with metastases at other 
sites, even with the availability of more potent chemotherapy regimens. 
It can be expected that with advances in research regarding genetic expression patterns, 
it will at some point in time be possible to identify factors influencing patterns of disease 
spread and sensitivity to different treatments. For example, specific mutations (e.g. k-ras in 
colorectal cancer, HER2/neu receptors in breast cancer) have been shown to be associated 
with tumour behaviour and treatment response. For PC, it would be of interest to identify 
factors that determine whether the spread of colorectal cancer cells will remain limited to 
the peritoneal cavity, as in these patients long-term survival and even cure may be achieved 
with locally applied treatment like cytoreductive surgery and HIPEC. This will have a great 
impact on patient selection for an aggressive surgical treatment. 
In addition, it is not unlikely that intraperitoneal chemotherapy will not only be applied as 
a treatment after cytoreduction, but also as adjuvant treatment after resection of primary 
colorectal carcinomas with high potential of peritoneal dissemination. This may prevent 
spilled cancer cells from attaching to the peritoneal surface and formation of solid peritoneal 
metastases. Another strategy aiming at increasing early diagnosis of PC is standard “second-
look surgery”, consisting of a scheduled laparoscopy or laparotomy in patients at high risk 
for developing metachronous PC. Factors increasing the risk for PC may for example be 
perforated tumours, malignant cells in ascites and unfavourable histology. Trials evaluating 
the feasibility and efficacy of this approach are currently undertaken. 
Finally, for the evaluation of patient selection criteria, cooperation between centres and 
the integration of results in databases are essential. As the performance of randomised 
trials in this area of research has shown to be very difficult, multicentre studies combining 
large numbers of patients are required to further define patient selection criteria. Globally, 
several large institutes already collaborate and this should be encouraged further. 
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Peritoneale uitzaaiingen komen frequent voor bij patiënten met colorectaal carcinoom. De 
diagnose ‘peritoneale metastasering’ is altijd beschouwd als een ongeneselijk stadium van 
ziekte, geassocieerd met een zeer slechte prognose. Bovendien leek de patiëntengroep die 
zich presenteerde met peritoneaalmetastasen nauwelijks baat te hebben bij systemische 
palliatieve chemotherapie. Deze factoren hebben ertoe geleid dat dit ziektebeeld in het 
verleden relatief weinig aandacht heeft gekregen.
De ontwikkeling van nieuwe chirurgische behandelstrategieën voor patiënten met peritoneale 
metastasen heeft gezorgd voor een hernieuwde belangstelling voor deze patiëntengroep. 
Deze technieken bestaan uit een combinatie van radicale cytoreductieve chirurgie en 
intraperitoneale chemotherapie. Met deze therapie kan een significante toename van de 
overleving bereikt worden ten opzichte van palliatieve zorg. Daarnaast wordt bij een deel 
van de behandelde patiënten langdurige ziektevrije overleving gerapporteerd. 
Om een optimaal resultaat te kunnen bereiken met nieuwe behandelstrategieën is 
aanvullende informatie over onder andere het natuurlijke beloop van de ziekte, resultaten 
van ‘standaard’ palliatieve behandeling en patiënt-afhankelijke factoren die van invloed zijn 
op het effect van de behandeling essentieel. De afwezigheid van deze data in combinatie 
met de toegenomen interesse in deze patiëntengroep heeft wetenschappelijk onderzoek 
naar dit ziektebeeld gestimuleerd.
In dit proefschrift worden populatie-onderzoeken, dierexperimenten en klinische studies 
beschreven. Hiermee wordt beoogd enerzijds een beeld te schetsen van de resultaten 
van palliatieve behandeling van patiënten met peritoneaal gemetastaseerd colorectaal 
carcinoom met systemische chemotherapie en chirurgie, en anderzijds meer inzicht 
te geven in de factoren die van invloed zijn op de effectiviteit van behandeling met 
cytoreductieve chirurgie en intraperitoneale chemotherapie. Onder dit laatste worden 
zowel de invloed van de afzonderlijke componenten van de behandeling op de effectiviteit 
als patiëntselectiecriteria verstaan. 
Deel	I	Palliatieve	behandeling	
Het doel van de studie beschreven in hoofdstuk 1 was om een indruk te geven van de 
incidentie van synchrone peritoneale metastasen bij patiënten met een primair colorectaal 
carcinoom. Hiervoor werden gegevens uit de database van de kankerregistratie in de 
regio Eindhoven geanalyseerd. Deze gegevens worden routinematig verzameld door 
medewerkers van het Integraal Kankercentrum Zuid (IKZ). In deze analyse werden alle 
patiënten geïncludeerd bij wie tussen 1995 en 2008 de diagnose primair colorectaal 
carcinoom gesteld werd. De incidentiedata van peritoneaalmetastasen werden gerelateerd 
aan relevante karakteristieken van deze patiënten en gegevens over de primaire tumor, 
om predisponerende factoren voor het bestaan van peritoneaalmetastasen ten tijde 
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van diagnose van een primair colorectaal carcinoom te identificeren. Daarnaast werd de 
mediane overleving van deze patiëntengroep berekend. Tijdens de studieperiode werd bij 
904 patiënten in de IKZ-regio de diagnose primair colorectaal carcinoom met synchrone 
peritoneaalmetastasen gesteld (dit komt overeen met 4.8% van het totale aantal patiënten 
gediagnosticeerd met colorectaal carcinoom, en 24% van de patiënten met synchroon 
gemetastaseerde ziekte). Het risico op synchrone presentatie met peritoneaalmetastasen 
bij diagnose van een colorectaal carcinoom was verhoogd bij een gevorderd T- stadium 
van de primaire tumor, gevorderd N stadium, slechte differentiatiegraad, jonge leeftijd, 
mucineuze classificatie van het adenocarcinoom en rechtzijdige localisatie van de primaire 
tumor. De overleving van patiënten met synchrone peritoneaalmetastasen is beperkt, en 
staat in contrast met de prognose van patiënten met levermetastasen, bij wie de laatste 
jaren veel vooruitgang in overleving gerapporteerd wordt. Mediane overleving van patiënten 
met peritoneaalmetastasen is 8 maanden. Indien behalve het peritoneum ook andere 
localisaties in het lichaam aangedaan zijn is de prognose zelfs nog slechter. Deze gegevens 
onderstrepen het belang van de ontwikkeling van nieuwe therapieën voor patiënten met 
peritoneaalmetastasen. De gegevens uit deze studie kunnen bijdragen aan een beter inzicht 
in het natuurlijke beloop van de ziekte en het identificeren van groepen patiënten met een 
verhoogd risico op peritoneaalmetastasen. 
De toegevoegde waarde van systemische chemotherapie bij patiënten met peritoneaal 
gemetastaseerd colorectaal carcinoom is niet vastgesteld. Door de beperkte grootte van de 
peritoneale tumordeposities is het vaak moeilijk om een eventuele respons op chemotherapie 
aan te tonen met beeldvormende technieken. Om deze reden voldoen patiënten met 
peritoneaalmetastasen vaak niet aan de inclusiecriteria voor gerandomiseerde studies 
die het effect van systemische therapieën evalueren. Indien ze wel geïncludeerd worden, 
wordt slechts zelden een aparte analyse van de resultaten van deze groep van patiënten 
uitgevoerd en beschreven. 
Hoewel er geen bewijs is over de effectiviteit van behandeling, kan worden aangenomen 
dat peritoneaalmetastasen in de kliniek beschouwd worden als “gemetastaseerde ziekte”, 
en dat patiënten die zich presenteren met deze ziekte behandeld worden met systemische 
palliatieve chemotherapie. In hoofdstuk 2 werden trends in het gebruik van palliatieve 
chemotherapie en het effect hiervan op de overleving in een grote ongeselecteerde 
populatie van patiënten met peritoneaalmetastasen retrospectief geanalyseerd. Er werd 
een toename van het gebruik van chemotherapie waargenomen in de tijd. In 1995 werd 
16% van alle patiënten met peritoneaalmetastasen behandeld met chemotherapie. In 
2008 was dit gestegen naar 46% (p=0.001). Bij jongere patiënten (<70 jaar oud) was deze 
toename nog sterker, van 29 naar 64%. Ondanks deze toename in behandelingsfrequentie 
en de beschikbaarheid van nieuwe middelen zoals oxaliplatin en irinotecan nam de mediane 
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overleving in deze tijdsperiode niet toe. Bij de totale groep van patiënten met peritoneale 
uitzaaiingen, maar zonder afstandsmetastasen werd een mediane overleving van 35 weken 
geregistreerd in de periode van 1995 tot 2000 en 34 weken tussen 2005 en 2008. 
Een opmerkelijke observatie was een trend naar verbeterde overleving (tot 66 weken) bij 
selectie van patiënten die behandeld werden met chemotherapie in de periode van 2005-
2008. In multivariate regressie analyse bleek het gebruik van chemotherapie het risico 
op overlijden te verlagen in de periode 2005-2008. In de tijd daarvoor werd het risico op 
overlijden niet gereduceerd door chemotherapie gebruik. Deze studie laat zien dat de 
prognose van patiënten met peritoneaalmetastasen slecht blijft ondanks ontwikkelingen in 
en betere beschikbaarheid van palliatieve chemotherapie. Sinds 2005 worden monoclonale 
antilichamen standaard toegevoegd aan palliatieve chemotherapieschema’s voor de 
behandeling van patiënten met gemetastaseerd colorectaal carcinoom. Deze ontwikkeling 
valt samen met de toename in overleving die geobserveerd werd bij patiënten met 
peritoneaalmetastasen die met chemotherapie behandeld zijn. Echter, momenteel zijn er 
geen gerandomiseerde studies gepubliceerd die resultaten van deze therapie bij patiënten 
met gemetastaseerd colorectaal carcinoom met peritoneaalmetastasen beschrijven. 
Teneinde de effecten van de meest recente chemotherapieschema’s bij patiënten met 
peritoneaalmetastasen verder te evalueren, werden de uitkomsten met betrekking tot 
effectiviteit en toxiciteit van systemische behandeling bij patiënten met peritoneaal 
gemetastaseerd colorectaal carcinoom uit twee grote gerandomiseerde studies (CAIRO and 
CAIRO2) retrospectief geëvalueerd. De resultaten hiervan worden beschreven in hoofdstuk 
3. Tevoren onbehandelde patiënten met gemetastaseerd colorectaal carcinoom werden 
behandeld met chemotherapie in de CAIRO studie en met chemotherapie en monoclonale 
antilichamen in de CAIRO2 studie. De resultaten van alle patiënten die deelnamen aan deze 
studies werden retrospectief geanalyseerd, waarbij onderscheid werd gemaakt in de aan- of 
afwezigheid van peritoneaalmetastasen ten tijde van randomisatie. Patiëntkarakteristieken, 
kenmerken van de primaire tumor, het optreden van toxiciteit en overlevingsuitkomsten 
werden vergeleken. 
Bij 34 patiënten in de CAIRO studie en 47 patiënten in de CAIRO2 studie waren er aan-
wijzingen dat peritoneaalmetastasen aanwezig waren ten tijde van randomisatie. 
Patiëntkarakteristieken verschilden niet tussen patiënten met en zonder 
peritoneaalmetastasen, behalve een frequenter voorkomen van WHO classificatie 1 (ten 
opzichte van classificatie 0) bij patiënten met peritoneaalmetastasen in de CAIRO2 studie. 
De mediane overleving van patiënten met peritoneaalmetastasen was significant minder 
dan die van patiënten zonder peritoneaalmetastasen, met 10.4 versus 17.3 maanden, 
respectievelijk, in de CAIRO studie (p=<0.001) en 15.2 versus 20.7 maanden in de CAIRO2 
studie (p<0.001). Het mediane aantal behandelcycli met chemotherapie verschilde niet 
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tussen patiënten met en zonder peritoneaalmetastasen. In de groep patiënten die behandeld 
werd met sequentiële chemotherapie in de CAIRO studie trad meer toxiciteit op bij patiënten 
met peritoneaalmetastasen dan bij patiënten met metastasen op andere locaties. Dit kwam 
echter niet tot uiting in de redenen om de behandeling te discontinueren. In de CAIRO2 
studie werden geen verschillen gevonden in het optreden van ernstige toxiciteit tussen 
patiënten met en zonder peritoneaalmetastasen. 
Patiënten met peritoneaalmetastasen hebben derhalve een slechtere prognose dan 
patiënten met metastasen op andere locaties, ook wanneer zij behandeld worden met 
de huidige standaard chemotherapie voor gemetastaseerd colorectaal carcinoom met 
of zonder monoclonale antilichamen. De observatie dat het aantal behandelcycli niet 
verschilden tussen patiënten met en zonder peritoneaalmetastasen suggereert dat de 
negatieve impact op overleving niet verklaard kan worden door onderbehandeling of een 
frequenter optreden van toxiciteit in deze groep. Vervolgonderzoek is nodig om de oorzaak 
van de geobserveerde relatieve resistentie van peritoneaalmetastasen voor systemische 
palliatieve therapie te verhelderen. 
Wanneer synchrone peritoneaalmetastasen onverwacht aangetroffen worden tijdens een 
operatie voor een primair colorectaal carcinoom staat de opererend chirurg voor een keuze. 
Besloten kan worden tot het uitvoeren van de geplande resectie van de primaire tumor, 
het aanleggen van een omleiding of stoma om obstructie te voorkomen, of het sluiten 
van het abdomen zonder verdere interventie. Het is niet bekend of chirurgische ingrijpen 
bij patiënten met colorectaal carcinoom en synchrone peritoneaalmetastasen zinvol is. In 
hoofdstuk 4 werden de postoperatieve morbiditeit, mortaliteit en de overlevingsresultaten 
geanalyseerd van patiënten met colorectaal carcinoom en peritoneaalmetastasen die een 
palliatieve chirurgische ingreep ondergingen. Doel van deze studie was om de voor- en 
nadelen van de verschillende chirurgische benaderingen te evalueren. Hiervoor werden 
alle patiënten geïncludeerd bij wie tussen 1995 en 2009 in drie regionale ziekenhuizen de 
diagnose primair colorectaal carcinoom met synchrone peritoneaalmetastasen werd gesteld. 
Voor de selectie van deze patiënten werd gebruik gemaakt van de kankerregistratiedatabase 
van het IKZ.
Tussen 1995 en 2009 werd bij 169 patiënten met een primair colorectaal carcinoom 
synchrone peritoneale metastasen gediagnosticeerd. Bij 142 patiënten werd een operatieve 
ingreep verricht. Peritoneaalmetastasen werden aangetroffen als toevalsbevinding tijdens 
de operatie bij 130 patiënten. De mediane overleving van patiënten was 14 weken indien 
geen interventie plaatsvond (n=22), 12 weken voor patiënten met een omleiding of stoma 
(n=46) en 55 weken bij patiënten bij wie de primaire tumor gereseceerd werd (n=91). 
Van de patiënten bij wie een omleiding of stoma werd aangelegd had 30% een gecompliceerd 
herstel, resulterend in een mortaliteit tijdens de opname van 41%. Het niet ondergaan 
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van een operatie of een operatie voor een omleiding of stoma was geassocieerd met een 
verhoogd risico op overlijden ten opzichte van resectie van de primaire tumor (Hazard 
ratio (HR) voor overlijden 2.33, p=0.0001 en HR 3.09, p=0.0007, respectievelijk). Andere 
factoren geassocieerd met een verhoogd risico op overlijden in multivariate analyse waren 
gevorderde leeftijd (>70 jaar), de aanwezigheid van een tweede primaire tumor, slechte 
differentiatiegraad van de primaire tumor en de aanwezigheid van metastasen op andere 
locaties naast het peritoneum. 
Deze studie laat zien dat peritoneaalmetastasen vaak per toeval aangetroffen worden tijdens 
chirurgische ingrepen voor colorectaal carcinoom. Resectie van de primaire tumor is mogelijk 
met een acceptabele postoperatieve morbiditeit en mortaliteit, maar sommige patiënten 
zouden mogelijk baat hebben gehad bij een agressievere behandeling. Terughoudendheid 
is geboden met het uitvoeren van een omleiding, aangezien deze gepaard gaat met een 
hoge postoperatieve morbiditeit en mortaliteit. Idealiter zouden peritoneaalmetastasen 
preoperatief gediagnosticeerd moeten worden. 
 
Deel	 II	 Experimenteel	 onderzoek	 naar	 in	 opzet	 curatieve	 chirurgische	
combinatiebehandelingen	
De enige gerandomiseerde studie die cytoreductieve chirurgie plus hypertherme 
intraperitoneale chemotherapie (HIPEC) vergeleken heeft met standaard palliatieve zorg 
rapporteerde een mediane overleving van 22.4 maanden in de cytoreductieve chirurgie 
plus HIPEC groep, en 12.6 maanden in de groep met de standaard palliatieve behandeling. 
Hoewel deze resultaten veelbelovend zijn, blijft het onduidelijk of het noodzakelijk is om 
de cytoreductieve chirurgie met HIPEC te combineren om de beschreven overlevingswinst 
te behalen. Helaas was in de studie in kwestie geen behandelgroep opgenomen met alleen 
cytoreductieve chirurgie. Het is niet waarschijnlijk dat een klinische studie deze vraag zal 
beantwoorden aangezien patiënten niet bereid zijn deel te nemen aan een dergelijk studie-
protocol. 
Een dierexperimentele studie werd uitgevoerd bij Wag/Rij ratten met peritoneaalmetastasen 
van een coloncarcinoom, om de adjuvante waarde van HIPEC na cytoreductieve chirurgie 
in de behandeling van peritoneaalmetastasen vast te stellen. De resultaten van deze studie 
worden gepresenteerd in hoofdstuk 5. Voor het experiment werd gebruik gemaakt van 
een gevalideerd en reproduceerbaar model voor peritoneaalmetastasen van colorectale 
oorsprong, dat de klinische situatie simuleert. Na intraperitoneale injectie van cellen 
afkomstig van de CC-531 ratten colon carcinoom cellijn ontwikkelen de peritoneaalmetastasen 
zich binnen een week. Een week na de tumor inoculatie werd cytoreductieve chirurgie 
verricht bij alle ratten. Deze behandeling werd in de verschillende groepen (elk n=20) gevolgd 
door respectievelijk geen verdere behandeling of perfusie met hypertherme mitomycine, in 
een concentratie van 15 of 35 mg/m2 lichaamsoppervlak. 
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De perfusie van de peritoneaalholte duurde 90 minuten bij een perfusiesnelheid van 10 ml/
min en een temperatuur van 41°C. Mitomycine C werd opgelost in 0.9% natriumchloride 
en in drie afzonderlijke giften toegevoegd met intervallen van 30 minuten. Elke toediening 
bevatte respectievelijk 50, 25 en 25% van de totale dosis. 
De mediane overleving van ratten die behandeld werden met alleen cytoreductieve 
chirurgie was 43 dagen. Bij de dieren waar de cytoreductie gevolgd werd door HIPEC 15 
mg/m2 of HIPEC 35 mg/m2 werd een significant langere mediane overleving waargenomen 
van 75 dagen (p = 0.003) en 97 dagen (p < 0.001) respectievelijk. Ratten die een HIPEC-
behandeling ondergaan hadden bleken een significant lagere hoeveelheid tumor te hebben 
op het moment van overlijden dan ratten die alleen met cytoreductieve chirurgie waren 
behandeld. Een complete macroscopische resectie van de peritoneale tumor deposities was 
geassocieerd met een gunstige uitkomst. Dit komt overeen met klinische observaties. 
Er werd geconcludeerd dat HIPEC in beide concentraties, wanneer dit wordt toegepast als 
adjuvante therapie na cytoreductieve chirurgie, zeer effectief is in het verlengen van de 
overleving en het vertragen van recidiverende intra-abdominale tumorgroei. De toevoeging 
van HIPEC aan cytoreductieve chirurgie is dus essentieel om de overlevingswinst te bereiken 
zoals die beschreven wordt in de enige afgeronde gerandomiseerde klinische studie. 
De HIPEC behandeling bestaat uit twee factoren, namelijk chemotherapie en hyperthermie. 
Naast een direct cytotoxisch effect wordt de werking van hyperthermie in deze setting 
vooral toegeschreven aan een versterking van het effect van cytostatica. Dit effect wordt 
bereikt op aanzienlijk lagere temperaturen dan die benodigd zouden zijn voor directe 
cytotoxiciteit. Het effect wordt toegeschreven aan stimulatie van de circulatie en verhoging 
van de zuurstofconcentratie in tumoren. Hierdoor zou de concentratie van cytostatica in 
tumorweefsel toenemen en daarmee de werking worden bevorderd. Echter, het is niet 
bekend of zowel de factoren hyperthermie als chemotherapie noodzakelijk zijn om een winst 
in overleving te bereiken na cytoreductieve chirurgie. Deze vraagstelling werd in hoofdstuk 
6 onderzocht, opnieuw gebruik makend van diermodel zoals hierboven beschreven. 
In deze studie werden 80 Wag/Rij ratten middels randomisatie verdeeld over vier 
behandelgroepen (elk n=20) en behandeld met een van de volgende therapieën: 
cytoreductieve chirurgie zonder verdere interventie, cytoreductieve chirurgie gevolgd 
door HIPEC (35 mg/m2 mitomycine verwarmd tot 41°C), cytoreductieve chirurgie gevolgd 
door intraperitoneale perfusie met mitomycine verwarmd tot 37°C, en cytoreductieve 
chirurgie gevolgd door intraperitoneale perfusie met fysiologisch zout verwarmd tot 41°C. 
Overleving was de primaire uitkomst van het onderzoek met een maximale follow-up van 
126 dagen. Een mediane overleving van 62 dagen werd bereikt in de groep behandeld met 
alleen cytoreductieve chirurgie, en van 57 dagen in de groep behandeld met cytoreductieve 
chirurgie gevolgd door hypertherme perfusie met fysiologisch zout. Er werd geen verschil 
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in overleving gevonden tussen deze groepen. Ratten die een HIPEC procedure ondergingen 
hadden een mediane overleving van 121 dagen (p = 0.022 vergeleken met de groep die alleen 
cytoreductieve chirurgie onderging). In de groep die behandeld werd met normotherme 
chemotherapie perfusie waren aan het einde van het experiment nog 13 dieren in leven 
(cytoreductieve chirurgie alleen versus normotherme perfusie: p= 0.002). 
Deze studie laat zien dat de effectiviteit van intraoperatieve intraperitoneale perfusie na 
cytoreductieve chirurgie met name toe te schrijven is van de aanwezigheid van cytostatica 
in de perfusievloeistof, en niet aan de toevoeging van hyperthermie. 
De huidige behandelprotocollen voor peritoneaalmetastasen die cytoreductieve chirurgie 
en intraperitoneale chemotherapie combineren maken niet allemaal gebruik van 
hyperthermie. De twee meest gebruikte toepassingsmethoden voor de intraperitoneale 
chemotherapie zijn HIPEC en de vroeg postoperatieve intraperitoneale chemotherapie (“Early 
Postoperative Intraperitoneal Chemotherapy” (EPIC)). Bij deze laatste maakt hyperthermie 
geen onderdeel uit van de behandeling. De effectiviteit van beide technieken is nooit in 
gerandomiseerde studies vergeleken. Hoofdstuk 7 beschrijft een experiment waarin de 
beide technieken werden toegepast na cytoreductieve chirurgie. De overlevingsresultaten 
van beide technieken werden vergeleken worden met de overleving na cytoreductieve 
chirurgie alleen. Tevens werd het effect van een combinatie van HIPEC en EPIC geevalueerd. 
Een week na inoculatie van de tumor werden 80 Wag/Rij ingedeeld in een van de volgende 
vier behandelgroepen (elk n=20): cytoreductieve chirurgie alleen, cytoreductieve chirurgie 
gevolgd door HIPEC (35 mg/m2 mitomycine verwarmd tot 41°C), cytoreductieve chirurgie 
gevolgd door EPIC gedurende 5 dagen (intraperitoneale injectie met mitomycine 10 mg/
m2 op dag 1 en 5-fluorouracil 15 mg/kg op dag 2 tot en met 5), en cytoreductieve chirurgie 
gevolgd door HIPEC plus EPIC. 
Mediane overleving van de ratten die alleen cytoreductieve chirurgie ondergingen was 53 
dagen. Ratten die behandeld werden met cytoreductieve chirurgie gevolgd door HIPEC 
lieten een significant langere overleving zien, met een mediaan van 94 dagen (p = 0.001). 
Twaalf dieren uit de EPIC groep waren nog in leven bij beëindiging van het experiment, na 
167 dagen (p<0.001 vergeleken met cytoreductieve chirurgie alleen). In de groep die een 
combinatie van HIPEC en EPIC toegediend kreeg werd een vroegtijdige uitval van elf ratten 
waargenomen door toxiciteit. Daarom werd deze groep niet in de overlevingsanalyses 
meegenomen.
Uit deze resultaten blijkt dat zowel HIPEC als EPIC de overleving van ratten met 
peritoneaalmetastasen kan verlengen na cytoreductieve chirurgie. Het gunstige effect 
van EPIC op de overleving lijkt sterker te zijn dan dat van de HIPEC. Vervolgonderzoek zal 
moeten uitwijzen welke mogelijke voor- en nadelen bij beide technieken een rol spelen in 
de klinische praktijk. 
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Deel	III	Klinische	aspecten	van	de	in	opzet	curatieve	chirurgische	combinatiebehandelingen
Een zorgvuldige patiëntenselectie blijft een van de belangrijkste factoren van invloed 
op het resultaat van de behandeling met cytoreductieve chirurgie en intraperitoneale 
chemotherapie. Bekende en algemeen geaccepteerde selectiecriteria zijn een goede fysieke 
conditie die een grote chirurgische ingreep toelaat, resectabele tumoren, afwezigheid 
van niet curatief behandelbare metastasen op afstand en een beperkte uitgebreidheid 
van peritoneale ziekte. Andere criteria worden minder uniform toegepast en zijn vooral 
afhankelijk van de ervaring en individuele voorkeur van de behandelend chirurg.  
In hoofdstuk 8 wordt de vraag gesteld of patiënten die peritoneale metastasen 
ontwikkelden tijdens of kort na het gebruik van adjuvante chemotherapie (en dus een 
relatieve resistentie lijken te hebben tegen systemische chemotherapie) in aanmerking 
zouden moeten komen voor een behandeling met cytoreductieve chirurgie en HIPEC. 
Om deze vraag te beantwoorden werden de overlevingsresultaten geanalyseerd van 
21 opeenvolgende patiënten die een vroeg recidief ontwikkelden na het ondergaan van 
adjuvante chemotherapie behandeling na resectie van een primair colorectaal carcinoom. 
Mediane tijd tot de diagnose van het recidief was 9 maanden na de eerste toediening van 
chemotherapie. De mediane overleving na diagnose van de peritoneale metastasen was 28 
maanden. De een- en tweejaars overleving was respectievelijk 71% en 43%. 
Deze resultaten zijn vergelijkbaar met de data die gerapporteerd worden in de literatuur 
voor patiënten die behandeld worden met HIPEC zonder gegevens over hun respons op 
systemische therapie. Er werd geen bewijs gevonden dat een beslissing zou rechtvaardigen 
om patiënten die niet op adjuvante systemische therapie reageren behandeling met 
cytoreductieve chirurgie en HIPEC te onthouden. Geadviseerd wordt dus om de reactie op 
systemische chemotherapie niet als selectiecriterium voor de HIPEC procedure te hanteren. 
Een andere categorie patiënten voor wie de indicatie voor een agressieve chirurgische 
behandeling ter discussie staat is de groep van oudere patiënten met een peritoneaal 
gemetastaseerd colorectaal carcinoom. Met de huidige ontwikkelingen in chirurgische 
technieken, anesthesie en perioperatieve zorg is het optreden van complicaties bij 
patiënten die behandeling met cytoreductie en intraperitoneale chemotherapie ondergaan 
aanzienlijk verminderd. Dit geeft aanleiding tot de vraag of deze procedures, die nog steeds 
de enige curatieve behandeling zijn voor peritoneale metastasen, uitsluitend aan jonge 
patiënten aangeboden zouden moeten worden. Hoofdstuk 9 beschrijft een studie naar de 
postoperatieve morbiditeit, mortaliteit en overleving van patiënten die een behandeling 
met cytoreductieve chirurgie en intraperitoneale chemotherapie ondergingen op 70-jarige 
leeftijd of ouder. Vierentwintig patiënten werden geïncludeerd met een gemiddelde leeftijd 
van 74 jaar. Bij acht patiënten traden ernstige complicaties op. Bij zes patiënten verliep 
het postoperatieve beloop licht gecompliceerd. Er was geen perioperatieve mortaliteit. 
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Mediane overleving was 35 maanden met een 6-, 12- and 18-maanden overleving van 
respectievelijk 94, 83 and 68%. Dit geeft aan dat de behandeling met cytoreductieve chirurgie 
en intraperitoneale chemotherapie veilig kan worden toegepast met een acceptabele 
morbiditeit bij oudere patiënten met peritoneale metastasen. Bij de selectie van patiënten 
voor deze behandeling zou bij voorkeur rekening moeten worden gehouden met de fysieke 
conditie en de uitgebreidheid van ziekte waarmee de patiënt zich presenteert in plaats van 
met kalenderleeftijd. 
Ondanks agressieve behandeling met cytoreductieve chirurgie en intraperitoneale 
chemotherapie ontwikkelt een aanzienlijk deel van de patiënten met peritoneaal 
gemetastaseerd colorectaal carcinoom een intraperitoneaal recidief. Dit roept de vraag 
op of een tweede procedure, bestaande uit cytoreductieve chirurgie en intraperitoneale 
chemotherapie, deze patiënten voordeel kan bieden. De uitvoerbaarheid en oncologische 
effectiviteit van herhaalde procedures met cytoreductie en intraperitoneale chemotherapie 
voor recidief peritoneaalmetastasen werden onderzocht in hoofdstuk 10. De gegevens van 
achttien patiënten uit drie centra in Nederland en Australië werden hiervoor geanalyseerd. 
Tijdens de herhaalde procedure traden bij 1 patiënt ernstige complicaties op waarvoor 
een additionele chirurgische ingreep noodzakelijk was. Er was geen mortaliteit in de eerste 
30 dagen na de procedures. Een- en tweejaarsoverleving na de tweede procedure waren 
respectievelijk 74 en 50%. Bij veertien patiënten werd een recidief gediagnosticeerd na de 
tweede procedure, met een mediane ziektevrije overleving van slechts 4.5 maanden. Hieruit 
werd geconcludeerd dat herhaalde cytoreductie en intraperitoneale chemotherapie voor 
recidief peritoneaalmetastasen na een eerdere agressieve behandeling uitvoerbaar en veilig 
is, met een acceptabele morbiditeit en zonder mortaliteit. Helaas is het recidiefpercentage 
na de tweede ingreep hoog, met een beperkte ziektevrije overleving. 
Om een definitieve uitspraak te kunnen doen over de waarde van herhaalde procedures zijn 
uitgebreider onderzoek en de rapportage van lange termijn resultaten noodzakelijk. 
Indien herhaalde cytoreductie overwogen wordt, zou dit aangeboden moeten worden aan 
patiënten die een goede respons laten zien op een kuur van systemische chemotherapie, die 
fit zijn en minimale, compleet resectabele ziekte hebben. Een multi-disciplinaire benadering 
is essentieel om die patiënten te selecteren die zouden kunnen profiteren van herhaalde 
cytoreductie aangezien inmiddels ook van systemische therapieën bekend is dat ze de 
overleving kunnen verlengen. 
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Yvonne Klaver was born on 25 April 1985 in Eindhoven, the Netherlands. She grew up in 
Veldhoven as the oldest child in a family of five children. 
After completing secondary school at the Sondervick College in Veldhoven (Gymnasium) in 
2003, she started her medical studies at Maastricht University. In 2007 she did an elective 
of 10 weeks at the Department of Pediatric Cardiology at Starship Children’s Hospital in 
Auckland, New Zealand in 2007. Yvonne’s involvement in research concerning treatment 
of peritoneal carcinomatosis from colorectal cancer started during her last year of medical 
school in the Department of Surgery at the Catharina Hospital, Eindhoven.
In 2009, Yvonne received her Medical Degree cum laude and started working as a fulltime 
PhD student in the Department of Surgery at the Catharina Hospital. Her PhD project involved 
close collaboration with the Radboud University Nijmegen Medical Centre, The Netherlands 
Cancer Institute - Antoni van Leeuwenhoek Hospital, Amsterdam and the Eindhoven Cancer 
Registry, Eindhoven. In 2010 a scientific collaboration with the Hepatobiliary and Surgical 
Oncology Unit of the St George Hospital, Sydney, Australia, was established. Yvonne joined 
this team as a research fellow from October 2010 until January 2011. The results of the 
studies performed in these years were presented at many national and international 
conferences. 
In November 2011, Yvonne started working in clinical practice at the Department of Internal 
Medicine of the Catharina Hospital, Eindhoven. 
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Onderzoek doe je nooit alleen. In de afgelopen jaren zijn veel mensen op hun eigen manier 
betrokken geweest bij mij en mijn promotie-traject. Aan iedereen die er zo voor gezorgd 
heeft dat dit proefschrift tot stand kon komen ben ik veel dank verschuldigd. Hoewel het 
onmogelijk is om iedereen te noemen, maak ik graag van deze gelegenheid gebruik om een 
aantal mensen persoonlijk te bedanken. 
Professor Bleichrodt. Als promotor bij dit project wist u altijd de klinische toepasbaarheid 
van onze studies te benadrukken en een brede denkwijze te stimuleren. Een bespreking 
van een experiment leidde zonder uitzondering tot nieuwe invalshoeken in de discussie. 
Bedankt voor uw deskundige begeleiding als promotor.
Ignace de Hingh. Ons gezamenlijke onderzoek begon met je woorden: “volgens mij verveel 
jij je”. Sindsdien is ’me vervelen’ geen moment meer in me opgekomen. Jouw aanstekelijke 
enthousiasme en energie hebben dit project succesvol gemaakt. ’Waar een wil is, is een 
weg’ gold zowel voor onderzoeken, publicaties, als voor een reis naar Australië. Je bent 
een fantastische copromotor voor me geweest. Ik hoop dat we de komende jaren nog vele 
gezamenlijke publicaties toe zullen voegen aan de lijst.
Thijs Hendriks. Het lab in Nijmegen is deze jaren voor mij een stabiele en vertrouwde 
uitvalsbasis geweest, waar jij als copromotor altijd aanwezig was om advies, zorgvuldig 
onderbouwde kritiek of een luisterend oor te bieden. Ik heb met heel veel plezier onder 
jouw leiding in Nijmegen gewerkt. Zoals Ignace zegt: “Als Thijs zegt dat het goed is, is het 
goed.” En zo is het. Dankjewel. 
Valery Lemmens. Bedankt voor je enthousiaste en betrokken begeleiding als copromotor. 
Jouw expertise op het gebied van statistiek en je bereidheid om geduldig een heldere uitleg 
te geven (en zo nodig te herhalen) heeft mij deze jaren veel geleerd. Ondanks je drukke 
agenda maakte je altijd tijd voor me. De volgende Piña Colada in Barcelona is voor mijn 
rekening.
Vic	Verwaal. Bij een project als dit is de steun van een autoriteit op het gebied van HIPEC-
chirurgie onmisbaar. Bedankt voor het delen van je ervaring en expertise. Of het nu ging 
om samenwerkingsverbanden, wetenschappelijk onderzoek of surfscholen, een advies was 
nooit teveel gevraagd. Ik hoop dat we onze samenwerking nog lang voort kunnen zetten. 
Roger Lomme. Het dierexperimenteel onderzoek was nooit iets geworden zonder jouw 
handigheid, vele praktische oplossingen en eindeloos geduld. Bedankt voor je hulp, maar 
vooral ook voor alle leuke uren die we op het lab hebben doorgebracht met opereren, ratten 
Dankwoord
206
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
wegen, voetbalwedstrijden beluisteren en koffie drinken. Ook nu mijn promotie erop zit 
geldt: bellen mag altijd.
Ben de Man. Ondanks dat je vanaf het begin van mijn promotietraject je eigen strijd aan 
het voeren was, bracht je regelmatig je inbreng in dit project. Je was daarbij altijd even 
optimistisch, betrokken en behulpzaam. Dat heb ik ontzettend gewaardeerd. Tijdens de 
afsluiting van mijn promotie-onderzoek ben je in gedachten bij ons. 
Onderzoekers in Nijmegen. Bedankt voor alle gezellige uren in het ‘onderzoekshok’. Michel, 
Thamar en Jillis: mijn dartkwaliteiten zullen nooit meer het niveau evenaren dat ik bereikte 
tijdens jullie deskundige leiding en met jullie muurbeschermende maatregelen. Guus, 
Ronald, Sharonne, Ankit, Rozemarijn: van het foute uur beluisteren tot de vele taart die ik 
heb moeten trakteren: voor jullie heel graag gedaan. 
Centraal Dieren Laboratorium, en met name Kitty en Bianca. Bedankt voor jullie hulp, tijd en 
goede zorgen en adviezen tijdens de dierexperimentele studies. De deskundige, zorgvuldige 
en betrokken manier waarop jullie met proefdieren omgaan is een voorbeeld voor alle 
onderzoekers. Jullie creëren een veilige omgeving waarin dierexperimenteel onderzoek op 
een verantwoorde manier uitgevoerd kan worden met het respect dat de dieren verdienen. 
Dank jullie wel.  
Maatschap chirurgie van het Catharina Ziekenhuis, en in het bijzonder Harm	Rutten en 
Grard	Nieuwenhuijzen. Bedankt voor het vertrouwen dat jullie in mij gesteld hebben, en 
voor de kansen die jullie mij geboden hebben door mij aan te nemen als arts-onderzoeker. 
Ik heb genoten van mijn jaren bij de chirurgie en ik hoop in de toekomst nog veel met de 
Heelkunde in het Catharina Ziekenhuis samen te mogen werken. 
Assistenten Heelkunde in het Catharina Ziekenhuis. Bedankt voor de fijne samenwerking 
en alle mooie momenten van de afgelopen jaren. Ik kijk met veel plezier terug op onder 
andere de skiweekenden, het chirurgencabaret en jullie trouwe support bij mijn praatjes 
op congressen. Mijn onderzoekstijd bij de chirurgie in ‘het Cathrien’ waren jaren met een 
gouden randje. 
David and Milja Morris. Thank you for offering me a home far away from home. My first 
Christmas overseas felt like celebrated with family. I will never forget the great time I had in 
Sydney, thanks to you. 
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Hepatobiliary and Surgical Oncology Unit, St George Hospital, Sydney. Thank you for your 
warm welcome in ‘the office’. I was deeply impressed by the way you work as a team to 
offer every patient the best available care and treatment in a very personal way. I have really 
enjoyed working in St George with you and I hope to come back for a coffee and a chat soon. 
Alle	 co-auteurs. In deze twee jaar heb ik met vele collega’s, werkzaam in verschillende 
vakgebieden, mogen samenwerken en gebruik gemaakt van de grote expertise en ervaring 
die bestaat in en buiten onze regio op het gebied van de behandeling van colorectaal 
carcinoom. Ik wil al mijn co-auteurs hartelijk bedanken voor deze multidisciplinaire 
samenwerking en feliciteren met de mooie resultaten die we samen behaald hebben.  
Martine en Karin, als paranimfen én vriendinnen zijn jullie er onvoorwaardelijk voor me 
met een theetje, advies en een helpende hand waar nodig. Al voor, maar ook tijdens mijn 
jaren als onderzoeker kon ik altijd op jullie rekenen, en ik ben er trots op dat jullie op deze 
bijzondere dag naast me staan. Ik had me geen betere paranimfen kunnen wensen. 
Aimée, bedankt voor al je inzet en betrokkenheid bij het organiseren van mijn promotiefeest 
als officiële ‘hulp-paranimf’. Ik ben ontzettend blij dat je dit voor me wilde doen. Je peptalks 
en de gezellige MTB-tjes in Den Haag hebben me er regelmatig doorheen gesleept als het 
even niet allemaal zo soepel liep. 
Rob, Niels, Dorien, Merel, Sandra. Bij jullie kan ik altijd terecht voor een lach, een traan, 
gekke verhalen, spontane acties, een drankje, een kopje thee of iets sterkers. De afgelopen 
jaren heb ik heel veel met jullie kunnen delen, en ik hoop dat nog vele jaren te kunnen doen. 
Dank jullie wel. 
Mariano, “A journey is best measured in friends, rather than miles”. After we met in the 
Australian desert, you have always been there for me, no matter the distance. Thank you for 
your support and for being so close.
Opa en oma. Of het nu gaat om mijn onderzoek, reizen of andere bezigheden, jullie zijn 
altijd even geïnteresseerd in mijn doen en laten en bereid om hulp te bieden waar nodig. 
Zelfs het tijdelijk bieden van een thuis voor mij tijdens mijn onderzoek in Nijmegen was niet 
te veel gevraagd. Ik vind het heel bijzonder om deze mijlpaal met jullie te vieren. Dank jullie 
wel.
Bart, Paul, Marianne en Ruud. Een oudste zus die om de wereld reist, regelmatig verhuist en 
met de vreemdste verhalen thuiskomt levert altijd genoeg stof voor gesprekken en humor. 
Bedankt voor jullie betrokkenheid en jullie hulp de afgelopen jaren. 
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En last but not least: pap en mam. Zonder jullie steun had ik niet hier kunnen staan. Ondanks 
dat mijn plannen en ideeën voor jullie niet altijd even logisch en verwacht zijn, hebben jullie 
me steeds gestimuleerd mijn eigen keuzes te maken om mijn dromen waar te maken. Jullie 
staan altijd voor me klaar. Dank jullie wel.
